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Introduction 
 
The imaging of rectal cancer has evolved considerably over the past two decades; there is a 
definite change in the imaging approach of this neoplasm. The methods of choice for imaging 
rectal cancer, in a pure morphological way, include endorectal ultrasound and magnetic 
resonance imaging. However, new imaging techniques for rectal cancer are emerging and others 
still evolving. Functional imaging through perfusion computed tomography or diffusion-weighted 
magnetic resonance imaging are now being increasingly used in clinical practice as additional 
tools with the purpose of helping to detect, characterize and stage rectal cancer (and also in the 
context of evaluating response to therapy and detecting local recurrence). 
 
The purpose of this thesis is to show some of the experience of the Radiology University Clinic 
of the Coimbra University Hospitals in these fields of imaging. It is also seeks to demonstrate the 
expertise of the Radiology and Surgery Departments of the Maastricht University Medical 
Centre, where I was fortunate to work on a daily basis and where part of the clinical research 
was performed. 
 
Thus, the subject of rectal cancer addressed herein will be divided into two parts. In the first 
part, the most relevant epidemiological, clinical and therapeutic issues will be discussed. Also, the 
various available diagnostic methods for imaging rectal cancer, both before and after therapy, will 
be reviewed. The second part substantiates a personal view on the aforementioned newer 
techniques, based on four clinical studies. These include the following: a study on the assessment 
of ADC measurements as a biomarker of tumor aggressiveness; a study of the role of 
conventional and diffusion-weighted MRI-based volumetry in the assessment of complete 
response after combined chemoradiation therapy; a study on the assessment of the influence of 
ROI size and positioning on observer variability and ADC values when measuring ADC of rectal 
cancers before and after chemoradiation treatment; and a study of the use of perfusion CT for 
prediction of response to combined chemoradiation therapy. 
 
This thesis represents, above all, the result of combined efforts from a team which generously 
and voluntarily contributed to its outcome.  
 
As such, gratitude is expressed to Prof. Dr. Filipe Caseiro Alves, Head of Department of the 
Radiology University Clinic of the University of Coimbra University Hospital and Professor at 
the Coimbra Medical School. From the outset, his support and scientific contribution were 
decisive; without him this thesis would not have been possible. His comments, suggestions, and 
encouragement created the necessary conditions for the work to be developed. I also thank him 
for his friendship. 
 
Thanks are also due to Prof. Dr. Júlio Soares Leite, surgeon at the Department of Surgery III of 
the University of Coimbra University Hospital and Professor at the Coimbra Medical School, for 
his availability, for providing insight into this thesis, and for his constructive criticism.  
 
My most sincere acknowledgement also goes to Prof. Dr. Regina Beets-Tan, Professor of 
Radiology at the Maastricht University Medical Centre, where part of the research for this thesis 
took place. She always received me in a most friendly way and was always willing to share her 
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extensive knowledge of rectal cancer with me. Moreover, she swiftly made me feel welcome in 
her research team. Those were certainly some of the most gratifying days of my professional life. 
 
I thank Prof. Dr. Geerard Beets, Professor of Surgery at the Maastricht University Medical 
Centre, for his clear and concise ideas and pertinent comments. 
 
I am very much in debt with Dr. Doenja Lambregts and Dr. Monique Maas, research fellows and 
currently residents at the Maastricht University Medical Centre. I am certain that this thesis 
would not have been possible without all their help and friendship. 
 
I would like to thank Dr. Margarida Borrego from the Department of Radiation Therapy of the 
University of Coimbra Hospital for the many ideas she shared on the management of our 
common patients and for allowing many of them to be included in one of the studies. I also 
thank her for the confidence she demonstrated in my opinions. 
 
Gratitude is expressed to all the professionals of the Universitary Clinic of Radiology of the 
University of Coimbra Hospitals, particularly those who allowed me to be momentarily relieved 
of my daily tasks in order to work on this thesis. I also thank those who collaborated on this 
scientific project, and improved it. 
 
I am very grateful to my friends for all their support during the difficult times, when some 
obstacles in the development of this thesis appeared. 
 
Last, but not least, I would like to thank my family, undoubtedly the cornerstone of my 
professional success. In particular, to my parents, Énio and Maria Helena, for their unconditional 
love and for having taught me their life values. To my brothers, Nuno Filipe nunc aeternam 
agitatque sanctam optime uitam and Ricardo Jorge, for the days of joy. To my wife, Ana Sofia, and 
my daughters, Ana Miguel and Maria Luís, for being my shelter. And for understanding that, 
despite my absences, they are never forgotten. 
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Chapter I 
From pathogenesis to therapy of rectal cancer  
 
1. EPIDEMIOLOGY 
 
1.1. Pathogenesis 
 
The development from a single cellular event to an overt rectal tumor occurs in a stepwise 
process, involving a progression from normal mucosa to adenoma and then to invasive 
carcinoma. This development of a malignant lesion occurs through the so-called ‘adenoma-
carcinoma sequence’ [Vogelstein et al, 1988]. In fact, it is now known that the majority of 
carcinomas develop from benign, pre-neoplastic lesions – adenomatous polyps – following a 
cascade of changes that take place within the cells of the bowel mucosa. Although the genetic 
sequence of events occurring in this process is now disclosed, the etiology is multifactorial, 
involving genetic susceptibility and environmental factors during the initiation and progression of 
this sequence [ACPGB2I, 2001]. The genetic model for the progression and development of a 
neoplasm can be represented in a series of genomic events involving alterations in several 
oncogenes (K-ras) and tumor-suppressor genes (APC, DCC/DPC4, P53), DNA repair genes 
(hMLH 1 and hMSH2), cell adhesion molecules (epCam), angiogenic factors (VEGF), as well as 
epigenetic changes (DNA methylation) and microsatellite instability (MSI) [Fisher and Daniels, 
2007].  
 
1.2. Incidence 
 
According to the National Oncological Registration [‘Registo Oncológico Nacional’] from the 
year of 2005 (published in 2009), 38519 new cancer cases were diagnosed by the end of that 
year in Portugal. The overall incidence rate was 284.64/100000.  
Among invasive cancers, in locations common to both genders, the most frequent was colorectal 
cancer (42.76/100000). Specifically rectal cancer by itself ranked as the 7th most common 
neoplasm in each gender (5.6% and 4.3% of newly diagnosed tumors, respectively in males and 
females), with 1158 new cases in males and 750 in females. The incidence rate was 22.91/100000 
and 13.90/100000 in males and females, respectively, with a global incidence rate for both 
genders of 18.26/100000.  
Over 90% of all rectal tumors corresponded to adenocarcinomas (including the mucinous type).  
Age had an impact on rectal cancer incidence greater than any other demographic factor: over 
90% of all new cases occurred in patients over 50 years old, with the highest incidence reported 
for patients older than 75 years old (75.46/100000).  
According to previously reported data [‘Registo Oncológico Nacional 2001’, published in 2008] 
colorectal cancer was estimated to account for about 10% of the deaths related to cancer in 
Portugal. 
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From a worldwide perspective, the incidence and mortality rates for colorectal cancer are 
greater in developed countries [Parkin et al, 1999; Henderson, 1992]. Nevertheless, in recent 
times, there is a trend toward a decrease of incidence and mortality rates in some, such as the 
United States [Jemal et al, 2007]. This modification is attributed to changes in dietary habits and 
lifestyle factors, as well as to the use of chemoprevention agents. Perhaps the most important 
factor, however, is a more widespread use of endoscopic methods for screening. In fact, 
screening for colorectal cancer has been proven to be an effective means of reducing both 
incidence and mortality from this disease by about 2% and 3% a year, respectively [Nelson et al, 
1999].  
 
1.3. Etiology and risk factors 
 
It is now thought that the etiology of colorectal cancer is complex and multifactorial, involving 
both genetic and environmental factors. These may work in concert to change the mucosa from 
a premalignant adenomatous polyp to an overt rectal cancer over the course of some years. 
Family history yields an increased lifetime risk of colorectal cancer. Familial factors that 
contribute significantly to increase the risk of sporadic cancer include involvement of at least one 
first-degree relative (doubling the risk) [Fuchs et al, 1994; Rozen et al, 1987] and appearance of 
cancer in a close (first or second-degree) relative prior to the age of 60. Furthermore, this 
increased risk is also established for pre-malignant adenomatous polyps [Pariente et al, 1998; 
Guillem et al, 1992; Winawer et al, 1996; Ahsan et al, 1998; Kerber et al, 1998]. 
A dominantly inherited susceptibility to colorectal adenomas and cancer that may account for 
the majority of sporadic cases of cancer has been suggested [Burt et al, 1985; Ponz de Leon et al, 
1992]. Genetic polymorphisms may be of paramount importance in this setting and they may 
also provide some insights into the geographic variation of this type of cancer as they are known 
to vary among different ethnic groups [Chen et al, 1998; Potter, 1999]. 
Regarding familial colorectal cancer, familial adenomatous polyposis (FAP) constitutes 1% of all 
colorectal cancer incidence. Hundreds of polyps develop in patients in their teen years to the 
mid-30s and, if the colon and rectum are not surgically removed, 100% of them will end up 
developing a cancer. There is also an association with extracolonic conditions, both benign (such 
as mandibular osteomas, supranumerary teeth, desmoid tumors, adrenal adenomas, epidermal 
cysts and hypertrophy of the retinal pigment epithelium) and malignant (thyroid cancers, 
duodenal/ampullary carcinomas and brain tumors – the association of brain tumors and colonic 
polyposis is named Turcot’s syndrome) [Rustgi, 1994; Hamilton et al, 1995]. There is an 
attenuated form of FAP with fewer polyps and a later age of cancer onset in comparison to the 
classical form [Spirio et al, 1993], related to a mutation of the MYH gene.  
Even though FAP is an autosomally dominant condition with almost 100% penetrance, in about 
30% of the cases there is a de novo mutation without a relevant family history. Patients inherit a 
mutation on the APC (adenomatosis polyposis coli) gene, and during life they acquire 
inactivation of the remaining APC gene copy, accelerating the progression to colorectal cancer.  
Hereditary non-polyposis colorectal cancer (HNPCC) is responsible for nearly 3% of all 
colorectal cancers. By opposition to FAP, in this condition there are fewer polyps but there is an 
accelerated rate of progression to colorectal cancer, with a lifetime risk of about 80% [Marra 
and Boland, 1996]. HNPCC is an autosomally dominant condition with 80% penetrance. 
Mutations in one mismatch repair gene result in microsatellite instability, which is responsible for 
somatic mutations of target genes in HNPCC-related tumors [Chung and Rustgi, 2003].  
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Hamartomatous polyposis syndromes are rare, representing less than 1% of all colorectal 
cancers annually. They include Peutz-Jeghers syndrome, juvenile polyposis and Cowden 
syndrome. 
The importance of environmental factors, such as diet and lifestyle, in the genesis of colorectal 
cancer, is exemplified by the fact that migrants from low-incidence areas to high-incidence areas 
assume the incidence of the host population in only one generation [Whittemore et al, 1990; 
McMichael and Giles, 1988] and that economically developed countries have higher incidence 
and mortality rates [Wilmink, 1997].  
Among environmental factors, obesity and high caloric intake were proved to be independent 
risk factors for colorectal cancer [Slattery et al, 1997; Singh and Fraser, 1998]. Other important 
risk factors include ingestion of red meat [Wilmink, 1997; Potter, 1999; Slattery et al, 1997; 
Singh and Fraser, 1998; Willett et al, 1990], as well as consumption of fried, barbecued or 
processed meat [Chen et al, 1998; Probst-Hensch et al, 1997]. It is however unclear if this 
carcinogenic effect is due to the high-protein content (that accelerates epithelial proliferation) 
[Caderni et al, 1999] or to the fatty components of red meat that are metabolized by intestinal 
bacteria to produce carcinogens (again stimulating epithelial proliferation) [Potter, 1999; 
Burnstein, 1993]. Furthermore, some authors suggest that saturated animal fats may be 
especially dangerous [Wilmink, 1997; Potter, 1999]. 
A sedentary lifestyle may account for an increased risk of developing colorectal cancer, although 
the exact mechanism remains unknown to date [Wilmink, 1997; Potter, 1999; Whittemore et al, 
1990]. Prolonged cigarette smoking is associated also with an increased risk of premalignant 
adenomas and colorectal cancer [Wilmink, 1997; Potter, 1999; Kikendall et al, 1989]. The 
associations with the ingestion of coffee, tea and alcohol are still unclear [Seitz et al, 1990; 
Hartman et al, 1998]. 
 
2. CLINICAL AND LABORATORY FINDINGS 
 
The signs and symptoms of rectal cancer do not always point toward a clear diagnosis as there is 
substantial overlap with some other more frequent proctological conditions such as irritable 
bowel syndrome, inflammatory bowel disease and especially haemorrhoidal disease. The clinical 
presentation of rectal cancer is usually with rectal bleeding and a change in bowel habits, which is 
often an increased frequency of defecation and/or looser stools [Vogelstein et al, 1988]. Rectal 
bleeding occurs without anal symptoms in over 60% of patients [Ellis et al, 1999; Dodds et al, 
1999]. In low rectal cancer, the symptom of tenesmus – the feeling of incomplete evacuation – 
may occur, and anal pain usually means that invasion of the anal sphincter has occurred [Fisher 
and Daniels, 2007]. Much less frequently, patients may experience changes in body habits, 
abdominal pain, weight loss, weakness, anorexia and obstruction [Stein et al, 1993]. A palpable 
rectal mass is present in 40% to 80% of patients with rectal cancer [Dixon et al, 1990; Finan et 
al, 1987; Barillari et al, 1996]. If metastatic disease is present, adenopathy, hepatomegaly, jaundice 
or even pulmonary signs may be apparent. Complications may include acute gastrointestinal 
bleeding, acute obstruction, perforation and functional impairment of distant organs from 
metastases. 
Laboratory findings may be entirely normal or demonstrate electrolyte derangements, iron-
deficiency anemia or abnormalities in liver function tests, as well as an elevation of the 
carcinoembryonic antigen (CEA) levels. Advances in molecular biological techniques permit 
extraction of genomic DNA or protein from stool and assay for evidence of genetic alterations 
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[Villa et al, 1996; Eguchi et al, 1996]. In patients with neoplasms harbouring genetic 
abnormalities, it is presumed that the stool samples will reveal similar alterations.  
 
3. PRIMARY PREVENTION AND SCREENING 
 
3.1. Primary prevention 
 
The classical belief that a high-fiber diet was protective against the development of colorectal 
cancer was recently challenged by large, well-controlled studies that failed to prove an inverse 
relationship between colorectal cancer and fiber intake [Willett et al, 1990; Schatzkin et al, 2000; 
Alberts et al, 2000]. Nevertheless, a protective effect of vegetables and fruits is thought to be 
true [Wilmink, 1997; Potter, 1999]. This may be due to the presence of antioxidant vitamins (A, 
C, E), folate, thioethers, terpenes or plant phenols [Wargovich, 1988]. 
There is some evidence suggesting that vitamin D may play an important role as an agent for 
prevention of colorectal cancer. In fact, studies showed that individuals with lower blood vitamin 
D levels have a higher risk of colorectal cancer and adenoma [Gorham et al, 2007]. 
The B vitamins – including folate, vitamin B6 and vitamin B12 – may be important for reducing the 
risk of colorectal cancer. Epidemiologic studies have yielded a link between low-folate intake and 
a high risk of colorectal cancer [Giovannucci, 2002]. Similarly, recent studies suggested that 
vitamin B6 may have a protective effect against colorectal cancer [Larsson et al, 2005].  
Calcium, through its mechanism of binding the bile acids with decrease of the intestinal epithelial 
proliferation, has also historically been assigned as a protective factor against colorectal cancer 
[Bostick et al, 1995; Potter, 1999]. Observational epidemiologic studies revealed a consistent 
inverse association between low calcium intake and an increased risk of colorectal cancer [Wu 
et al, 2002; McCullough et al, 2003].  
Population-based studies strongly support a protective role against the appearance of both 
colorectal adenomas and cancer for aspirin and other non-steroidal anti-inflammatory drugs 
[Thun et al, 1991; Rosenberg et al, 1998]. 
 
3.2. Screening 
 
Screening for rectal cancer usually takes place in the context of the more widespread colorectal 
cancer screening. It seems well worthwhile to screen for this cancer: it is frequent, and lethal in 
a large proportion (approximately 50%) of individuals who develop it. Those requisites, however, 
are not sufficient to warrant a good candidacy for screening: it is mandatory that an effectively 
curative treatment should be offered for those in whom a diagnosis of early-stage cancer is 
achieved through screening [Halligan, 2007].  
The idea of detecting colorectal cancer early enough to improve survival came from the 
observation that Dukes’ stage A cancers were frequently successfully treated by excision of the 
tumor [Dukes, 1932]. Since most cancers are believed to begin as adenomas that go additional 
mutations to become invasive carcinomas (the “adenoma-carcinoma” sequence) and that the 
malignant transformation is believed to take an average of 10 to 15 years, the removal of polyps 
has been advocated as a method to prevent colorectal cancer. The relatively slow growth of 
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adenomatous polyps and cancers, allied to the high incidence rate of these neoplasms, are good 
reasons warranting an ‘aggressive’ screening program.  
Thus, patients are prevented from ever developing cancer by the screening program and the 
incidence of the disease is reduced (as opposed to schemes that aim to detect cancer only). 
Also, the costs of treating (and palliating) cancer are largely eliminated, as is surgery-related 
morbidity and mortality. Because malignant transformation occurs during the course of many 
years in the majority of cases, screening can be less frequent than programs that aim to identify 
overt cancer. Also, screenees who test positive may be less anxious because they are aware that 
the target lesions (i.e., polyps) are not malignant. However, polyps are smaller and thus more 
difficult to detect than cancers, and an enormous number of polyps need to be removed to 
prevent a single cancer [Halligan, 2007].  
At least 75% of patients who develop colorectal cancer have no specific risk factors that can be 
recognized in advance (the most significant risk factor for most individuals is merely age). This 
means that mass population screening is required in order to impact extensively on the disease. 
In addition, the large majority of adenomas are destined never to turn into malignancies, but 
there is essentially no reliable way to distinguish in advance those that will from those that will 
not. In fact, all detected adenomas can be regarded as potential cancers and should be removed. 
The larger the adenoma, the more likely it is to become malignant: 1 % at 1 cm or less versus 
50% at 2 cm or more [Halligan, 2007].  
There is some controversy, however, as to the best approaches and methods to screen patients, 
since there are several screening methods available.  
Cancers tend to bleed and it is this phenomenon on which the rationale for fecal occult blood 
testing (FOBT) is based. Nevertheless, cancers frequently only bleed intermittently and so 
multiple testing is needed to enhance sensitivity (conventionally three samples). Even with 
multiple sampling, sensitivity is just about 40% for cancer. Overall, patients with a repeatedly 
positive test have a 10% chance of having cancer and a 30%-40% chance of harbouring a large 
polyp (usually an adenoma 2 cm or larger since these bleed more than smaller ones). 
Consequently, about 50%-60% of patients with a positive FOBT will have no disease, so FOBT 
has a relatively low specificity for cancer in those that have tested positive. A major drawback of 
FOBT is that it is an indirect test – the tumor or polyp itself is not directly seen. Rather, FOBT 
relies on an epiphenomenon and another test is mandatory to confirm the diagnosis of neoplasia 
(and to remove it if it is a polyp). However, the majority of adenomas do not bleed and, 
accordingly, FOBT is poorly suited to a screening program that aims to prevent cancer. In spite 
all of the problems mentioned above, FOBT is the only screening test for which there are 
randomized controlled data that demonstrate reduced disease-specific mortality from colorectal 
cancer when the test is applied to the relevant population. Large-scale trials have shown a 
decline in disease-specific mortality. Meta–analysis of these trials, performed on data from 
329642 screenees, found the reduction in colorectal cancer mortality to be of 23% for those 
who attended for screening [Towler et al, 1998]. Furthermore, FOBT can be combined in a 
program with other tests described below.  
Newer immunochemical tests that can be used without dietary restrictions, assuring a greater 
compliance of patients, have been developed [Levin et al, 2003]. They have been studied in case-
control studies, and in comparison to the older tests they provide lower rates of false positives 
and equal or greater sensitivity for polyp detection [Rozen et al, 2000]. 
Nowadays, research is centred in examining molecular methods in both stool and blood 
[Ahlquist and Shuber, 2002; Hayes et al, 2005]. Finding the right molecular marker in both 
approaches is the key to an effective and widespread implementation of these strategies, as large 
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populations need to be evaluated in order to determine efficacy in comparison to the other 
screening methods. 
Both colonoscopy and flexible sigmoidoscopy are unanimously regarded as viable approaches to 
screening for colorectal cancer. Contrarily to FOBT, endoscopy is very sensitive for even small 
adenomas and has a sensitivity for cancer that likely exceeds 95%, mainly because bowel lesions 
are visualized directly by the operator. Endoscopy is well suited to schemes that aim to detect 
adenomas and so prevent cancer by polypectomy. However, colonoscopy in particular is 
expensive, resource-demanding, and difficult to master. Moreover, its potential adverse events 
such as the risk of perforation are also well recognized, and even the small mortality associated 
with colonoscopy could theoretically become a true matter of concern in the context of a mass 
screening program where colonoscopy would be used as the primary screening test [Garvican, 
1998]. Other disadvantages of this method include its inherent invasiveness and the need for a 
thorough bowel cleansing.  
Nevertheless, in current US guidelines, colonoscopy is recommended every 10 years in those at 
average risk. This is based in observational studies, as it is believed that since the average time 
from development of a polyp to an invasive malignancy is at least 10 years, by screening 
individuals every 10 years nearly all polyps will be detected before they turn malignant, due to 
the high sensitivity of the technique [Winawer et al, 2003].  
Because of the problems with colonoscopy, it has been suggested that flexible sigmoidoscopy 
would be a more adequate alternative for screening. Heavy sedation is not required and the left 
colon is less at risk of perforation during the procedure than the right. It is also less technically 
demanding than total colonoscopy. Most cancers and adenomas are left-sided and therefore 
within reach of the sigmoidoscope [Atkin et al, 1993]. Flexible sigmoidoscopy would also 
determine indirectly those who may be most at risk of right–sided cancer by using left-sided 
adenomas as a surrogate marker [Garvican, 1998]. Despite the criticisms about the whole colon 
not being explored, they ignore the particular conditions applying to the screening programs; 
screenees are asymptomatic and it is fundamental that they come to as little harm as possible as 
a consequence of the test used [Halligan, 2007].  
As such, flexible sigmoidoscopy has replaced rigid proctoscopy/sigmoidoscopy as a method of 
evaluating the rectum and the sigmoid colon. Several observational studies have estimated a 
reduction in mortality and incidence of cancers and polyps by screening asymptomatic individuals 
[Church, 1999].  
Barium enema has long been regarded (particularly by radiologists) as an appropriate method for 
screening for colorectal cancer. It affords the advantages of lack of sedation and hemodynamic 
monitoring and ability to detect lesions (Figure I.1).  
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Figure I.1. Barium enema discloses a rectal polyp with its characteristic ‘bowler hat’ appearance (white arrow). 
 
It is also relatively cheap and safe. However, we have been witnessing accumulating evidence 
suggesting that sensitivity for both significant adenomas and early cancers is not high when 
compared to other methods. For example, the US national polyp study found sensitivity for 
adenomas 1 cm or larger to be only 48% in 862 paired enema and colonoscopic examinations 
performed in 580 patients [Winawer et al, 2000]. There are no randomized trials of barium 
enema that aim to demonstrate an effect on disease-specific mortality from colorectal cancer, 
and such trials seem unlikely to be performed when there is overwhelming evidence in favour of 
newer emerging techniques. Therefore, it is uneasy to recognize barium enema playing a major 
role in a screening program both presently or in the future [Halligan, 2007]. 
Computed Tomography colonography (CTC), the combination of helical computed tomography 
(CT) scanning of a cleansed pneumocolorectum with advanced 3D image rendering simulating 
the colonoscopist’s perspective, was first described in 1994 [Vining et al, 1994]. It appears to 
merge the ideal attributes for a screening test for colorectal cancer – sensitive, specific, safe, and 
acceptable. It seems widely recognized nowadays that this method can detect polyps with high 
sensitivity, offering the potential for cancer prevention rather than cure alone. However, debate 
persists as to with what facility CTC detects polyps overall, with some studies finding it 
equivalent to optical colonoscopy [Pickhardt et al, 2003] while others have found it no better 
than barium enema [Rockey et al, 2005]. There have been some attempts to meta-analyze 
studies of CTC. The most recently published meta-analysed data from 24 studies with 4181 
participants [Halligan et al, 2005]. The investigators found a high per-patient average sensitivity of 
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93% (95% Cl: 73% - 98%) and an average specificity of 97% (95% CI: 95% - 99%) for CTC when 
used to detect polyps 1 cm or larger [Halligan et al, 2005]. Needless to say, test performance 
decayed when smaller polyps were included in the analysis, with a per-patient average sensitivity 
of 86% (95%CI: 75% - 93%) and an average specificity of 86% (95%CI: 76% - 93%) when the 
diagnostic threshold was adjusted to include patients whose polyps were 6 mm or larger. In this 
meta-analysis, 144 of 150 cancers were detected by CTC, with an overall detection rate of 96% 
(95%Cl: 91% - 99%) [Halligan et al, 2005].  
As a screening method, it is of paramount importance that CTC is acceptable to patients. Taylor 
and colleagues [2005] investigated the experiences of patients having both barium enema and 
CTC, finding that patients suffered significantly less physical discomfort during CTC and were 
more satisfied with the procedure overall. Taylor and colleagues [2003a] also investigated the 
experiences of 186 subjects undergoing CTC followed by flexible sigmoidoscopy or 
colonoscopy. Again, they found that CTC was significantly less uncomfortable than endoscopy, 
better tolerated, and was the preferred follow-up investigation of those expressing a preference 
[Taylor et al, 2003a]. 
Even if the initial perception was that CTC comprised no risks except for those associated with 
radiation, this is untrue and this method carries a risk of adverse effects. Burling and colleagues 
[2006] performed a survey, gathering data on 17067 procedures from 50 United Kingdom 
centres: 13 patients (0.08%) suffered a potentially serious adverse event attributable to CTC, 9 
of which were perforations. Four of them were asymptomatic, yielding a symptomatic 
perforation rate of 0.03% (1 in 3413 patients) versus 0.13% for optical colonoscopy [Burling et 
al, 2006]. The same group investigated the degree of cardiovascular compromise experienced by 
patients undergoing both CTC and colonoscopy, since it is believed that cardiovascular 
depression as a consequence of sedation is a significant cause of serious adverse events during 
colonoscopy [Taylor et al, 2003b]. CTC was associated only with a mild tachycardia related to 
administration of intravenous spasmolytics whereas colonoscopy was associated with potentially 
serious cardiac arrhythmias and cardiovascular depression. 
Computer-assisted detection (CAD) systems have recently become widely available in the 
commercial marketplace. They accelerate interpretation, making it more time-efficient and less 
tedious [Bond, 2005]. The largest study to evaluate its performance in isolation – i.e., the CAD 
algorithm is applied to CTC studies where the location of polyps is known – was performed by 
Summers and colleagues who found that CAD detected 89.3% of polyps 10 mm or larger in a 
test set of 792 patients [Summers et al, 2005]. The potential benefit of CAD assistance has been 
inferred indirectly by comparing the sensitivity of CAD and radiologists when asked to interpret 
the same dataset: Taylor and co-workers found that CAD was more sensitive than any of three 
experienced observers [Taylor et al, 2006]. Also, interpretation time decreased significantly; by a 
mean of 1.9 minutes per patient for those with polyps and by 2.9 minutes for those without 
[Halligan et al, 2006]. 
There is no proof whatsoever that CTC is able to reduce disease-specific mortality in the 
context of screening for colorectal cancer. However, case-control studies provided indirect 
evidence that polypectomy reduces the incidence of subsequent cancer [Atkin et al, 1992; Selby 
et al, 1992]. It is on this type of study that the success of CTC is predicated; if polypectomy 
reduces cancer, and CTC is good at detecting polyps, then it must follow that it can prevent 
cancer [Halligan, 2007]. 
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4. STAGING AND PROGNOSIS 
 
Standard clinical-pathological staging is the best indicator of prognosis for patients with rectal 
cancer and nowadays they have both a clinical presurgical staging, as well as a postoperative 
surgical stage. Since a significant proportion of patients (10% to 30%) experience a substantial 
downstaging with disappearance of the primary tumor (pathological complete response) 
presurgical clinical staging should be still the cornerstone for decisions on the administration of 
neoadjuvant therapy and on the surgical procedure of choice. As such, we are presently 
witnessing a growing need for the initial staging to be as accurate as possible, as it impacts 
significantly on both management and prognosis of patients. 
The routine non-imaging staging procedures include a clinical history, a physical examination, 
blood cell count, liver and kidney function tests and a CEA level determination. A thorough 
physical examination is an essential part of the pretherapeutic evaluation in order to assess the 
distance of the tumor from the anal verge or the dentate line, involvement of the anal sphincter, 
amount of circumferential involvement, clinical fixation and sphincter tone. So far the digital 
examination has not been replaced by any endoscopic or imaging methods in this regard.  
The imaging techniques for staging rectal cancer will be discussed further ahead, in Chapter II. 
The Dukes classification [Dukes, 1932] was used for many years but it should now be regarded 
as of historical significance only and discarded for clinical use. 
Staging is now performed according to the tumor-node-metastasis (TNM) classification of the 
American Joint Commission on Cancer (AJCC) / Union Internationale Contre le Cancer (UICC) 
staging system [Edge et al, 2010]. 
The TNM staging system classifies the extent of cancer based on anatomical information about 
the size and extent of primary tumor (T), the regional lymph node status (N) and the distant 
metastases (M), grouping the cases with similar prognostic. The 7th revision of TNM staging was 
recently published by the AJCC and UICC, and became operational starting from 2010.01.01 
[Edge et al, 2010]. 
Research studies during the last years yielded a much better understanding of carcinogenesis and 
emphasized the significant role of an increasing number of non-anatomic markers in establishing 
the prognosis and treatment response of the neoplastic patient. This led to the recognition that 
staging based only on anatomical features no longer provides an adequate answer to the recent 
advances in clinical evaluation and therapeutic decisions. 
The 7th revision of TNM staging was designed to respond to these needs, including – in 
comparison with the previous editions – more markers which were fully validated as being 
relevant in clinical practice for accurate therapeutic decision making [Edge et al, 2010]. 
Despite that, by recognizing the fact that anatomical data still possess a crucial prognostic role, 
the actual TNM system maintains a division between the anatomic and non-anatomic factors. 
Therefore, the anatomic extent of the neoplastic disease remains the nucleus of the staging for 
two reasons: (1) to keep a reporting format which is compatible with previous versions, in order 
to allow comparability of the prognosis of present patients (treated according to new prognostic 
markers, including non-anatomic ones) vs. patients who have been staged according to previous 
versions, and (2) the inclusion of new prognostic factors is limited both by their validation only 
for discrete subsets of patients and by the achieved level of evidence, which is still unsatisfactory 
at the light of the current knowledge. The accepted non-anatomic factors were considered to be 
significant, thus being included in a separate section in the staging form. Clinical (c) and 
pathologic (p) stages can be complementary for a complete staging [Edge et al, 2010]. 
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According to the 7th edition of the AJCC/UICC TNM staging, the descriptions of the several 
stages for each parameter are the following: 
 
- Primary Tumor (T)    
TX - Primary tumor cannot be assessed 
T0 - No evidence of primary tumor 
Tis - Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 - Tumor invades submucosa 
T2 - Tumor invades muscularis propria 
T3 - Tumor invades through the muscularis propria into pericolorectal tissues 
T4a - Tumor penetrates to the surface of the visceral peritoneum 
T4b - Tumor directly invades or is adherent to other organs or structures 
 
- Regional Lymph Nodes (N) 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1 - Metastasis in 1–3 regional lymph nodes 
N1a - Metastasis in 1 regional lymph node 
N1b - Metastasis in 2–3 regional lymph nodes 
N1c - Tumor deposit(s) in the subserosa, mesentery, or non-peritonealized 
perirectal tissues without regional nodal metastasis 
N2 - Metastasis in 4 or more regional lymph nodes 
N2a - Metastasis in 4–6 regional lymph nodes 
N2b - Metastasis in 7 or more regional lymph nodes 
 
- Distant Metastasis (M) 
M0 - No distant metastasis 
M1 - Distant metastasis 
M1a - Metastasis confined to one organ or site (for example, liver, lung, ovary, 
non-regional node) 
M1b - Metastases in more than one organ/site or the peritoneum 
 
By AJCC/UICC convention, the designation “p” refers to the pathologic classification of the TNM, 
as opposed to the clinical classification, and is based on gross and microscopic examination. 
Clinical classification (cTNM) is usually performed before treatment during an initial evaluation of 
the patient or when pathologic classification is not possible. For identification of special cases of 
TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do 
not directly affect the stage grouping, they indicate cases needing separate analysis. The “m” suffix 
indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: 
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pT(m)NM. The “y” prefix indicates those cases in which classification is carried out during or 
following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both 
chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. 
The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that 
examination. The “r” prefix indicates a recurrent tumor when staged after a documented disease-
free interval, and is identified by the “r” prefix: rTNM [Edge et al, 2010]. 
Patients are then grouped according to the following anatomic stage/prognostic groups: 
 
 Stage 0 Tis N0 M0 
 Stage I T1 N0 M0 
  T2 N0 M0 
 Stage II A T3 N0 M0 
 Stage II B T4a N0 M0 
 Stage II C T4b N0 M0 
 Stage III A T1-T2 N1 M0 
  T1 N2a M0 
 Stage III B T3-T4a N1 M0 
  T2-T3 N2a M0 
  T1-T2 N2b M0 
 Stage III C T4a N2a M0 
  T3-T4a N2b M0 
  T4b N1-N2 M0 
 Stage IV A Any T Any N M1a 
 Stage IV B Any T Any N M1b 
 
The 7th edition of the TNM staging shows some changes in comparison with the previous 
version, which include the following [Obrocea et al, 2011]:  
- T4 category has been subdivided into T4a (tumor penetrates to the surface of the 
visceral peritoneum) and T4b (tumor directly invades or is adherent to other organs and 
structures). 
- The recommendation of 6th edition to harvest at least 12 to 14 regional lymph nodes 
[Goldstein and Turner, 2000; Puppa et al, 2007; Chang et al, 2007; Greene et al, 2006; 
Rigby et al, 1999] is rephrased. It is emphasized the importance of mentioning in the 
pathological report the total number of nodes evaluated, since data from recent years 
suggest the prognostic significance of this issue [Chang et al, 2007]. 
- pN1 – metastasis in 1 to 3 regional lymph nodes – has been subdivided in N1a 
(metastasis in 1 regional lymph node), N1b (metastasis in 2–3 regional lymph nodes) and 
N1c (tumor deposits in the perirectal tissue without regional lymph node metastasis). 
Tumor deposits (TD, formerly named satellite nodules) are included both in Site-Specific 
Factors (or Prognostic Factors) category and also in the N category. They have been 
described in recent studies as an independent prognostic factor [Goldstein and Turner, 
2000; Puppa et al, 2007] and are defined as discrete foci of tumor lying in the perirectal 
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fat, in the absence of residual lymph node tissue, but within the lymphatic drainage area 
of the primary tumor. The TD’s should be mentioned (by number) in the Site-Specific 
Prognostic Factors section and also in the N1c category in case of T1 or T2 stage lesions. 
- pN2 – metastasis in 4 or more regional lymph nodes – has been subdivided in pN2a – 
metastasis in 4 to 6 regional lymph nodes – and pN2b – metastasis in 7 or more nodes. 
- M – MX is no longer included in the 7th edition of the TNM system. The M0 category 
cannot be documented on pathological evaluation, but only clinical, based on the clinical 
history and physical examination. M1 has been subdivided in M1a (metastasis confined to 
one organ or site) and M1b (metastasis in more than one organ/site or the peritoneum). 
- Stage II – is now subdivided in II A (T3N0), II B (T4aN0) and II C (T4bN0). 
- Stage III – T4bN1, previously classified as III B, has been reclassified as III C. For the same 
reasons (different survival rates), a number of N2 categories (formerly included in stage 
III C) have been restaged as follows: T1N2a in stage III A and T1N2b, T2N2a-b and 
T3N2a in stage III B. 
Meanwhile, seven new prognostic factors have been incorporated. Even though none of them is 
considered mandatory for staging in the present classification, their prognostic and predictive 
value has been acknowledged, making them extremely helpful for a personalized diagnosis and 
targeted therapy, in light of recent research [Obrocea et al, 2011; Edge et al, 2010]: 
- Tumor deposits, mentioned above, are recorded numerically.  
- For circumferential resection margin (CRM), the distance in mm from the closest tumor 
margin to the mesorectal fascia (MRF) must be reported. A margin <1 mm is considered 
to be positive (invaded by tumor) [Edge et al, 2010]. 
- Perineural invasion (PN) – presence or absence of PN must be mentioned. 
- Microsatellite instability – sporadic cancers which are microsatellite unstable (MSI-H 
phenotype) have a better prognostic than tumors with similar anatomic stage and 
histological grade but without MSI-H phenotype. The MSI status must be reported as 
follows: stable, MSI-low, MSI-high and not registered. 
- Tumor regression grade (TRG) – should be interpreted as a marker of response to 
neoadjuvant therapy. A 4-grade system is recommended [Edge et al, 2010]: 
- Grade 0 (complete response) – no viable cells present; 
- Grade 1 (moderate response) – single cells or small groups of cancer cells; 
- Grade 2 (minimal response) – residual cancer outgrown by fibrosis; 
- Grade 3 (poor response) – minimal or no tumor kill, extensive residual cancer. 
- k-ras gene analysis – mutation of k-ras gene is associated with an unfavorable response to 
treatment with anti-EGFR antibodies. 
- 18q loss of heterozygoity (LOH) assay – is considered currently a prognostic marker; based 
on 18qLOH assay it could be possible to decide which stage II patients should receive 
neoadjuvant treatment. 
The L (lymphatic vessel invasion) and V (venous invasion) discriminators have now been merged 
into lymph-vascular invasion (LV), together with a new subdivision: LV not present (absent/not 
identified), LV present/identified, not applicable and unknown/indeterminate. 
The R category (residual tumor) has been reconfigured as follows: RX – presence of residual 
tumor cannot be assessed, R0 – no residual tumor, R1 – microscopic residual tumor, and R2 – 
macroscopic residual tumor. 
These prognostic features are able to differentiate outcomes of rectal tumors. The involvement 
of the MRF was identified as a poor prognostic marker two decades ago. A recent meta-analysis 
of studies, including 17,000 patients by Nagtegaal and Quirke [2008] showed that a positive 
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CRM strongly predicts for local recurrence, especially in patients who have received neoadjuvant 
CRT (hazard ratio [HR] = 6.3) but also distant metastases (HR = 2.8) and poor survival (HR for 
survival = 1.7). Other prognosticators that influence outcomes include for example the presence 
of extramural venous invasion (3-year relapse-free survival, 35% vs. 74.1%, P < 0.001) [Smith et 
al, 2008a,b], extramural spread beyond 5 mm (5-year disease-specific survival, 54.1% vs. 85.4%, P 
< 0.0001) [Merkel et al, 2001; MERCURY Study Group, 2007], increased nodal stage (5-year 
overall survival [OS] by stage: T3N0, 64% vs. T3N1, 52.4% vs. T3N2, 37.5%) [Gunderson et al, 
2010] and a low rectal tumor requiring abdominoperineal resection (5-year cancer-specific 
survival 65.1% for APR vs. 76.6% for low anterior resection, P < 0.001) [Hawkes et al, 2011]. 
These features highlight the need for careful staging and individualized management based on 
prognostic factors. 
 
5. TREATMENT OPTIONS 
 
The universal implementation of total mesorectal excision (TME) and neoadjuvant (short-
course) radiotherapy (SCRT) or long-course combined chemoradiation therapy (CRT) have 
reduced local recurrence rates from 25% - 40% to under 10% [Heald et al, 1998; Kapiteijn et al, 
2001; Havenga et al, 1999; Nesbakken et al, 2002]. 
 
5.1.  Surgery 
 
It is generally considered that the surgical management of primary rectal cancer may present 
particular problems to surgeons due in part to anatomic constraints of the pelvis and also to the 
complex anatomy of the region. 
For selected superficial lesions without evidence of nodal disease, transanal local excision often 
provides adequate resection of the primary tumor mass and can avoid a more extensive 
resection, sparing the patient to considerable morbidity, and has long been used as an alternative 
surgical option for patients not fit to undergo a major abdominal resection or unwilling to have a 
permanent stoma. According to several authors [Winde et al, 1996; Sengupta and Tjandra, 2001; 
Blair and Ellenhorn, 2000], local excision may be curative for patients with a primary tumor 
limited to the mucosa. Even if the tumor invades the submucosa, local excision may be 
potentially curative as long as high-risk features, which increase the likelihood of local and 
regional nodal metastatic disease, are not present. As such, tumors should be within 8 to 10 cm 
of the anal verge, encompass less than 40% of the bowel wall circumference, show no ulceration, 
have a well or moderately-well differentiated non-mucinous histology and show absence of 
pathological evidence of venous or lymphangiovascular invasion on biopsy. The benefits of local 
excision for these patients are preservation of anal continence as well as bladder and sexual 
functions, with identical oncologic results [Lezoche et al, 2005; Winde et al, 1996; Sengupta and 
Tjandra, 2001; Blair and Ellenhorn, 2000].  
Even if rectal tumors limited to the submucosa (T1) are reported to be at low risk for local 
recurrence and may therefore be eligible for local excision, once the tumor invades the 
muscularis propria (T2), the available evidence [Lezoche et al, 2005; Varma et al, 1999; Balch et 
al, 2006; Rodel et al, 2005; Martling et al, 2000, Marijnen and Glimelius, 2002] shows that local 
excision alone may be associated with high local recurrence rates. In fact, success of local 
excision in the management of rectal cancer depends on the depth of tumor invasion, and this is 
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correlated with the risk of lymph node metastases [Bozzetto et al, 1999]. Accurate preoperative 
assessment of the level of invasion is important because the risk of lymph node metastases 
increases with T stage. The risk is 0%–12% for T1, 12%–28% for T2, and 36%–79% for T3–T4 
lesions [Varma et al, 1999]. 
Performing a good transanal excision requires substantial expertise as the surgeon must retain 
control over the primary tumor and obtain adequate mucosal margins as well as adequate deep 
resection into perirectal fat. The staging of such lesions should be performed using endorectal 
ultrasound (EUS) to minimize the likelihood of performing a local excision for T3 tumors 
[Herzog et al, 1993]. 
The primary treatment of patients with stages II and III rectal cancer (T3/4 and/or N positive) is 
surgical. However, contrarily to patients with stage I cancers, it is now widely accepted that 
combined modality therapy with radiation therapy (RT) with or without chemotherapy should 
be used in conjunction with surgery. Surgery should aim at the preservation of intestinal 
continuity and sphincter mechanism, and at the same time should maximize tumor control. 
Lesions in the upper third of the rectum are usually managed with a low anterior resection in 
much the same way as a sigmoid cancer. An adequate distal margin can be obtained for these 
lesions way above the sphincteric complex [Colquhoun and Wexner, 2002]. 
Lesions in the two distal thirds lie below the peritoneal reflection and are usually more difficult 
to manage surgically. This is related to the confines of the pelvic bones and also to the fact that 
depending on the size and location of the neoplasm, the sphincteric complex may be invaded and 
an adequate distal margin may not be achievable. Despite this, tumors of the middle third can 
usually be resected safely with a low anterior resection. For neoplasms of the distal third of the 
rectum, the surgical excision could be particularly challenging. Here the main concern is 
sphincter preservation, which is influenced by the extent of invasion of the lesion into the 
muscles of the sphincteric complex and also by the distance between the distal end of the lesion 
and the musculature of the anal canal. For these tumors, the classical surgical approach consisted 
of an APR. This type of resection, despite its association with a relatively low local recurrence 
rate, implicates a permanent colostomy with loss of the intestinal continuity and of the 
sphincteric function.  
In order to increase the number or sphincter-preserving operations performed, several authors 
cite the use of preoperative CRT as a mean to decrease the local recurrence rate [Ota et al, 
2002]. Such an approach would be able to reduce the need for APR to an incidence of 10% or 
less. When performing a sphincter-preserving operation, in order to preserve the lateral 
musculature and therefore a functional sphincter complex, the resection by necessity does not 
have a margin as wide as one performed during an APR. In order to improve the margin status, 
intersphincteric resections have been performed [Tiret et al, 2003]. This approach includes a 
partial sphincteric resection designed to improve margin status without sacrificing sphincter 
function. In small series, functional results have been comparable to less aggressive sphincter-
preserving operations. The impact on oncologic outcome is difficult to interpret and will require 
larger series.  
Not infrequently, large rectal tumors invade through the wall of the rectum and the mesorectal 
fat into contiguous structures. However, carefully selected patients with locally advanced or 
recurrent rectal cancers may benefit from an aggressive approach such as a total pelvic 
exenteration, since most recurrences remain limited to the pelvis [Mukherjee, 1999]. 
Despite a strong debate about the impact of total pelvic exenteration over survival, its potential 
benefits on controlling loco-regional disease and preventing significant morbidity from 
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recurrence (including pain, tenesmus, obstruction and fistula) keep this technique as an 
important tool in the surgical approach of large rectal tumors. 
 
5.1.1. Total Mesorectal Excision 
 
The goal of the resection of rectal cancer is to eradicate the neoplasm with an adequate margin 
and at the same time to resect the draining lymph nodes and lymphatics in order to satisfactorily 
stage the tumor and to decrease the risk of local recurrence and spread. 
During the later part of the past century, refinements of the surgical technique led to an 
improvement in survival, principally through a reduction in surgical morbidity; but the major 
problem facing surgeons who performed rectal resection was the subsequent development of 
local recurrence within the pelvis. When present, there was a 5-year survival lower than 5%. In 
fact, the series reported from 1940 to 1980 in the surgical literature report local recurrence 
rates from 10% to 49% [Philips et al, 1984; Pescatori et al, 1987]. The identification that the 
cause of local recurrence was the incomplete removal of the rectum and its draining lymphatics 
contained within the mesorectum was the key determinant in improving surgical outcome 
[Heald et al, 1982]. This, in parallel with the recognition of the pathologically assessed CRM, 
which have been shown to be more important than the distal mucosal margins with respect to 
the risk of local recurrence [Kuvshinoff et al, 2001; Willett, 2000], led to the dramatic fall in local 
recurrence rates that have been seen following the acceptance of the principle of TME [Heald et 
al, 1998]. The key feature of this surgical principle is the identification of the plane of cleavage 
along which surgical resection must be performed. This has become recognized as the “Holy 
Plane” (of Heald) [Heald, 1988]. The theory behind TME is that cancer spread will tend, at least 
initially, to remain within the embryological hindgut “envelope” – the mesorectum. The bowel 
remains separate from the other organs by a collagenous areolar tissue that surgically forms a 
“plane that can be cleaved at operation” and is almost entirely avascular. In performing a TME, it 
is the dissection along this perimesorectal avascular plane around the midline hindgut into the 
depths of the pelvis that led to an improvement in local recurrence rates [Heald, 1988]. This 
procedure has reduced local recurrence rates in rectal cancer from 39% to 10% and increased 
5-year-survival rates to 71% [Köckerling et al, 1998], becoming one of the most influential 
factors in rectal cancer outcomes and considered nowadays the standard of care for surgical 
practice [Nelson et al, 2001]. Moreover, Leite et al [2011] demonstrated that the outcome of 
surgical treatment of rectal cancer is related to the completeness of mesorectal excision, which 
is a more discriminative prognostic factor than the classic tumour-node-metastasis (TNM) 
system. 
The radiologist has an important role in providing the surgeon relevant information about the 
tumor location within the rectum, its depth of spread within the mesorectum, its relationship to 
the MRF, the surrounding organs and to the anal sphincter, and the presence of other adverse 
factors, such as involved lymph nodes or vessels. These data will further allow significant 
improvements in the planning of the surgery.  
The surgical consequences of TME may include erectile or bladder impairment due to disruption 
of sympathetic or parasympathetic nerves located in proximity of the mesorectum. Therefore, 
the procedure should be performed by an experienced surgeon in order to minimize morbidity 
[Mancini et al, 2000]. Several authors have now demonstrated the feasibility of laparoscopic TME 
in a safe manner [Zhou et al, 2003; Tsang et al, 2003; Morino et al, 2003], but there is no 
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adequate follow-up yet that can demonstrate whether there are oncologic advantages to such an 
approach.  
 
5.2. Neoadjuvant therapy 
 
Since the 5-year survival rates now are greater than 90% in stage T1-T2, N0 tumors, the 
addition of neoadjuvant treatment to surgery is usually reserved for patients with operable T3-4, 
N0-2 neoplasms as determined by imaging methods [Hawkes et al, 2011]. 
The advantages of such a pre-operative treatment strategy are pertinent and include the 
following: allowing downstaging of the primary tumor, thus increasing the likelihood of an R0 
resection and/or sphincter-preserving surgery; improving tumoral radiosensitivity by delivering 
radiation to better oxygenated tissues; offering early relief from tumor-related symptoms; and 
decreasing acute and chronic toxicity rates in comparison with postoperative CRT. 
A number of treatment regimens have been given to patients with rectal cancer. The most 
commonly used consist of RT (with or without combined chemotherapy) and chemotherapy. 
 
5.2.1. Radiation Therapy 
 
In Europe several large trials have evaluated a short preoperative course of RT followed by 
immediate surgery, indicating an important benefit of this regimen over surgery alone [Kapiteijn 
et al, 2001; Sebag-Montefiore et al, 2009; Swedish Rectal Cancer Trial, 1997].  
The advantages of neoadjuvant RT are thought to be due to improved responsiveness of tissue 
which has not already been rendered hypoxic by previous surgery. In theory, ionizing radiation is 
more effective in the irradiation of virgin tissue due to the increased oxygen tension in it [Julien 
and Thorson, 2010]. 
As a result, such a short course of preoperative RT has now become standard in many European 
institutions for some patients with rectal cancer. The SCRT protocol consists of a daily dose of 
5 Gy delivered during 5 days (to a total of 25 Gy) with surgery carried out during the following 
5–10 days [Julien and Thorson, 2010]. Nevertheless, this short course is insufficient for the more 
advanced tumors where downsizing is required, and these patients are normally submitted to a 
long course of combined CRT pre-operatively [Beets-Tan and Beets, 2011]. 
Neoadjuvant RT for rectal cancer was studied quite extensively. Initial randomized studies 
compared neoadjuvant RT followed by surgery to surgical therapy alone in order to determine 
whether there was a difference in the outcome of patients. Two landmark studies performed 
during this period included the Swedish Rectal Cancer Trial [Swedish Rectal Cancer Trial, 1997] 
and the Dutch Rectal Cancer Study Group [Kapiteijn et al, 2001]. Both demonstrated a decline 
in the local recurrence rates in the preoperative RT plus surgery groups in comparison to the 
surgery alone groups. In the Swedish Rectal Cancer Trial [1997] the local recurrence rate after 5 
years was 11% in the group receiving RT prior to surgery and 27% in the group treated with 
surgery alone (P < 0.001). The 5-year overall survival rate was 58% in the RT plus surgery group 
compared to 48% in the surgery-alone group (P < 0.004) [Swedish Rectal Cancer Trial, 1997]. 
The Dutch Rectal Cancer Study Group found a local recurrence rate of 2.4% in the RT plus 
surgery group and a rate of 8.2% in the surgery-only group (P<0.001) [Kapiteijn et al, 2001]. 
However, unlike the Swedish Trial, this study did not confirm a difference in the overall survival 
of both groups. Despite these discrepancies in overall survival, the data from both studies 
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consistently demonstrated that neoadjuvant RT is able to afford a significant reduction in local 
recurrence rates for stage II and III rectal cancers. 
Heterogeneous results have been found in over 20 randomized controlled trials (RCTs) 
comparing preoperative RT and surgery to surgical therapy alone. Three meta-analyses which 
have been conducted to better understand inconsistencies between these trials [Colorectal 
Cancer Collaborative Group, 2001; Figueredo et al, 2003; Cammà et al, 2000], concurred in the 
demonstration of a significant reduction in the local recurrence rate of stage II and III rectal 
cancers treated with RT prior to resection, whereas only two of the three studies found an 
improvement in overall survival. The meta-analysis by Cammà et al [2000] evaluated 14 RCTs to 
report a significant reduction in 5-year-overall-mortality rates, cancer-related mortality rates, 
and local recurrence rates. Another meta-analysis conducted by the Colorectal Cancer 
Collaborative Group [2001] analysed 22 RCTs comparing preoperative, postoperative, or no RT 
in rectal cancer. This study concluded that preoperative RT, at doses of 30 Gy, reduces the risk 
of local recurrence and death from rectal cancer. A third meta-analysis of RCTs by Figueredo et 
al. [2003] found local recurrence rates to be lower with preoperative RT but also concluded 
that a benefit on survival is achieved when postoperative chemotherapy is used in combination 
to preoperative RT. 
In summary, there is a clear association of pelvic RT with decreased local recurrence and a high, 
but somewhat lesser likelihood of improved survival. 
Despite these important benefits, the toxicity of pelvic RT for rectal cancer can be 
problematical. Although acute side effects and surgical complications are only marginally 
increased with the addition of preoperative RT to surgery [Marijnen et al, 2005], the impact of 
neoadjuvant SCRT on long-term toxicities has been established in large randomized trials. In the 
Dutch Colorectal Cancer Group study, irradiated patients experienced significantly higher rates 
of fecal incontinence (62% vs 38%, P < 0.001), including the need for incontinence pads, anal 
blood loss (11% vs 3%, P < 0.004) and mucous loss (27% vs 15%, P < 0.005), and increased bowel 
frequency when compared with those who underwent TME alone [Peeters et al, 2005]. The 
long-term follow-up from the Swedish Rectal Cancer Trial reported higher hospital admission 
rates in irradiated patients within the first 6 months (relative risk = 1.64; 95% confidence interval 
[CI], 1.21-2.22). No difference was seen in late admissions overall, but irradiated patients had an 
increased likelihood of being admitted for bowel obstruction (P = 0.02), abdominal pain (P = 
0.01), and nausea (P = 0.03) as late sequelae [Birgisson et al, 2005]. Sexual dysfunction is also a 
major issue as shown by the same Dutch group that evaluated 990 patients for quality of life and 
sexual function. The most notable deterioration was in the irradiated group in terms of sexual 
activity (males, P = 0.06; females, P = 0.01), and both erectile and ejaculatory problems were 
higher in irradiated males (P = 0.02) [Marijnen et al, 2005]. One should remember that these 
trials evaluated SCRT, which is generally given to patients with better prognosis tumors at a 
lower risk of recurrence, and, therefore, in whom the acceptability of late sequelae is lower. 
However, RT techniques are evolving rapidly, and there is the potential for more focused 
delivery, with increased sparing of normal tissue and reduced toxicity [Hawkes et al, 2011]. 
 
5.2.2. Combined Chemoradiation Therapy 
 
The clinical advantages of RT in locally advanced rectal cancer, combined with the evidence that 
adjuvant chemotherapy also improves survival, provided a solid rationale to study the 
combination of these therapies [Julien and Thorson, 2010]. Following a consensus statement of 
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the National Institutes of Health (NIH) in 1990, postoperative combined CRT became the 
standard of care for stage II–III rectal cancer in the US and many other countries [NIH 
Consensus Conference, 1990]. However, in 2004 a trial convincingly showed that CRT is better 
administered preoperatively than postoperatively (as it is more effective in producing tumor 
necrosis in the non-disturbed presurgical tumor bed and cancer cells of the tumor periphery 
compared to the hypoxic postsurgical bed), a fact that gave rise to a gradual change in practice 
[Sauer et al, 2004]. The combination of neoadjuvant chemotherapy and RT is now considered 
the standard of care in the treatment of locally advanced rectal cancer.  
Long-course CRT uses conventional fractionated RT (45–50 Gy) divided into 1.8 or 2.0 Gy over 
25–33 days concurrently with chemotherapy. Patients typically undergo surgery 4 to 8 weeks 
after CRT is given. 
The German Rectal Cancer Study Group [Sauer et al,2004] evaluated stage II and III rectal 
cancer treated with a combination of preoperative chemotherapy, RT, and TME versus TME 
combined with postoperative CRT. Preoperative therapy consisted of 50 Gy over 5 weeks with 
120-hr continuous intravenous infusion of 5-fluorouracil (5-FU) per day during the first and fifth 
weeks of RT. TME was performed 6 weeks after treatment. The chemotherapy and RT was 
identical in the postoperative group, except for the delivery of a 540 cGy boost to the tumor 
bed. No difference in 5-year survival rates were found between these two groups (76% and 74%, 
P = 0.80) [Sauer et al, 2004]. The study did find, however, a significant decrease in local 
recurrence rate in the preoperative treatment arm compared to the arm receiving CRT in the 
postoperative period (6% vs. 13%) (P = 0.006) [Sauer et al, 2004]. Findings in the group receiving 
preoperative CRT also included evidence of improved tumor downstaging, appreciated as earlier 
TNM stages (P < 0.001) and, obviously, more pathologic complete response (pCR) rates (8% vs. 
0%) (P < 0.001) [Sauer et al, 2004]. Other noteworthy results included the analogous rates of 
sphincter preservation and morbidity and mortality between these groups despite a superior 
number of distal tumors in the preoperative group (39 vs. 30 at <5 cm; P = 0.008) [Sauer et al, 
2004]. The study also found an improved treatment compliance in the preoperative group (92% 
vs. 50%) along with less acute serious toxic side effects (P = 0.001) and long-term toxic effects (P 
= 0.01) in the preoperative treatment group (27% vs. 40%) [Sauer et al, 2004]. These results 
clearly show that, although the primary outcome of overall survival was not different among 
these groups, there are a number of advantages of preoperative CRT over therapy given in the 
postoperative period in stage II and III rectal cancer. 
A more recent clinical trial found similar results in the assessment of preoperative CRT in 
patients with locally advanced rectal cancer. The Fédération Francophone de Cancérologie 
Digestive (FFCD) 9203 trial [Gérard et al, 2006] enrolled 733 patients with resectable T3 or T4, 
Nx, M0 rectal adenocarcinoma. Patients were randomly assigned to preoperative RT alone (45 
Gy in 25 fractions over 5 weeks), or preoperative RT (same protocol) plus concurrent 
chemotherapy, consisting of 5-FU and leucovorin during the first and fifth weeks of treatment. 
Neoadjuvant CRT resulted in increased pCR rates (11.4% vs. 3.6%, P < 0.05) and decreased 
rates of local recurrence (8.1% vs. 16.5%, P < 0.05) [Gérard et al, 2006]. However, this trial 
similarly did not find a difference in 5-year-survival rates between the two arms of the study. 
Similarly, multiple randomized trials have been unable to show a survival benefit with CRT 
compared to RT alone. Despite this, lower local recurrence rates with the addition of 
chemotherapy are consistently found. Furthermore, secondary outcomes in these trials have 
provided even more evidence of the advantages in using CRT in the preoperative setting as 
opposed to providing it postoperatively: improved rates of tumor downstaging, significantly 
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higher pCR rates, and enhanced treatment compliance rates in groups who received CRT before 
surgery [Bosset et al, 2006; Gérard et al, 2006; Sauer et al, 2004].  
Tumor downstaging has been reported to occur in approximately 60% of patients who undergo 
preoperative RT with concurrent continuous intravenous infusion 5-FU [Garcia-Aguilar et al, 
2003]. After mesorectal excision, the pCR rates are reported to be comprised between 10% and 
30% [Janjan et al, 1999; Brown et al, 2003]. 
 
5.2.3. Chemotherapy 
 
Despite the efficacy of postoperative chemotherapy, only 40% to 60% is administered at full 
dose, most commonly because of toxicity [Bosset et al, 2006; Rodel et al, 2007; Sauer et al, 
2004]. Thus, several phase II studies have incorporated chemotherapy into the preoperative 
management of high-risk patients.  
In a single-arm phase II study, Chau et al [2003] administered 12 weeks of 5-FU plus mitomycin 
C before CRT and postoperatively to 36 patients with locally advanced tumors (at least T3 
disease on digital rectal examination and imaging). The overall response rate to neoadjuvant 
chemotherapy was 27.8%, increasing to 81% after CRT, with 65% of patients experiencing 
improved symptoms during neoadjuvant chemotherapy. R0 resections were achieved in 28 of 34 
patients. Treatment was well tolerated, with 61% completing postoperative chemotherapy. 
The larger EXPERT trial [Chua et al, 2010] enrolled 105 eligible poor-risk patients (defined as at 
least one of CRM-positive, T3 low-lying tumor at or below the levators, extension >5 mm into 
perirectal fat, T4N0-2 or T1-4N2 tumor) to a similar design, replacing 5-FU and mitomycin C 
with capecitabine and oxaliplatin (CAPOX). Results showed considerably higher radiologic 
response rates with the neoadjuvant chemotherapy (74%) and CRT (89%). Ninety-three of 97 
patients had R0 resections with 21 patients achieving a pCR with evidence of downstaging in 76% 
of tumors. Seventy-eight of the 97 patients (80%) who underwent surgery completed 
postoperative chemotherapy. Eleven patients (10%) did not complete neoadjuvant chemotherapy 
because of toxicity, whereas 19% were unable to receive any adjuvant chemotherapy, mainly 
because of postoperative complications. 
The Grupo Cancer de Recto 3 study [Fernández-Martos et al, 2010] randomized 108 patients to 
receive induction CAPOX or adjuvant CAPOX in combination with CRT and surgery and 
reported that R0 resection, pCR, and tumor downstaging rates were similar in both arms. 
Tumor downstaging was lower than reported in the EXPERT study (58% in the induction arm vs. 
89% in the EXPERT study); however, this study incorporated a lower ratio of cT4 or CRM-
involved tumors than previous studies, and the RT dose was also slightly lower (50.4 vs 54 Gy). 
Nonetheless, these results still provide a strong argument for induction chemotherapy based on 
the toxicity profile. Only 2% of patients in the induction arm were unable to complete study 
treatment because of adverse events compared with 17% in the adjuvant arm, whereas rates of 
serious toxic effects were significantly more common in the adjuvant arm (19% induction arm vs. 
54% adjuvant arm, P = 0.0004).  
From these trials, it appears that the delivery of neoadjuvant chemotherapy is better tolerated 
than adjuvant treatment and may offer benefit over CRT alone; however, this approach needs 
evaluation in a phase III randomized controlled setting. 
Rationale for neoadjuvant chemotherapy without CRT includes the ability to begin anti-tumor 
therapy immediately, rather than delaying systemic therapy to administer local strategies and 
better surgical outcomes because of tumor downstaging. Omitting CRT would avoid important 
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RT-associated toxicities, such as infertility and loss of sexual function, preoperative fibrosis, and 
tissue friability. Chemotherapy also provides an opportunity for the early recognition of patients 
who will not benefit from standard protocols and may necessitate intensified regimens. The 
EXPERT trial showed promising downstaging and symptom improvement after CAPOX 
chemotherapy [Chua et al, 2010], suggesting that further evaluation of neoadjuvant 
chemotherapy alone is warranted. 
Serious long-term toxicity from chemotherapy is infrequent. There is a theoretical risk of 
secondary malignancies; however, studies relating to this did not take into account drugs used in 
modern regimens for rectal cancer. As such, the most problematical long-term side effect is 
peripheral neurotoxicity secondary to oxaliplatin. 
 
5.2.4. Monoclonal Antibody Therapy 
 
Blockade of both VEGF and EGFR with monoclonal antibodies has proven to be helpful in 
advanced colorectal cancer [Van Cutsem et al, 2009; Bokemeyer et al, 2009; Cunningham et al, 
2004; Van Cutsem et al, 2007; Jonker et al, 2007; Hurwitz et al, 2004]. Bevacizumab, a VEGF 
antibody, has been integrated into neoadjuvant CRT with variable toxicity and pCR rates (0% - 
32%), but reports so far are limited to small numbers and no solid conclusions concerning its 
additional benefit can presently be drawn [Willett et al, 2009; Crane et al, 2010; Resch et al, 
2010]. Two recent studies have added bevacizumab to neoadjuvant chemotherapy before CRT, 
again with small numbers. The Avacross single-arm study [Nogue et al, 2009] administered 4 
cycles of CAPOX plus bevacizumab before CRT with capecitabine plus bevacizumab in 47 MRI-
defined high risk patients with inclusion criteria similar to those of the EXPERT trial. Ninety-
three percent underwent surgery with 38.6% achieving a pCR (95% CI, 24.7-54.5). DiPetrillo et 
al [2008] combined bevacizumab with FOLFOX6 for 2 cycles before CRT (delivered with 
bevacizumab, oxaliplatin, and capecitabine) and surgery with 23 patients at the time of reporting. 
Five patients achieved a pCR, but toxicity was an issue during the CRT phase with 75% 
developing moderate to severe toxicity. 
A further study recruited 31 patients with FOLFOX plus bevacizumab followed by surgery 
[Schrag et al, 2010]. No pre-operative RT was given. A pCR rate of 27% was observed. 
The incorporation of anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, 
into the management of rectal cancer patients has been evaluated in a number of phase I and II 
studies because of their proven effectiveness in patients with advanced disease not harboring a 
Kirsten-RAS (K-RAS) gene mutation. Cetuximab is a known radiosensitizer, and its addition to 
neoadjuvant CRT is viable; still, in phase I and II studies of unselected populations to date, no 
improvements in clinical outcomes have been demonstrated [Machiels et al, 2007; McCollum et 
al, 2010]. 
The EXPERT-C phase II trial randomized patients to the EXPERT treatment regimen with our 
without cetuximab, delivering the antibody therapy during both the neoadjuvant chemotherapy 
and CRT treatment phases, rather than using it purely as a radiosensitizer [Dewdney et al, 
2011]. Between 2005 and 2008, 164 patients were recruited. Among those with K-RAS and B-
RAF wild type tumors, radiological response rates were significantly better with the addition of 
cetuximab to neoadjuvant chemotherapy (50% vs. 70%; P = 0.038) and CRT (72% vs. 89%; P = 
0.028). In addition, a significant improvement in overall survival was observed with the addition 
of cetuximab (HR: 0.27; P = 0.035). 
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5.3. Adjuvant Therapy 
 
Distant failure rates remain as high as 36% with neoadjuvant CRT alone, deeply contributing to 
the lack of survival benefit of this approach [Sauer et al, 2004]. Therefore, intensification of the 
systemic component of management is desirable, and chemotherapy without RT has been 
evaluated in the adjuvant setting. A number of studies have revealed a survival benefit with 
adjuvant chemotherapy [Fisher et al, 1988; Krook et al, 1991; Tepper et al, 2002; Wolmark et al, 
1993]. In a pooled analysis of 5 phase III trials, overall survival was significantly improved by 
adjuvant chemotherapy either alone, as part of a CRT regimen, or as maintenance in addition to 
CRT compared with surgery alone or surgery plus adjuvant RT (P < 0.0001) [Gunderson et al, 
2004]. 
The QUASAR (Quick and Simple and Reliable) trial of adjuvant fluorouracil (5-FU) plus folinic 
acid in stage II colorectal cancer included 948 patients with resected rectal cancer, 21% of whom 
received neoadjuvant RT [Quasar Collaborative Group, 2007]. Adjuvant chemotherapy provided 
a modest overall survival benefit for stage II colorectal cancer; in the subset analysis of rectal 
cancer patients who received neoadjuvant RT, chemotherapy significantly reduced the risk of 
recurrence (HR = 0.68; 95% CI, 0.48-0.96) but not death (HR=0.77; 95% CI, 0.55-1.08). 
The European Organization of Research and Treatment of Cancer (EORTC) Radiotherapy 
Group assessed the addition of 5-FU plus leukovorin to RT plus surgery in a 4-arm design, 
randomizing 1,011 patients to get either preoperative RT alone or CRT with or without 
postoperative chemotherapy [Bosset et al, 2006]. No difference was seen with the addition of 
preoperative chemotherapy to RT, and although there was a trend toward improved overall 
survival with postoperative chemotherapy, it did not reach statistical significance (5-year overall 
survival, 67.2% vs. 63.2%; P = 0.12). An exploratory subgroup analysis of those patients achieving 
an R0 resection showed that in the event of significant downstaging (ypT0-2 tumors) by 
preoperative treatment, adjuvant chemotherapy improved both disease-free survival (HR = 0.64; 
95% CI, 0.45-0.91; P = 0.013), and overall survival (HR=0.64; 95% CI, 0.42-0.96; P = 0.030). No 
benefit was seen in the population without downstaging [Collette et al, 2007]. 
Because of the modest benefit with single-agent chemotherapy, routine care has more recently 
incorporated combined fluoropyrimidine/oxaliplatin adjuvant chemotherapy for high-risk 
individuals, extrapolating data from the colon cancer adjuvant NSABP C07 [Wolmark et al, 
2008] and MOSAIC [Andre et al, 2004] studies.  
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Chapter II 
Imaging rectal cancer 
 
1. DIAGNOSIS  
 
The diagnosis of rectal cancer is usually achieved by means of digital examination and endoscopic 
methods which include biopsy samples of the lesion. Occasionally, though, imaging techniques 
such as barium enema (Figure II.1) or CTC may be responsible for the detection of neoplastic 
lesions in the rectum. 
 
 
Figure II.1. Double contrast enema demonstrates a narrowing of the upper third of the rectum, with irregular borders and 
shouldering (the classical ‘apple-core’ appearance), consistent with a rectal carcinoma. 
 
The double contrast enema is based on the instillation of a barium sulphate suspension and of its 
evacuation followed by inflation of air, with double contrast examination of the colon. A perfect 
colonic cleansing is a fundamental prerequisite, its inadequacy being one of the major causes of 
non-diagnostic examinations [Tinetti et al, 1989]. Indications for the procedure are the same as 
those for colonoscopy. Absolute contraindications for barium enema are: pregnancy; toxic 
megacolon; suspected colonic perforation; immediately preceding an endoscopic exam, especially 
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if with biopsy; acute diverticulitis or peritonitis; acute colonic obstruction; peritoneal fistulae, 
anatomical malformations (malrotation, hernia); and ischaemic colitis. 
The strong points of barium enema are represented by: (1) concomitant visualization of the 
whole length of the viscus; (2) stenotic portions do not constitute an obstacle; (3) it allows 
functional assessment of the bowel; (4) radiographs enable an objective documentation of the 
lesions. 
Technical limitations are for the most part due to fecal residues or artifacts (flocculation of 
barium, gas bullae) which may mimic true lesions such as inflammation, ulcerations or polyps. 
The most severe complication is undoubtly perforation, which in most cases involves the rectum 
and is associated to the air inflation, especially when balloon catheters in a diseased rectum are 
used. 
In a report from the literature, 15% of the lesions missed by rectal exploration and rectoscopy 
and were detected during a barium enema [Evers et al, 1981]. However it can be affirmed that 
both exams miss some lesions and that in the rectum the two methods show a similar sensitivity 
in the identification of neoplasms [Kelvin et al, 1981; Miller et al, 1978].  
As for CTC, it can similarly detect rectal lesions with ease, although some pitfalls have been 
reported [Mang et al, 2007]. 
The cross-sectional methods [CT and Magnetic Resonance Imaging (MRI)] are particularly useful 
for tumoral staging, but occasionally may permit detection of a rectal cancer. 
Primary rectal tumors on CT may appear as an intraluminal focal mass or a plaque thickening of 
the viscus wall. The normal thickness of the rectal wall is less than or equal to 3 mm [Becker et 
al, 1986]. Focal or diffuse thickening should categorically point toward a neoplastic disease when 
the wall is over 5–6 mm thick [Thoeni, 1989; Angelelli et al, 1990]. However, most lesions are 
over 2 cm [Becker et al, 1986]. The CT attenuation of the neoplastic tissue is about 40–60 
Hounsfield Units, usually slightly hypodense when compared to the normal wall (Figure II.2). 
 
 
Figure II.2. CT image of a patient with rectal cancer shows a slightly hypodense and heterogeneous asymmetric thickening of the 
left rectal wall. 
 
On MRI, carcinomas appear as wall lesions exhibiting a signal intensity which is somewhat higher 
than that of the muscularis propria on T2-weighted (w) images (Figure II.3a). High signal intensity 
of the tumor on T2-w images suggests the presence of mucinous carcinoma (Figure II.3b). 
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Figure II.3. Axial T2-weighted MR images of two patients with rectal cancer. On (a) the tumor shows an intermediate signal 
intensity, higher than that of the hypointense muscularis propria. On (b) the neoplasm is markedly hyperintense, which is 
consistent with a mucinous-type cancer. 
 
Diffusion-weighted (DW)-MRI is based on the dephasing effect by the Brownian motion of 
extracellular water molecules. At DW-MRI, high signal intensity (diffusion restriction) on high b 
value DW MR images reflects high cellular density which is suggestive of a malignant lesion 
(Figure II.4b). The apparent diffusion coefficient (ADC) is the quantitative parameter of diffusion 
in DW-MRI, with a low ADC value reflecting diffusion restriction in a viable tumor (Figure II.4c).  
 
 
Figure II.4. Axial MR images of a patient with rectal cancer. On T2-w image (a) the tumor shows intermediate signal intensity, 
higher than that of the hypointense muscularis propria. On DWI (b=1000s/m2, b) the neoplasm is markedly hyperintense, with 
diffusion restriction, which is confirmed by a low ADC on the ADC map (c). 
 
A recent study has shown the potential interest of high b value DW-MRI in detection of 
colorectal cancer [Hosonuma et al, 2006]. A report on the detectability of rectal cancer with 
T2-w imaging combined with DW imaging (DWI) (sensitivity, 93%–95%; specificity, 95%–100%; 
PPV, 97%–100%; NPV, 86%–91%) showed better detection of rectal cancer than with T2-w 
imaging alone (sensitivity, 82%–84%; specificity, 85%–90%; PPV, 92%–95%; NPV, 68%–72%) [Rao 
et al, 2008]. 
Positron Emission Tomography (PET)-CT is not recommended as the first choice examination 
for the initial diagnosis of rectal cancer, due to the low specificity (less than 50%) – resulting 
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from the high number of false-positive results secondary to bowel radiotracer uptake, 
inflammatory conditions, and/or radiotracer stasis during the elimination process – despite its 
high sensitivity that can exceed 95% [Delbeke and Walker, 2010]. 
 
2. LOCAL STAGING  
 
The prognosis of rectal cancer strongly depends on several factors that have routinely been 
assessed by histopathological examination. These factors comprise the depth of tumor invasion 
into and beyond the bowel wall [Harrison et al 1994; Willett et al 1999], the number of lymph 
nodes involved with tumor [Wolmark et al 1986; Tang et al 1995], extramural venous invasion 
(EMVI) [Talbot et al. 1980], involvement of the CRM [Adam et al 1994], and the presence of 
ulceration of the peritoneum by tumor [Shepherd et al. 1995]. Accurate preoperative 
assessment of these prognostic factors is a pivotal prerequisite for selecting patients for 
neoadjuvant therapy and planning surgical approach to optimize complete excision [Barrett, 
1998]. 
As such, in order to improve patient selection for individually tailored therapies, a trustworthy 
imaging modality that should be able to differentiate early-stage tumors from advanced tumors is 
warranted. A variety of examinations have been used for the preoperative evaluation of rectal 
cancer, including EUS, CT and MRI (Mathur et al, 2003). 
 
2.1. Mesorectal fascia status  
 
The main challenge for radiological staging today is to address accurately the relationship 
between the tumor and the MRF, which determines the status of the CRM, since the MRF 
corresponds to the dissection plane in TME surgery (Figure II.5).  
 
 
Figure II.5. Axial T2-weighted MR image clearly depicting the MRF, which appears as a hypointense linear structure (white arrows) 
encircling the mesorectal fat and the rectum. 
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Some authors suggest that CRM status, in combination with lymph node status, provides a 
better prognostic model than the existing TNM system [Nagtegaal et al, 2007; Gosens et al, 
2007; Leite et al, 2011]. A study of 686 patients undergoing TME showed that local recurrence 
was only 5% in those with a disease-free CRM as opposed to 22% if infiltrated [Schnall et al, 
1994]. Histopathology of resected specimens has revealed that the frequency of local recurrence 
significantly decreases when a tumor-free CRM greater than 1 mm can be obtained [Adam et al, 
1994; de Haas-Kock et al, 1996; Quirke et al, 1986]. 
It has been proved that MRI provides detailed and accurate information about CRM status 
[Brown et al, 2003a]. 
Beets-Tan et al [2001a] reported that the prediction of MRF involvement was addressed with 
excellent interobserver agreement, thus allowing an MRI disease-free distance of 5 and 6 mm to 
correspond to a histopathological disease-free margin of 1 and 2 mm, respectively. Another 
study in 43 patients not only confirmed a high accuracy (95%) for prediction of CRM status but 
in addition showed in cadavers that the thin linear structure seen on MRI indeed corresponds to 
the MRF [Bissett et al, 2001]. One study in 98 patients with rectal cancer showed 92% 
agreement between MR images and histological findings for prediction of the CRM [Brown et al, 
2003a].  
Since sometimes staging (particularly T staging and specifically the differentiation between some 
T2 and T3 tumors) will not appreciably affect or alter the overall preoperative or operative 
management of the patients, the clinically pertinent benefit of MRI is the assessment of the 
distance from the tumor to the MRF which will is strongly predictive of local recurrence [Wibe 
et al, 2002; Nagtegaal et al, 2002] (Figure II.6).  
 
 
Figure II.6. Axial T2-weighted MR images of two patients with rectal cancer, both staged as T3. On (a) the tumor extends beyond 
muscularis propria but does not reach the MRF (double arrows). On (b) the neoplasm is invading the MRF (thick arrow) and there 
are some tumoral deposits within the MRF itself (thin arrows). 
 
Despite the widely accepted efficiency of MRI in estimating the infiltration of the MRF by tumor, 
there is still some debate about the definition of MRI prediction of CRM involvement. Various 
earlier works have proved that tumor within 1 mm of the CRM on the resected specimen in 
rectal cancer surgery is a powerful predictor of local recurrence and poor survival [Quirke et al, 
1986; Birbeck et al, 2002; Cawthorn et al, 1990; Wibe et al, 2002; Nagtegaal et al, 2008; Adam 
et al, 1994]. However, there is no consensus about the MRI criteria for an involved margin: the 
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study by Beets-Tan showed a correlation between a measured MRI distance of more than 5 mm 
to the MRF and subsequent negative CRM on histopathology [Beets-Tan et al, 2001a], whereas 
the Mercury study demonstrated that histopathologically negative margins could be predicted 
using a 1-mm cut-off and additionally showed that this was reproducible across 11 different 
centres with 18 distinct radiologists [MERCURY Study Group, 2006]. These variations have led 
to differences in the selection criteria of patients for preoperative CRT.  
In a very recent study by Taylor et al. [2011], in which positive margin and local recurrence rates 
were compared for MRI distances from the tumor to the MRF of 1 mm or less, more than 1 mm 
up to 2 mm, more than 2 mm up to 5 mm, and more than 5 mm, the authors have reached the 
conclusion that a margin of 1 mm or less measured by MRI correlates accurately with 
pathological CRM involvement and poor outcome and thus constitutes the best cut-off distance 
for predicting CRM involvement using MRI. The use of a cut-off greater than 1 mm does not 
improve the accuracy of MRI in predicting CRM status, but would have resulted instead in 
substantial overtreatment that would achieve only minimal gain based on very low local 
recurrence rates observed following TME surgery. The rate of pathological CRM positivity was 
53% in the group with a margin of 1 mm or less defined by MRI, and fell to 7 – 8% when the 
tumor distance to the MRF was greater than 1 mm but no more than 5 mm. The 5-year local 
recurrence rate for patients classified as CRM-positive on MRI using a cut-off 1 mm or less was 
20%, compared with 4 – 8% in those with larger margins, giving a significantly worse hazard ratio. 
Nevertheless, CRM status is not the only factor involved in the prediction of local recurrence 
[Taylor et al, 2009] and it is well recognized that some patients develop local recurrence despite 
having an uninvolved margin [Wibe et al, 2002; Quirke et al, 2009; Merkel et al, 2001]. In this 
same study, up to 8% of patients developed a local recurrence despite possessing a free CRM. 
Wolberink et al [2007] reported in a retrospective study of 125 patients with and without a 
short course of RT on the value of conventional CT in predicting MRF invasion. The area under 
the curve (AUC) of the receiver-operator-characteristics (ROC) curve ranged between 0.697 
and 0.813, the sensitivity was just below 50%, and the majority of false negatives occurred in 
tumors located in the distal anterior rectum. Similarly, Vliegen and co-workers [2008a] evaluated 
the accuracy of multidetector (MD)-CT for the prediction of tumor invasion of the MRF, with 
MRI as reference standard. They found poor accuracy (54–66%), low AUCs (0.62–0.71) and high 
inconsistency among observers for the prediction of tumor invasion of the MRF. Evaluation of 
the staging accuracy of CT at different anatomical locations showed very poor AUCs (0.31–0.50) 
for low-anterior tumors, but the performance significantly improved for mid-high lateral-
posterior located rectal tumors (AUC: 0.84–0.88; P < 0.04).  
 
2.2. T Staging 
 
Preoperative T staging of a rectal tumor by imaging is a complex task. At present, there is no 
widely accepted protocol on the role of diagnostic imaging in the preoperative T staging of rectal 
cancer. 
Even if the present T-staging system is sometimes used for clinical decision making, it has its 
shortcomings, for it does not discriminate between tumors with a wide CRM and tumors with a 
close or involved CRM. Although most of these tumors are classified in the same stage (T3), 
they have a completely different risk for local recurrence. Moreover, it has been repeatedly 
shown that the distance from the tumor to the CRM is a more powerful predictor for the local 
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recurrence rate than is the T stage [Wibe et al, 2002; Nagtegaal et al, 2002; Quirke et al, 1986; 
Heald and Ryall, 1986].  
The successful introduction of MRI for pelvic diseases has, in recent years, led to the steady role 
of this imaging modality for local and regional staging of rectal cancer. Initial studies on MRI were 
performed with a body coil, but because conventional body coil techniques showed a resolution 
that was still unsatisfactory to distinguish between the different layers of the rectal wall, overall 
accuracies reported for MRI with a body coil were relatively low, with values varying from 59% 
to 88% [Hodgman et al, 1986; Cova et al, 1994; Zerhouni et al, 1996; Butch et al, 1986; Guinet 
et al, 1990; Okizuka et al, 1993; Starck et al, 1995]. The introduction of endoluminal coils 
improved image resolution and made a detailed evaluation of the layers of the rectal wall 
possible [Vogl et al, 1998]. This was also reflected in improved and more consistent T staging, 
with accuracy ranging between 71% and 91% [Gualdi et al, 2000; Maldjian et al, 2000; Chan et al, 
1991; Schnall et al, 1994; Indinnimeo et al, 1996; Zagoria et al, 1997; Pegios et al, 1996; Vogl et 
al, 1997]. Endorectal MRI can be very accurate for staging of superficial tumors, as shown in 
studies comparing it to endorectal ultrasound (EUS) [Gualdi et al, 2000; Maldjian et al, 2000; 
Zagoria et al, 1997]. However, some problems remain with endorectal MRI. Besides the limited 
availability and high cost, MRI with an endoluminal coil, especially when solely used, has a limited 
field of view. Like EUS, the MRF and surrounding pelvic structures are difficult to visualize owing 
to the sudden signal drop-off at a short distance from the coil [deSouza et al, 1996]. 
Furthermore, the positioning of an endoluminal device can be difficult or impossible in patients 
with high and/or stenosing tumors, and failed insertion rates of as high as 40% have been 
reported [Hunerbein et al, 2000]. 
The development of phased-array coils, gradients and pulse sequences obviated the need for 
endorectal coils with a predicted improvement in MRI performance [Beets-Tan et al, 1999; 
Beets-Tan et al, 2001b; Beets-Tan et al, 2001c; Brown et al, 1999; Blomqvist et al, 2000]. The 
advantages of high spatial resolution techniques with a large field of view make MRI with phased-
array coils appropriate for staging of both early-stage and advanced rectal tumors. An optimized 
MRI technique should include sagittal T2-w turbo spin-echo sequences through the pelvis to 
detect the tumor, and then high-resolution T2-w examinations perpendicular to the tumor’s 
long axis and in coronal plane, parallel to the tumor’s long axis. Axial T1-w images of the entire 
pelvis may be used for detecting lymphadenopathy. 
However, authors of the first studies on MRI with the multiple surface coil technique reported 
an overall accuracy for T staging of only 55%–65% and showed no benefit compared with the 
use of a body coil or even CT [Hadfield et al, 1997; de Lange et al, 1989]. The low performance 
of MRI in these studies could have been attributed to the low spatial resolution that was used 
with the early phased-array techniques. But even when a higher spatial resolution was applied 
with the new generation of phased-array coils, the accuracy for T staging was not as high as 
anticipated, with values varying between 65% and 86% [Blomqvist et al, 2000; Blomqvist et al, 
1997, Beets-Tan et al, 2001a; Gagliardi et al, 2002], and was not as reproducible as expected, 
with considerable interobserver variability [Beets-Tan et al, 2001a] (Figure II.7).  
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Figure II.7. Axial T2-weighted MR images of two patients with low rectal cancers staged as pT1 (a) and pT2 (b). The distinction 
between the two stages is virtually impossible by MRI with phased-array coils, as both tumors possess a similar appearance. 
However, MRI may suggest that these are both tumors limited to the rectal wall, as there is integrity of the hypointense muscular 
layer of the rectum. 
 
One exception to the above was the study by Brown and colleagues [1999], who reported 100% 
accuracy and complete agreement between two readers on the prediction of tumor stage with 
phased-array MRI.  
The use of an intravenous gadolinium-based contrast agent is not generally established as an 
adjunct to local staging of rectal cancer. Vliegen et al [2005] reported that the addition of 
gadolinium-enhanced T1-w MRI sequences to T2-w fast spin-echo sequences did not significantly 
improve the diagnostic accuracy for the assessment of tumor penetration through the rectal 
wall. Okizuka et al [1996] also found no improvement in T staging after adding a gadolinium-
enhanced fat-suppressed sequence to conventional T1- and T2-w images. 
Important MRI criteria relevant for the vast majority of rectal neoplasms are summarized in 
accordance with the findings of Brown et al [2003a] as follows: 
 
- Stage T1: low signal in the submucosal layer, replacement of the submucosal layer by 
abnormal signal not extending into the muscle coat 
- Stage T2: intermediate SI within muscularis propria 
- Stage T3: broad-based bulge or nodular projection or intermediate SI projecting beyond 
outer muscle coat 
- Stage T4: extension of abnormal signal into adjacent organ, extension of tumor signal 
through the peritoneal reflection 
 
Therefore, the outermost margin of the muscularis propria will remain intact with stage T2 
tumors or less (Figures II.7 and II.8).  
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Figure II.8. Sagittal (a) and axial (b) T2-weighted MR images of a patient with a stage pT2 rectal cancer, showing integrity of the 
hypointense muscular layer.  
 
Differentiation between T2 and T3 tumors may be difficult, however [Beets-Tan et al, 2001a; 
Brown et al, 1999]. In fact, most staging failures with MRI occur in the differentiation between 
T2-stage and borderline T3-stage lesions, with overstaging as the main cause of errors, often 
caused by desmoplastic reactions [Vogl et al,1997; Brown et al, 1999; Beets-Tan et al, 2001a; 
Meyenberger et al, 1995], since it is difficult to distinguish on MR images between spiculation in 
the perirectal fat caused by fibrosis alone (stage pT2) and spiculation caused by fibrosis that 
contains tumor cells (stage pT3) [Beets-Tan et al, 2001a]. Underestimation is generally 
attributable to microscopic invasion which is basically undetectable on MRI [Akasu et al, 2005] 
(Figure II.9). 
 
 
Figure II.9. Axial T2-weighted MR images of 2 patients with rectal cancers staged as pT2 (a) and borderline pT3 (b). A considerable 
similarity of the MR appearance of both tumors is noted, illustrating the difficulties of imaging in differentiating between tumors 
limited to the rectal wall (a) and tumors with microscopic invasion of the mesorectal fat (b). 
 
However, differentiating between minimal T3 infiltration and T2 lesions is probably of little 
consequence for patient management, as patients with minimal T3 infiltration into perirectal fat 
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are also at low risk of surgical failure from CRM involvement [Cawthorn et al, 1990; Chung et al, 
1983]. 
Conversely, the depth of tumor invasion is known to be an important prognostic factor in rectal 
carcinoma [Hermanek et al, 1995; Park et al, 1999]. The prognostic heterogeneity of these pT3 
rectal cancer patients has been recognized in a number of studies [Cawthorn et al, 1990; Krook 
et al, 1991; Willett et al, 1999]. In the Erlangen Registry of Colorectal Carcinomas (ERCRC) 
series, patients with rectal cancer invading beyond the border of the muscularis propria 5 mm or 
less (pT3a) had a more favorable prognosis than those with invasion greater than 5 mm (pT3b) 
when considering local recurrence and cancer-related survival. The local recurrence rate was 
10% for pT3a and 26% for pT3b. Statistically significant differences in cancer-related 5-year 
survival rates were found between pT3a and pT3b (85% vs. 54%). The analysis of the ERCRC 
data also confirmed that some lymph node-negative pT3 patients had results similar to pT2 
patients. For node-negative pT3 patients with less than or equal to 5 mm of invasion beyond the 
muscularis propria (pT3a) and for node-negative pT2 patients, the local recurrence rates were 
10% and 9%, with 5-year survival rates of 91% and 94%, respectively [Merkel et al, 2001]. 
Stage T4 tumors are diagnosed by depicting infiltration into an adjacent organ (Figure II.10).  
 
 
Figure II.10. Axial T2-weighted MR images of 3 patients with rectal cancers staged as T4. On (a) there is invasion of the prostate 
gland. On (b) the tumor is extending posteriorly, invading the sacral spine. On (c) there is invasion of the right seminal vesicle. 
 
Endorectal ultrasound is helpful in determining the depth of invasion of early-stage disease 
[Rifkin et al, 1989; Hunerbein, 2003]. The degree to which the tumors disrupt and penetrate the 
rectal wall layers suggests the local stage. T1 tumors do not penetrate the hypoechoic 
muscularis propria and the preservation of a bright sonographic layer medial to the muscularis 
represents an intact submucosa. T2 tumors penetrate the muscularis propria and so merge with 
it. T3 tumors extend beyond the muscularis propria and infiltrate the perirectal fat to a variable 
degree.  
EUS is nowadays the most accurate imaging method for the assessment of tumor ingrowth into 
rectal wall layers, with accuracies for T staging ranging between 69% and 97%, [Beynon et al, 
1986; Glaser et al, 1990; Katsura et al, 1992; Herzog et al, 1993; Hulsmans et al, 1994; Akasu et 
al, 1997; Milsom and Graffner, 1990; Lee et al, 1999; Garcia-Aguilar et al, 2002; Genna et al, 
2000; Gualdi et al, 2000; Kim et al, 1999; Massari et al, 1998; Sailer et al, 1997; Marone et al, 
2000; Maldjian et al, 2000; Akasu et al, 2000]. In a meta-analysis [Solomon and McLeod, 1993] of 
11 studies, sensitivity was shown to be affected by T stage. Despite being very accurate for 
staging of superficial rectal tumors, EUS is not as useful for staging advanced rectal cancers. A 
large study on the use of the technique in 1,184 patients with rectal tumors confirmed these 
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findings [Garcia-Aguilar et al, 2002]. The overall staging accuracy of 69% for EUS in that study 
was lower than previously reported values because the limited depth of acoustic penetration 
prevents accurate assessment of local tumor extent in bulky T3 and advanced rectal cancers. 
The discrepant results of that study may be attributable to the operator-dependent nature of US 
and the substantial interobserver variability, which was also reported in former studies on EUS 
[Garcia-Aguilar et al, 2002; Enck et al, 1997; Gold et al, 1999; Solomon et al, 1994]. Furthermore 
EUS cannot consistently visualize the MRF and thus cannot indicate whether the planned surgical 
CRM will be clear from tumor. Other limitation of EUS is the inability to pass the probe through 
large obstructing tumors. For all the above reasons, EUS has not been widely adopted as the 
preferred imaging modality for preoperative local staging of rectal cancer. 
Initial studies with conventional CT [Thoeni et al, 1981; Zaunbauer et al, 1981; van Waes et al, 
1983; Grabbe et al, 1983; Rotte et al, 1989; Hodgman et al, 1986] mainly focused on locally 
advanced rectal cancer, and high accuracies for T staging were reported to vary between 79% 
and 94%. However, later studies [Rifkin et al, 1989; Kim et al, 1999; Goldman et al, 1991; Cova 
et al, 1994; Shank et al, 1990; Zerhouni et al, 1996; Thoeni, 1997; Butch et al, 1986] that 
included less advanced tumors have shown accuracies that were not as high as anticipated 
previously, varying between 52% and 74%. In a meta-analysis of 78 studies conducted between 
1980 and 1998 in 4,897 patients with rectal cancer, CT showed an accuracy of 73% for T staging 
[Kwok et al, 2000]. The low spatial and contrast resolution of conventional CT does not permit 
a detailed evaluation of the rectal wall and may have contributed to the low performance of CT 
for staging superficial tumors.  
The more recent MD technology allows for multiplanar imaging, but there are limited 
prospective studies to address a newer role for CT in this respect [Filippone et al, 2004]. 
Theoretically, the new generation MD-CT scanners, providing superior spatial resolution and 
multiplanar capabilities, are expected to offer better performance than conventional CT 
scanners [Chiesura-Corona et al, 2001; Horton et al, 2000]. In a study on 105 rectal cancer 
patients who underwent spiral CT [Chiesura-Corona et al, 2001], a superior overall accuracy for 
T staging (82%) was reported, but only four T4 tumors were included in that report. Although 
spatial resolution has improved considerably with MD-CT, its main limitation remains the 
intrinsic low contrast resolution. 
When comparing MRI with CT, Blomqvist et al [1997] found superior performance for the 
former method in predicting bladder and uterine invasion. Beets-Tan et al [2000] compared 
phased-array MRI with CT in 26 patients with advanced or recurrent rectal cancer and found 
MRI to be far more accurate than CT in the assessment of organ invasion, pelvic wall invasion, 
and subtle bone marrow invasion. However, the large dissimilarity in outcome between the two 
modalities could be partly attributed to the fact that a state-of-the-art MRI technique was 
compared with conventional CT technique [Beets-Tan et al, 2000].  
Considering the detail of T staging, PET / PET-CT is not useful for T-staging purposes because of 
its relatively low spatial resolution of around 5 mm, and its poor anatomic resolution compared 
with EUS and MRI [Grassetto et al, 2011]. 
 
2.3. N staging 
 
The fact that nodal disease is a powerful prognostic indicator not only for distant metastases but 
also for local recurrence has been confirmed in the large Dutch TME trial, where patients with 
stage III (TxN1) disease had a 10-fold higher risk for local recurrence than did those with stage I 
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(T1–2N0 stage) disease and a threefold higher risk than did those with stage II (T3N0 stage) 
disease [Kapiteijn et al, 2001]. In addition, patients with stage N2 disease have a significantly 
higher risk of local recurrence compared with those with N0 or N1 disease [Moran et al, 1992].  
Evaluation of surgical specimens indicates that rectal cancer most frequently spreads to the 
lymph nodes located in the mesorectal fat, and, to a lesser degree, along the superior rectal 
artery [Dworak, 1991; Steup et al, 2002] irrespective of whether the tumor arises from the 
upper, middle or lower third of the rectum. Koh et al [2005] demonstrated that the majority of 
mesorectal nodes associated with rectal cancer were found at the level of the primary tumor. 
The likelihood of metastases was also found to increase with the T stage of the tumor, occurring 
in up to 50% of patients with stage-T4 disease [Hida et al. 1997a].  
Lateral tumor spread to pelvic sidewall nodes is a matter of some controversy. It has been 
suggested that pelvic sidewall nodal dissemination occurs in 10% to 25% of patients with rectal 
cancer [Hojo et al, 1982; Morikawa et al, 1994]. Lateral spread has been reported more often in 
patients with low rectal cancers [Hocht et al, 2002, 2004]. Involved nodes in the pelvic sidewall 
augment the risk of systemic dissemination [Ueno et al, 2001]. Not surprisingly, the 5-year 
survival in patients with pelvic sidewall lymph node metastasis is low (25–42%) [Ueno et al, 2001; 
Takahashi et al, 2000; Hida et al, 1997b]. Unlike mesorectal nodes, pelvic sidewall nodes are not 
routinely removed during TME surgery and extended lymphadenectomy may be required to 
achieve clearance of the tumor [Billingham, 1994; Suzuki et al, 1995]. 
When the treatment strategy is postoperative CRT for patients with N1 disease, there is little 
need to identify the lymph node status preoperatively. On the contrary, when the emphasis is on 
preoperative CRT and one wants to select patients at high risk, determination of lymph node 
status becomes vital. 
Only approximately 65% of mesorectal nodes found by histopathology can be identified on in vivo 
MRI, and despite non-visualization of a substantial proportion of small mesorectal nodes, the 
incidence of malignancy in them is low [Koh et al, 2006]. 
However, identification and characterization of nodal disease is still a diagnostic challenge for the 
radiologist, and N staging can be considered the ‘Achilles’ heel’ of rectal cancer imaging. 
Despite the identification of lymph nodes as small as 2–3 mm on high-spatial-resolution MR 
images, reliable detection of nodal metastases is presently not achievable. The evaluation of 
nodal involvement normally relies on morphologic criteria such as the size and shape of the 
node [Jager et al, 1996; Williams et al, 2001; Carrington, 1998]. The dilemma with morphologic 
imaging, however, is that with enlarged nodes it is difficult to discriminate between reactive and 
metastatic nodes, and with small nodes micrometastases are easily missed. An additional 
problem in rectal cancer, as compared with other pelvic tumors, is the elevated frequency of 
micrometastases in normal-sized nodes [Monig et al, 1999; Andreola et al; 1996, Bjelovic et al, 
1998; Dworak, 1989] (Figure II.11).  
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Figure II.11. Axial T2-weighted MR images of a patient with rectal cancer (a) depicting a small (< 5 mm), homogeneous and 
sharply-marginated mesorectal lymph node and H&E stain (b) of the same node, showing some microscopic islands of tumoral cells 
within it. 
 
There has been limited success in the application of size criteria to determine the absence or 
presence of nodal disease. This is chiefly due to the fact that mesorectal nodes, whether benign 
or malignant, tend to be small. In a study of 424 surgical rectal specimens containing 12,759 
nodes, the mean nodal diameter was 3.34 mm and the mean diameter of metastasis was 3.84 
mm [Dworak, 1991]. In addition, nodal hyperplasia was common, which resulted in benign nodal 
enlargement. In another pathological study of 698 lymph nodes [Monig et al, 1999], 70 of 132 
(53%) of nodes harboring metastases were < 5 mm in diameter. 
Moreover, there is no consensus on the size criterion for prediction of metastatic nodes. In the 
reports of MRI studies, criteria used were: any detectable node [Maier et al, 2000; Okizuka et al, 
1996; deLange et al, 1990], lymph nodes > 3mm [Vogl et al, 1997], lymph nodes > 5mm 
[Blomqvist et al, 1999; Gagliardi et al, 2002; Blomqvist et al, 2000; Thaler et al, 1994;], lymph 
nodes > 8mm [Kusunoki et al, 1994], and lymph nodes > 1 cm [Kim et al, 2000; Urban et al, 
2000]. A cutoff value of 10 mm yields high specificity but low sensitivity [Zerhouni et al, 1996], 
whereas the reverse is true if a cutoff of 3 mm is employed [Vogl et al, 1997]. The citations of 
long- or short-axis diameter were also unclear in most articles and the accuracy widely ranged 
(43–85%). 
In a meta-analysis of imaging studies used for staging rectal cancer, there were no significant 
differences among EUS, CT, and MRI in nodal staging [Bipat et al, 2004]. Many of these studies 
adopted size criteria of 5 mm in discriminating between malignant and benign nodes. 
Unsurprisingly, the application of a size criterion of 5 mm maximum short axis nodal diameter 
for discriminating between benign and malignant nodes has at best a moderate sensitivity and 
specificity for the detection of nodal metastases [Kim et al, 2000; Hadfield et al, 1997; Matsuoka 
et al, 2004]. EUS was found to have a sensitivity of 67% (95% CI: 60%–73%) and a specificity of 
78% (95% CI: 71%–84%). CT was found to have a sensitivity of 55% (95% CI: 43%–67%) and a 
specificity of 74% (95% CI: 67%–80%). MRI was found to have a sensitivity of 66% (95% CI: 54%–
76%) and a specificity of 76% (95% CI: 59%–87%). 
The borders and the signal characteristics of lymph nodes on high–spatial resolution T2-w MRI 
sequences were found to be more accurate than nodal size in discriminating between benign and 
malignant nodes [Brown et al, 2003b; Kim et al, 2004]. Metastatic nodes have irregular borders 
or display heterogeneous signal intensity on T2-w sequences (Figure II.12).  
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Figure II.12. Axial T2-weighted MR images of three patients with rectal cancer, showing large-sized metastatic mesorectal lymph 
nodes with irregular borders and heterogeneous signal intensities. In these situations, MRI can accurately assign them as metastatic. 
 
Irregular nodal outline related to partial or complete nodal replacement with tumor results in 
gross distortion, and extranodal extension in incompletely involved nodes leads to irregularity of 
the surrounding capsule, while signal heterogeneity reflects tumor foci within the involved node, 
likely to contain areas of necrosis or extracellular mucin. If either of these criteria was present, a 
sensitivity of 85% (95% CI: 74%–92%) and a specificity of 97% (95% CI: 95%–99%) was achieved 
for detecting nodal metastases in nodes ≥ 3 mm [Brown et al, 2003b]. 
In a study by Kim et al [2004], spiculated and indistinct nodal borders on T2-w images were 
found to have 45% and 36% sensitivity, respectively, but 100% specificity.  
The disparity in diagnostic accuracy when applying morphological criteria may be caused in part 
by difficulties and differences in interpreting nodal features. A normal node often has a low-
signal-intensity nodal capsule on T2-w images that appears different from the nodal center and 
should not be misinterpreted as nodal heterogeneous signal intensity. Furthermore, reactive 
nodal hyperplasia can cause heterogeneous signal intensity on T2-w images, leading to an 
incorrect judgement of whether the node is metastatic or not. False-negative findings may be 
seen in partially replaced lymph nodes, resulting in no noticeable changes in nodal contour or 
signal intensity characteristics. Metastatic foci measuring 1–2 mm within nodes are presently 
impossible to detect because they are beyond the spatial resolution of the current MRI 
technique [Koh et al, 2010]. 
Using EUS, nodes measuring 2 to 3 mm in size can be resolved within the mesorectum 
[Rafaelsen et al, 1992]. A few studies found that the internal nodal architecture on sonography 
can discriminate between benign and malignant nodes [Katsura et al, 1992; Hildebrandt et al, 
1990]. A key observation in EUS studies is that the internal texture of a node may correlate 
better with the presence of metastases than nodal size, and that inhomogeneity and hilar 
reflectivity are important discriminators of nodal status [Hildebrandt et al, 1990; Hildebrandt et 
al, 1995]. In fact, Katsura et al [1992] noted that the specificity of EUS could be improved if the 
echogenicity of a node was considered in addition to its size. Metastases were more common in 
nodes of mixed intranodal echogenicity than in those of uniform hyperechogenicity. However, 
other authors have found that it was impossible to discriminate between benign and malignant 
nodes based on nodal appearance [Rafaelsen et al, 1992]. 
Due to the lack of accuracy demonstrated by all the conventional imaging methods, ‘functional’ 
imaging has been gaining an increasing significance in the preoperative evaluation of mesorectal 
LN. 
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In this way, MRI with the administration of ultrasmall superparamagnetic iron oxide (USPIO) 
contrast agents has shown promising results for staging nodal metastases. These iron oxide 
particles are taken up by cells of the reticuloendothelial system of non-metastatic nodes [Mack 
et al, 2002; Weissleder et al, 1990; Tanoura et al, 1992; Guimaraes et al, 1994; Lee et al, 1991; 
McLachlan et al, 1994]. As it has been shown in prior studies, iron oxide deposition originates a 
decrease in the signal intensity in non-metastatic nodes due to the T2 shortening effects of iron, 
whereas metastatic nodes, devoid of macrophages, will not undergo signal intensity changes 
when using T2-w sequences [Weissleder et al, 1990]. Metastatic deposits appearing as white 
areas within the node as small as 2 mm could be identified in nodes deemed to be normal by 
both dimensional and morphological criteria [Koh et al, 2004]. 
A study by Lahaye et al [2008] demonstrated that an estimated area of white region within the 
node larger than 30% was highly predictive for a malignant node, with a sensitivity of 93% and a 
specificity of 96%. The larger the area of the white region, the more likely the node was 
metastatic. The white region in the lymph node was caused by no or very little uptake of USPIO 
in that malignant part of the node which is devoid of phagocytic capacity. Benign conditions such 
as focal nodal fibrosis, granulomatous disease, or fatty metaplasia, a feature that can be found in 
about 5% of nodes [Anzai et al, 1997; Van der Brekel et al, 1990] also can be depicted as a white 
region because of the lack of macrophages, thus mimicking malignant nodes. These white 
regions, however, usually do not occupy more that 30% of the nodal area [Lahaye et al, 2008]. 
A more recent study published by Koh et al [2010] could not replicate such high values of 
diagnostic accuracy: use of USPIO resulted in an average sensitivity of 65% (95% CI, 35–88%); 
specificity, 93% (87–96%); positive predictive value, 43% (21–67%); and negative predictive value, 
97% (92–99%). Nevertheless, these authors used a range of patterns of contrast enhancement in 
order to discriminate between malignant and non-malignant lymph nodes, thus potentially 
introducing a certain level of subjectivity and creating a potential source of erroneous 
interpretation. However, this study also showed that USPIO-enhanced MRI had significantly 
higher (P < 0.01) diagnostic specificity than morphological MRI criteria alone [Koh et al, 2010]. 
Improvement in specificity could be due to a better classification of benign reactive lymph nodes. 
However, the lack of substantial improvement in sensitivity might be related to partially replaced 
and small involved mesorectal nodes which are beyond the resolution of the current imaging 
techniques to confidently detect small metastatic foci. In this way, the technique may be of value 
in identifying patients with node-negative disease who are being considered for local excision 
surgery. 
A recent work by a Dutch group [Lambregts et al, 2011a] evaluated the value of a gadolinium-
based contrast medium (gadofosveset) in the characterization of mesorectal lymph nodes in 
patients with rectal cancer. The authors showed that gadofosveset-enhanced MRI improved the 
diagnostic performance for nodal staging compared with standard MRI, attributed to both better 
detection and characterization of lymph nodes. Even though the exact mechanism is still 
unknown, it was proved that normal or reactive lymph nodes demonstrated gadofosveset 
uptake, inducing a strong increase in signal intensity which was comparable to that of 
neighboring blood vessels [Herborn et al, 2002; Lahaye et al, 2009a]. Due to this local increase 
in signal intensity, a ring-shaped artifact surrounding the lymph node was accentuated, creating 
the visual impression of a relief effect or “relief sign”. In metastatic nodes, where tumor replaces 
normal lymphoid tissue, there was no gadofosveset uptake. 
Therefore, in malignant nodes, dark areas corresponded to tumoral deposits. The “relief sign” 
was absent when the whole node was involved. These criteria—signal enhancement and nodal 
relief—were highly advantageous for a more accurate distinction between benign and malignant 
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lymph nodes. The high negative predictive value of more than 95% on a per lesion and more 
than 85% on a per patient basis for gadofosveset-enhanced MRI was equivalent to that of 
previous reports with USPIO [Lahaye et al, 2008; Koh et al, 2004; Will et al, 2006; Lahaye et al, 
2009b]. The PPV was also in the same range as with USPIO: 70% to 80%. 
DWI has not yet been shown to be valuable in characterizing lymph nodes in patients with rectal 
cancer. Although high b-value DWI is sensitive for detecting the location of lymph nodes, its 
characterization value is unproven in cancer, with necrotic neoplastic nodes yielding false-
negative results and reactive hyperplastic nodes causing false-positive cases [Figueiras et al, 
2010].  
A recent study published in a surgery journal [Mizukami et al, 2011] examined patients with 
rectal cancer for nodal staging using DWI + conventional (T1-w and T2-w) MRI and CT. Results 
showed a clear benefit of MRI over CT: the overall patient-based sensitivity, specificity, PPV, 
NPV and accuracy of DWI + conventional MRI were 93, 81, 81, 93, and 87%, respectively, while 
corresponding values for CT were 73, 79, 74, 77, and 76%, respectively. The overall node-based 
sensitivity, specificity, PPV, NPV, and accuracy of DWI + conventional MRI were 97, 81, 52, 99, 
and 84%, respectively, whereas corresponding values for CT were 86, 80, 48, 96, and 81%, 
respectively. However, it is unclear from the study design which were the criteria used by the 
authors to differentiate normal from metastatic nodes, since these were considered to be soft 
tissue nodules with high signal intensity that were detected on DWI with their existence 
confirmed on T1-w and T2-w conventional MRI. It remains to be explained whether the signal 
intensity of normal nodes on DWI was different, since non-metastatic nodes are generally very 
cellular and may also cause restricted diffusivity.  
Furthermore, despite the higher accuracy of MRI in this study, it remains to be known the real 
benefit, if any, of DWI (isolated or in combination with conventional sequences) over 
conventional MRI alone. 
Although PET has substantially altered the landscape of oncologic practice in the last few years, it 
is unlikely that it can contribute to the visualization and characterization of mesorectal nodes. 
First, these are typically small and may be beyond the spatial resolution of the technique. Second, 
mesorectal nodes are most frequently found at the level of the tumor, and the avid metabolic 
uptake of the radioactive tracer within the primary lesion obscures visualization of the adjacent 
nodes. However, PET and PET-CT imaging could play a potential role in identifying lateral spread 
to nodes along the internal iliac chain [Koh et al, 2006]. 
 
2.4. Extramural venous invasion  
 
Even in patients undergoing careful TME, venous invasion remains an important independent 
prognostic factor [Heald and Ryall, 1986; Bokey et al, 1999]. Extramural venous invasion (EMVI) 
is associated with higher risk of local recurrence [Rich et al,1983], distant metastases [Gunther 
et al, 2002; Krasna et al, 1988; Ouchi et al, 1996; Horn et al, 1991] and death [Harrison et al, 
1994; Krasna et al, 1988; Ouchi et al, 1996; Chapuis et al, 1985; Newland et al, 1994]. The 
presence of EMVI on a pre-operative MRI scan is associated with a four-fold higher risk of 
distant metastasis (52% vs. 12%), and a drop in relapse-free survival at 3 years to only 35% vs. 
74% for patients with no EMVI [Newland et al, 1994].  
By definition, histologically defined EMVI has to be associated with tumors that are at least stage 
T3. 
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The typical appearances on MRI, which is the only imaging modality that has been shown to 
consistently demonstrate EMVI in rectal cancer [Brown et al, 2003a], include the following four 
components: 
 
- Pattern of tumor margin 
- Location of tumor relative to major vessels 
- Caliber of vessel 
- Vessel border 
 
The tumor margin may appear nodular or smooth. Tumor invasion into the small non 
characterizable veins that radiate outward from the bowel wall creates a nodular border. This 
finding can be differentiated from desmoplasia, which normally appears as fine stranding. 
Whenever a tumor is seen close to a vessel, the possibility of EMVI should be considered. The 
presence of tumoral signal intensity within a vascular structure is highly suggestive of EMVI. As a 
tumor invades along the lumen, the vessel expands, and the tumor may eventually expand 
through and beyond the vessel wall, disrupting the border, which can be described either as 
irregular or nodular [Smith et al, 2008] (Figure II.13). 
 
 
Figure II.13. Axial T2-weighted MR images of three patients with rectal cancer. There is tumoral signal intensity within vascular 
structures, associated with expansion of the vessel lumen (white arrows). In (b), the tumor margin appears nodular, as there is 
invasion into the small veins that radiate outward from the rectal wall. 
 
The sensitivity and specificity of MRI for detecting EMVI has been reported to be around 62% 
and 88% respectively [Smith et al, 2008]. Some patients with microscopic vascular invasion could 
not be resolved on MRI, while others with very obvious EMVI on the pre-operative images had 
false-negative histopathology due to obliteration of normal venous architecture which makes it 
difficult for the pathologist to recognize that a certain tumor deposit lies within the course of a 
vessel, which may be more readily appreciated on serial MR images. 
 
2.5. Peritoneal involvement 
 
In rectal cancer, peritoneal involvement predicts for local recurrence [Smith and Brown, 2007]. 
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The typical appearance on MRI is one of a nodular extension of intermediate signal intensity 
through the fine low-signal-intensity peritoneal reflection at or above the level of its attachment 
to the anterior surface of the rectum, best demonstrated on axial images (Figure II.14). 
 
 
Figure II.14. Axial T2-weighted MR image of a patient with rectal cancer, displaying a nodular extension of intermediate signal 
intensity (thick arrow) through the fine low-signal-intensity peritoneal reflection (thin arrows) above the level of its attachment to 
the anterior surface of the rectum. 
 
Although cases of peritoneal perforation were undoubtedly identified using preoperative MRI, 
many cases will be missed by MRI due to failure to resolve microscopic infiltration of peritoneal 
lined clefts [Smith and Brown, 2007]. 
The accuracy of MRI in correctly identifying peritoneal involvement at this site is therefore less 
reliable than detection of other prognostic factors [Brown and Daniels, 2005]. However, 
knowledge of the relationship of the tumor to the peritoneal reflection anteriorly should prompt 
a careful search for subtle peritoneal infiltration. 
 
3. ASSESSMENT OF THERAPY RESPONSE  
 
The objective of neoadjuvant therapy is to downstage and downsize the tumor in order to 
improve resectability and achieve better local control [Sauer et al, 2004; Reerink et al, 2003]. 
Tumor downstaging may lead to complete clinical response or pCR (pT0N0M0). These 
situations may occur in 10% to 30% of patients treated by neoadjuvant CRT and may be referred 
as stage 0 disease [Grann et al, 1997; Habr-Gama et al, 1998; Hiotis et al, 2002; Janjan et al, 
1999; Luna-Perez et al, 2001; Medich et al, 2001]. 
 
3.1. MRF clearance 
 
MRF involvement may be even more important in the post-neoadjuvant therapy setting than in 
the primary evaluation of rectal cancers. In advanced tumors with a positive margin on 
preoperative imaging, the prognosis is better if the margin becomes free after treatment. In 
Chapter II     Page 55 
contrast, if the margin remains positive, the prognosis is worse than in cases without 
neoadjuvant therapy, because the remaining tumor consists of a selected population of tumor 
cells which are resistant to therapy [Nagtegaal and Quirke, 2008] (Figure II.15). 
 
 
Figure II.15. Axial T2-weighted MR images of two patients with rectal cancer before CRT (a, c) and after completion of CRT (b, d). 
Before CRT, both lesions show an intimate contact with the MRF. However, after completion of CRT, despite the presence of 
downsizing for both lesions, on (b), a fat pad between the outer border of the tumor and the MRF develops, whereas on (d), 
there are still signs of MRF invasion. Both are ypT3tumors, but the prognosis is significantly better for the former, as the MRF 
became unthreatened after CRT. 
 
Vliegen et al [2008b] reported an AUC for post-CRT MRI for assessing MRF/CRM invasion on 
the basis of morphologic criteria alone of 0.81 and 0.82 and a high sensitivity and NPV (both 
100%) for two observers. However, their results showed only a moderate specificity (32% and 
59%) and PPV (57% and 68%). The main challenge of post-CRT MRI in the judgment of 
MRF/CRM tumor invasion is the assessment of diffuse hypointense “fibrotic” tissue in the initial 
tumor area, which was seen in more than 50% of patients in whom this fibrotic tissue at MRI 
showed tumor infiltration at histological examination. Residual tumor within these fibrotic areas 
is often restricted to small tumor nests that are beyond the resolution threshold of MRI 
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[Dworak et al, 1997; Beets-Tan et al, 2000]. It is therefore virtually impossible based on 
morphological criteria alone to differentiate these from completely tumor-free areas of fibrosis. 
Despite the problems of MRI in the interpretation of post-RT fibrosis, the same authors proved 
that the presence of diffuse iso or hyperintense tissue infiltration of the MRF on MRI was 
associated with tumor invasion at histological examination in 90% of the quadrants in which this 
pattern was seen [Vliegen et al, 2008b]. 
Recently, a Korean group [Park et al, 2011] evaluated the added value of DWI in combination 
with T2-w MRI compared with T2-w imaging alone for predicting tumor clearance of the MRF 
after neoadjuvant CRT in patients with locally advanced rectal cancer. The study included 45 
patients and key results showed that the diagnostic performance regarding prediction of tumor 
clearance of the MRF for two observers improved significantly after additional review of DW 
images: AUC improved from 0.770 to 0.918 (P = 0.017) for observer 1 and from 0.847 to 0.960 
for observer 2 (P = 0.026). Diagnostic accuracy (observer 1, P < 0.001; observer 2, P = 0.022), 
sensitivity (observer 1, P < 0.001; observer 2, P = 0.002), and NPV (observer 1, P = 0.013; 
observer 2, P = 0.025) were significantly higher when both DW and T2-w images were evaluated 
than when T2-w images alone were reviewed for both observers. Most overstaged cases on T2-
w images (82%) were attributed to iso- or hyperintense masses abutting the MRF, corresponding 
to inflammation, fibrosis, or abundant mucin components at histological examination. 
Understaging of tumor clearance was due to microscopic tumor cell infiltration into the MRF 
despite fat pads larger than 2 mm between the area of viable tumor signal intensity and the MRF 
at MRI.  
Tumor invasion within the MRF appears hyperintense at DWI and hypointense on ADC maps 
because of the diffusion restriction of the motion of protons. Therefore, these DWI features can 
help differentiate neoplastic from non-neoplastic lesions such as radiation-induced fibrosis and 
inflammation within the MRF, thus potentially improving the overall diagnostic accuracy of the 
prediction of MRF clearance after CRT in patients with rectal cancer. When DW images are 
used in combination with T2-w images, these serve as an anatomic reference for tumor location, 
which in turn leads to a more accurate assessment of the distance between viable tumor and the 
MRF, in spite of the comparatively low spatial resolution of DW images alone. 
 
3.2. T and N downstaging 
 
After CRT, Allen et al [2007] found that tumor downstaging occurred in 17% of cases, while 
nodal downstaging occurred in 68% of the patients. 
The reported overall accuracy of MRI in assessing the pathologic stage of irradiated rectal cancer 
is 47%–54% (50%) for T staging and 64%–68% (65%) for N staging [Kuo et al, 2005; Chen et al, 
2005; Vliegen et al, 2008b; Allen et al, 2007].  
The relatively low accuracy of MRI in predicting the pathologic stage of irradiated rectal cancer 
seems to be associated to both overstaging and understaging. The major MRI finding that causes 
overstaging is diffuse hypointense tissue infiltration into the mesorectal fat. This is related to two 
histopathologic phenomena: marked fibrosis of the bowel wall and peritumoral infiltration with 
inflammatory cells and vascular proliferation (desmoplastic reaction). Most of the inaccuracy is 
associated with overstaging of pathologic stage T1 and T2 tumors [Kuo et al 2005; Chen et al, 
2005; Valentini et al, 1998]. Also, radiation proctitis or ulceration can sometimes cause 
overstaging, so it is important to carefully compare post-CRT images with the pre-CRT images. 
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The most important cause of understaging is nonvisualization of the tumor mass on MRI. 
Changes in the rectum after CRT—such as histopathological alterations in the tumor, 
replacement by fibrotic scar tissue, and an island of residual adenocarcinoma—can make it 
difficult to identify viable tumor on MR images [Kuo et al, 2005, Chen et al, 2005, Valentini et al, 
1998].  
Understaging with MRI after CRT is not a problem in cases where curative surgery is to be 
performed; however, it is a dilemma when a change in the surgical strategy is considered for 
some patients, especially those experiencing a complete tumor response. 
In patients in whom CRT has led to downstaging of tumors to lesions confined to the rectal wall 
(ypT0–2 tumors) and in whom there are no longer involved lymph nodes (ypN0 lesions), local 
transanal full-thickness excision of the bowel wall may be sufficient to achieve cure. Thus, the 
major challenge for the radiologist is to be able to recognize those tumors that, after CRT, are 
most appropriate for local excision – tumors confined to the rectal wall (Figure II.16).  
 
 
Figure II.16. Axial T2-weighted MR images of a patient with rectal cancer before CRT (a) and after completion of CRT (b). The 
reappearance of an intact hypointense muscular layer after CRT is indicative of a tumor limited to the rectal wall (ypT2). 
 
In this regard, a previous study [Dresen et al, 2009] included 67 patients who underwent 
radiation therapy with concomitant chemotherapy and surgery. Results showed a PPV for 
prediction of tumor confined to rectal wall (ypT0–2) ranging from 86% to 91% on the basis of 
morphological criteria alone. The visualization of an intact hypointense bowel wall on T2-w MR 
images was highly predictive of a tumor limited to the bowel wall, explaining the high PPV.  
However, when this appearance of the rectal wall could not be delineated, as for example when 
it has thickened owing to RT, fibrosis was suggested. The interpretation of fibrosis with or 
without residual tumor on MR images remains a challenge, also reported by other authors [Allen 
et al, 2007; Chen et al, 2005; Kuo et al, 2005; Hoffmann et al, 2002; Kahn et al, 1997; Kim et al, 
2005; Maretto et al, 2007; Muthusamy and Chang, 2007]. Because of the presence of fibrosis, 
many ypT2 tumors were overstaged, and this factor was the cause of a low NPV as well as of a 
low sensitivity (which ranged from 25% to 42%) (Figure II.17).  
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Figure II.17. Axial T2-weighted MR images of two patients with rectal cancer after CRT. Both demonstrate hypointense areas 
corresponding to fibrosis, as well as irregular borders with thin spiculations extending to the mesorectal fat. MRI cannot 
differentiate between purely fibrotic spiculations in a tumor confined to the rectal wall (a, ypT2) and spiculations containing 
microscopic foci of tumor (b, ypT3). As a result, many lesions similar to (a) are overstaged. 
 
In the same study, the authors showed that ypT0–2 tumors had significantly smaller volumes 
than did ypT3–4 tumors before radiation therapy with concomitant chemotherapy (55 vs. 92 
cm3, P = 0.038). Volume reduction rates were significantly higher in ypT0–2 than in ypT3–4 
tumors (89% vs. 61%, P < 0.001). If volume before CRT was 50 cm3 or smaller and volume 
reduction rate was 75% or higher, the excised tumor was shown to be always confined to rectal 
wall (ypT0–2). By using these criteria, 43% of overstaged cases could have been correctly 
assigned as tumors confined to the bowel wall. Furthermore, when combined with 
morphological criteria, the PPV was very high (94%). While these tumors might be treated less 
extensively, in tumors with a volume reduction of less than one-third, the whole initial tumor 
area should be resected with standard TME, and, when necessary, the surrounding organs should 
be resected as well, because all these tumors remained as T3–4 tumors [Dresen et al, 2009]. 
After CRT, erradication of tumor in involved lymph nodes also occurs, with a reported decline 
in the rate of tumors with malignant lymph nodes found at histopathologic evaluation from 40% 
before CRT to 25% after it [Govindarajan et al, 2006; Reerink et al, 2003; Lehnert et al, 2002; 
Sauer et al, 2004]. Although a good response in the primary tumor generally is accepted to 
correspond with a good response in the lymph nodes, there are some conflicting findings, with 
reported rates of involved nodes ranging from 1.7% to 17% in patients with a complete response 
of the primary tumor [Hughes et al, 2006; Coco et al, 2007]. Only few reports on the accuracy 
of MRI to detect lymph node disease after CRT on a patient-by-patient basis have been 
published, with accuracy rates of 65%–88% and sensitivity and specificity varying from 33% to 
82% and from 68% to 95%, respectively [Chen et al, 2005; Maretto et al, 2007; Suppiah et al, 
2009; Koh et al, 2008]. 
In a study evaluating 201 histologically-matched lymph nodes, Lahaye et al [2009b] found that 
conventional T2-w MR images yielded an AUC for the short- and long-axis diameters of the 
nodes of 0.87 and 0.88 for observer 1 and 0.89 and 0.87 for observer 2, respectively. The 
optimal cutoff value of the short-axis diameter was 3.3 mm, with corresponding sensitivity and 
specificity for the detection of malignant nodes of 85% and 78%, respectively. The optimal cutoff 
value of the long-axis diameter was 4.8 mm, with corresponding sensitivity and specificity for the 
detection of malignant nodes of 82% and 82%, respectively [Lahaye et al, 2009b]. 
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In a recent report, Lambregts et al [2011a] found an AUC of 88% for nodal characterization 
after CRT using standard MRI. A possible explanation for the good nodal staging results on MRI 
after CRT is that many irradiated nodes disappear, and of the remaining small nodes over 80% 
are sterilized [Koh et al, 2008]. Nodes that remain large after CRT are thus more likely to be 
malignant (Figure II.18).  
 
 
Figure II.18. Axial T2-weighted MR image of a patient with rectal cancer after CRT, displaying a large and slightly heterogeneous 
lymph node (white arrow). Histology of the surgical specimen confirmed its metastatic nature.  
 
This allows a more reliable assessment of the nodal status on restaging MRI based on 
morphological criteria only [Lambregts et al, 2011a]. 
There are a number of observations that could explain the better performance of size criteria 
after CRT than in the primary staging setting. Small nodes often originate interpretation 
difficulties on standard T2-w fast spin-echo images, and after CRT, the number of lymph nodes 
harvested during histopathological evaluation drops by about 30% [Koh et al, 2008; Habr-Gama 
et al, 2008]. This could lead to fewer interpretation errors in small nodes, improving the 
accuracy. In addition, usually the lymph nodes that are still malignant after CRT are initially the 
larger nodes and small malignant nodes on primary staging often are benign after CRT [Lahaye et 
al, 2009b].  
Regarding other imaging methods, in reports on nodal restaging with EUS and CT after CRT, 
investigators reached only moderate accuracy values of 0.61 and 0.62, respectively, which are 
comparable to those of primary nodal staging [Maretto et al, 2007]. 
Lahaye et al [2008] assessed the usefulness of USPIO-enhanced MRI for nodal restaging after 
CRT. They found that tumoral nodes that show no uptake of nanoparticles before CRT regain 
their capability for uptake of the USPIO contrast agent when the tumor is eradicated. This 
finding suggests that tumor cells are replaced by normal lymphoid tissue with macrophages, 
which are responsible for the uptake of nanoparticles of iron oxide [Harisinghani et al, 2002]. 
On a node-by-node analysis, USPIO-enhanced MRI yielded an AUC for the prediction of the 
nodal status of 0.99 for observer 1 and 0.98 for observer 2 on 3D T2*-w images. On a patient-
by-patient basis, the sensitivity of USPIO-enhanced MR imaging for detection of malignant lymph 
nodes after CRT is close to 90%, with a specificity of 80% [Lahaye et al, 2008]. 
Lambregts et al [2011a] demonstrated a gain in accuracy in restaging lymph nodes with 
gadofosveset-enhanced MRI: the per lesion AUC improved from 0.88 on standard MRI to 0.94 
on gadofosveset-MRI for reader 1 (P = 0.01) and from 0.87 to 0.95 for reader 2 (P = 0.04). On a 
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patient basis AUC changed from 0.75 to 0.79 for reader 1 (P = 0.54) and from 0.73 to 0.86 for 
reader 2 (P =0.06). 
Recently, the same group published their work on the use of DWI-MRI in restaging mesorectal 
lymph nodes after CRT [Lambregts et al, 2011b]. Signal intensities did not differ between benign 
and metastatic nodes and rendered an AUC of 0.64 (95% CI 0.53–0.75) for reader 1 and 0.52 
(95% CI 0.40–0.64) for reader 2. The AUC for detection of metastatic nodes was 0.66 using 
ADC values. The optimal ADC threshold was 1.25 x10−3 mm2/s, resulting in a sensitivity of 53%, 
specificity 82%, PPV 35% and NPV 91%.  
The predicted probability for the combined assessment of T2w-MRI + ADC rendered an AUC 
of 0.91 for reader 1 and 0.96 for reader 2, which resulted in a sensitivity of 56%, specificity 98%, 
PPV 83% and NPV 92% for reader 1. These values were 56%, 99%, 95% and 93% for reader 2. 
The diagnostic performance when using ADC only was significantly lower than for T2w-MRI (P = 
0.02 and P = 0.0003 for readers 1 and 2, respectively) and T2w-MRI + ADC combined (P = 
0.001 and P < 0.0001). There was no significant difference in diagnostic performance between 
T2w-MRI and the combination of T2w + ADC (P = 0.17 and P = 0.26). ADC combined with 
standard T2w-MRI improved the diagnostic performance, however without accomplishing a 
significant improvement compared with T2w-MRI alone. 
Again, these results suggest that after CRT, T2w-MRI alone is already satisfactory for nodal 
evaluation, reaching an AUC of 0.88–0.95. Such good results have also been reported by other 
groups, with high NPVs ranging between 81% and 100%, indicating that a restaging MRI after 
CRT can reliably recognize the ypN0 patients [Lahaye et al, 2009b; Suppiah et al, 2009]. 
Apparently, morphological criteria (size, shape and border) work better in a restaging setting. 
Many small (2–5 mm) nodes disappear after CRT, while up to 50% of these nodes initially 
harbored metastases [Dworak, 1989; Wang et al, 2005]. Interestingly, although it did not 
improve the overall performance, the addition of ADC to standard T2w-MRI did improve the 
PPV from 60–61% to 83–95%, thus reducing overstaging errors. The foremost advantage from 
the addition of DWI in this study was the higher number of detected nodes compared with 
conventional T2w-MRI. On DWI, high signal intensity nodes were more straightforwardly 
detected against the suppressed background signal of the neighboring tissues. DWI can thus be 
used to immediately focus a radiologist’s eye on the presence of nodes and their location. When 
radiologists will become able to provide an imaging tool for the selection of patients with truly 
sterilized nodes, patients with a small tumor remnant limited to the rectal wall (ypT1-2N0) may 
be safely stratified for local excision, while patients with a complete response (ypT0N0) could be 
included in a wait-and-see policy with deferral from surgery [Lezoche et al, 2008; Borschitz et al, 
2008; Habr-Gama et al, 2006]. 
Studies comparing the appearance on EUS and histopathology have shown that this imaging 
technique cannot reliably differentiate between fibrosis and tumor [Rau et al, 1999; Gavioli et al, 
2000] and, hence, the degree of downstaging. In a study of 84 patients with locally advanced 
rectal cancer, EUS was performed 4 - 6 weeks after the completion of CRT [Rau et al, 1999]. 
The T stage was correctly determined in 15 of the 51 responders (29%) and in 27 of 33 non-
responders (82%), whereas misinterpretation occurred in 36 of the responders (71%) and in 6 of 
the non-responders (18%) (P < 0.001). The distance of the tumor from the anal verge and tumor 
location on EUS did not correlate with the staging accuracy. Lymph node involvement was 
correctly assessed in 48 patients (57%) [Rau et al, 1999]. These findings supported previous data 
which showed an accuracy of only 47% in determining T stage [Napoleon et al, 1991]. 
Post-CRT EUS cannot visualize the MRF or the peritoneum and therefore is unable to determine 
their status. Therefore, EUS is not recommended for the assessment of patients after CRT or 
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RT because its sensitivity and specificity for the reassessment of the primary tumor are too 
unreliable [Evans et al, 2011]. 
Regarding PET, Calvo and colleagues [2004] showed a correlation of tumor downstaging with 
standard uptake value (SUV). In this study, tumors that were downstaged had a post-CRT 
maximum SUV of 1.9, compared with nondownstaged lesions that had a SUV of 3.3 (P = 0.03). 
Similarly, another study proved that all downstaged and downsized tumors showed a post-
treatment low SUV ( < 2.5 ) [Di Fabio et al, 2005]. Post-CRT SUV alone might be better than 
mean SUV reduction as a prognostic indicator [Oku et al, 2002]. 
Studies on the use of PET in restaging rectal cancer after CRT focused principally on the 
accuracy to detect complete responders or to evaluate the response, and data on the prediction 
of nodal status are scarce. In the prediction of the nodal status in primary rectal cancer, PET 
performs poorly, with a sensitivity of 21%–29%, and it is not presumed to perform much better 
after CRT [Abdel-Nabi et al, 1998; Llamas-Elvira et al, 2007], since in this setting the foci of 
tumor in malignant nodes are expected to be even smaller than in untreated rectal cancer, and 
the detection of small volumes of tumor is a well-known limitation of PET. 
 
3.3. Complete response  
 
The introduction of preoperative, rather than postoperative, CRT has led to a decline in local 
recurrence rates and has become standard of care for patients with locally advanced rectal 
cancer [Sauer et al, 2004].  
If CRT is chosen for a patient with locally advanced rectal cancer, the patient is usually scheduled 
for an operation after completion of it. In 10–24% of patients, no residual tumor is found at 
histology after surgery [Maas et al, 2010]. 
These complete responders are known to have a very good prognosis, in terms of both overall 
and disease-free survival [Maas et al, 2010]. A complete response also raises the hotly debated 
and still controversial question of whether surgery is still necessary for these patients, 
particularly because TME may have associated morbidity and even mortality and has the 
potential risk of a permanent colostomy. Recently, a more conservative treatment was 
advocated in patients who showed a good or complete response to neoadjuvant treatment: in 
2006, Habr-Gama et al [2006] presented the long-term results of a prospective trial that 
investigated a ‘‘wait-and-see’’ policy in a carefully selected group of patients with clinical and 
radiological evidence of a complete response after neoadjuvant CRT. Results at 5-year follow-up 
were favorable for the nonsurgical group, with an overall and disease-free survival of 93% and 
85%, respectively [Habr-Gama et al, 2006].  
However, in order to securely suggest such a deferral from surgery, it is essential to select 
accurately the correct candidates – the true complete responders.  
The role of imaging for restaging after CRT has been the subject of a number of studies and all 
suggest that neither MRI nor EUS or PET are sufficiently accurate for identifying the true 
complete responders, with positive predictive values ranging from 17–50% [Janssen et al, 2010; 
Capirci et al, 2004; Kristiansen et al, 2008; Suppiah et al, 2009; Kim et al, 2009; Vanagunas et al, 
2004]. 
In fact, when MRI is performed 4–6 weeks after the completion of preoperative CRT for locally 
advanced rectal cancer, it is seldom normal, even in patients who will demonstrate a pCR at 
surgery. Rather, in the majority of patients with an optimal response at MRI, a scar - represented 
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by a focal area of low-signal intensity on T2-w MR images - replaces the site of disease (Figure 
II.19).  
 
 
Figure II.19. Axial T2-weighted MR images of a patient with rectal cancer before CRT (a) and 8 weeks after completion of CRT (b). 
Before treatment there is a tumoral thickening extending over 50% of the rectal circumference. After CRT, the tumor has turned 
fully hypointense, which indicates a scar (white arrow). 
 
The precise cellular composition of such an area of low signal intensity cannot be known, and a 
single MRI scan may not be able to diagnose complete response. In fact, the major component of 
error on MRI is overstaging due to its limited capability to allow differentiation between viable 
tumor, residual fibrotic non-tumor tissue, and desmoplastic reaction. [Kuo et al, 2005; Chen et 
al, 2005; Valentini et al, 1998] (Figure II.20). 
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Figure II.20. Axial T2-weighted MR images of two patients with rectal cancer before CRT (a, c) and after completion of CRT (b, d). 
After CRT, both tumors suffer downsizing and become partially hypointense, with a very similar appearance. Morphological imaging 
cannot differentiate a complete response with only a fibrotic scar (b, ypT0), from fibrosis with viable tumor remnants within it (d, 
ypT3).  
 
However, if surgery is deferred, then the scar can be followed with serial MRI examinations to 
monitor any change. 
Due to the limitations of purely morphological MR images, recent attention has been directed 
toward DWI-MRI as a complement to standard morphological MRI for detection of complete 
responders, because on DWI viable tumor remnants are recognized as hyperintense foci 
compared with the low signal intensity of the surrounding nonneoplastic background tissue [Kim 
et al, 2009; Lambregts et al, 2011c] (Figure II.21).  
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Figure II.21. Axial T2-weighted MR images of a patient with rectal cancer before CRT (a, b, c) and after completion of CRT (d, e, 
g) and axial high b-value DW images after CRT (f, h). Before treatment the tumor contacts the MRF and there are several large 
and heterogeneous lymph nodes in the mesorectum. After CRT, the tumor suffers downsizing and becomes mostly hypointense, 
corresponding to fibrosis, which precise composition could not be determined on purely morphological images. DWI clearly depicts 
hyperintense areas (of diffusion restriction), corresponding to zones where there are still viable tumor remnants. Additionally, a 
large lymph node, which was proved to be metastatic, remains after CRT (e), showing also diffusion restriction (f).  
 
Kim et al [2009] showed in a study including 40 patients that DWI in addition to standard MRI 
significantly improved the performance of radiologists to select complete responders compared 
with standard MRI only. 
A recent study by Lambregts et al [2011c], indicated that the diagnostic performance for 
predicting a pCR after CRT improved for the combination of standard MRI + DWI (AUC 0.78–
0.8) compared with standard MRI only (AUC 0.58–0.76). Moreover, it resulted in a substantial 
decrease in the number of equivocal scores and an improved interobserver agreement. 
The superior sensitivity for the combination of MRI + DWI resulted in less overestimation of 
residual tumor in patients with a pCR. This was true mainly because on the restaging MRI 
without DWI many interpretation difficulties were observed when the primary tumor bed had 
become ‘fibrotic’ as a result of the neoadjuvant treatment. In these cases, as mentioned 
previously, it becomes hard to differentiate small areas of residual tumor from simple fibrosis 
and readers tend to overestimate the presence of tumor [Barbaro et al, 2009; Kuo et al, 2005; 
Dresen et al; 2009, Jonas and Bahr, 2006]. In this particular setting, the functional information 
from DWI might be valuable: areas of fibrosis typically have low cellular density, which results in 
low signal intensity on high b-value diffusion images [Vandecaveye et al, 2007]. On the other 
hand, areas of residual tumor have a relatively high cellular density and show high signal on DWI, 
which is easily recognizable within the low signal of the surrounding tissue/fibrosis, thus allowing 
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a better depiction of small areas of residual tumor on DWI [Kim et al, 2009; Vandecaveye et al, 
2007]. 
Specificity for MRI and DWI is > 90%, indicating that residual tumor is accurately detected and 
the risk for undertreatment will be < 10%. Although DWI allows detection of even small tumor 
volumes, the detection of microscopically small clusters of residual tumor cells, which are 
difficult to detect—even at histology— and are currently beyond the detection threshold of any 
available imaging modality (including DWI) will remain the major challenge for imaging. 
Studies on the use of PET in restaging rectal cancer after CRT focusing on the accuracy to 
detect complete responders yielded a sensitivity to detect a pCR (in both the primary tumor and 
the lymph nodes) of 45%, with a specificity of 79% [Capirci et al, 2004; Kristiansen et al, 2008]. 
These results derive, at least partially, from the fact that initially following the completion of 
CRT, an increased tracer uptake may be caused by inflammatory changes and not always 
associated with residual tumor [Haberkorn et al, 1991; Engenhart et al, 1992; Moore et al, 
2003]. 
 
3.4. Prediction of therapy response before and during CRT 
 
One of the most remarkable findings associated with the use of DWI in patients with cancer has 
been that ADC measurements appear to be predictive of tumor response to CRT. 
Studies in rectal cancer have shown that tumors with low baseline pre-treatment ADC values 
responded better to chemotherapy or RT than neoplasms that exhibited high pre-treatment 
ADC values [DeVries et al. 2003; Dzik-Jurasz et al. 2002]. Sun and co-investigators [2010] 
observed that the mean pre-CRT ADC value (1.07±0.13×10−3 mm2/s) in the group of tumors 
that showed T-downstaging (17 out of 37 patients) was lower than that (1.19±0.15×10−3 mm2/s) 
in the T-non-downstaged group (P = 0.013). One possible explanation is that tumors with high 
pre-treatment ADC values are likely to exibit more necrotic areas than those with low values 
[Koh and Collins, 2007]. Necrotic tumors are frequently hypoxic, acidic, and poorly perfused, 
which leads to reduced sensitivity to chemotherapy and RT.  
However, other studies have failed to replicate those results. Kim and collaborators [2011] 
could not reliably discriminate pCR from non-pCR based on the pre-CRT ADC, and Heo and 
co-authors [2010] also reported that the pre-CRT ADC value was not significantly correlated 
with TRG after the analysis of 39 patients.  
These differences may be attributable, at least partially, to the distinct definitions of response: 
some authors used the tumor size (50% reduction) as a criterion [Dzik-Jurasz et al, 2002], while 
others predefined responders as the T-downstaged group [Sun et al, 2010] and others 
considered pCR as the endpoint for response [Kim et al, 2011].  
A recent study by Sun et al [2010] showed that at the end of the 1st week of CRT, the mean 
tumor ADC increased significantly from 1.07x 10- 3 mm2 /s to 1.32 x 10-3 mm2 /s (F = 37.63, P < 
0.001) in the downstaged group, but there was no significant ADC increase in the non-
downstaged group (F = 1.18, P = 0.291). It is believed that increases in ADC are a consequence 
of cellular damage leading to necrosis [Chenevert et al, 1997; Thoeny et al, 2005]. Another 
reason for the increase in ADC seen within 1 week is tumor edema caused by the massive 
release of VEGF within hours of even the first fraction of RT. That would lead to increased 
vascular permeability and increased interstitial volume, which would in turn increase ADC [Sun 
et al, 2010]. The mean percentage of tumor ADC change in the downstaged group was 
significantly higher than that in the non-downstaged group at each time point (F = 18.39, P < 
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0.001). This phenomenon may be explained by a higher degree of cellular necrosis achieved with 
CRT in the downstaged group than in the non-downstaged group. So, the difference of increase 
of the ADC after the beginning of CRT reflected mainly the different sensitivity of the tumor 
cells to CRT in the two groups [Sun et al, 2010]. In this way, these authors suggest that early 
temporal changes in ADC and pre-therapy ADC can potentially discriminate patients with locally 
advanced rectal cancers that are resistant to pre-operative CRT, which may allow a prompt 
modification of the treatment protocols [Sun et al, 2010]. 
Dynamic contrast-enhanced (DCE)-MRI studies have been performed most commonly for 
evaluating the effects of novel therapies such as antiangiogenic agents that affect blood vessels, 
usually in the setting of clinical drug trials [Morgan et al, 2003].  
Signal enhancement seen on T1-w DCE-MRI sequences can be assessed semiquantitatively by 
analyzing signal intensity changes or quantitatively by pharmacokinetic modeling of contrast agent 
concentration changes. 
The most commonly used model for analyzing DCE-MRI data uses two compartments where the 
contrast agent resides (blood plasma and extravascular–extracellular space). The volume transfer 
constant between the blood plasma and the extravascular–extracellular space, the wash-in rate 
(Ktrans, measured in minutes−1) and the rate constant between the extravascular–extracellular 
space back to the blood plasma, the wash-out rate (kep, measured in minutes
−1) determine the 
transport between these two compartments [Figueiras et al, 2010]. 
Physiologically, Ktrans indicates a variable combination of the flow and permeability properties 
[Sessa et al, 2008]. For blood vessels where leakage is rapid (that is, when the extraction fraction 
during the first pass of the contrast agent is high, as typically is found in tumors), perfusion will 
determine contrast agent distribution and Ktrans approximates to tissue blood flow per unit 
volume. There are circumstances in which transport out of the vasculature does not significantly 
deplete intravascular contrast medium concentration (that is, tissues with lower first-pass 
extraction fraction). This is typically found after treatment with chemotherapy or late after RT 
and in fibrotic lesions, and in these situations, Ktrans approximates to the product of permeability 
and the surface area (permeability surface area product) [Figueiras et al, 2010]. 
There has been some work evaluating response to CRT of primary rectal cancer. Tumors with 
higher Ktrans values at presentation appear to respond better to CRT than those with lower 
values. After CRT, Ktrans values in general are lower, with persistent high values indicating 
residual active disease [George et al, 2001]. 
PET has also been used to predict response to CRT. For example, Cascini et al [2006] described 
a group of 33 patients with locally advanced rectal cancer submitted to neoadjuvant CRT, in 
whom PET could predict pathologic response to preoperative treatment. All patients had PET at 
baseline and 12 days after starting chemoradiotherapy (interim PET). For all examinations, the 
percentage decrease in SUV mean and max was correlated with pathologic response classified as 
TRG. The study reports that interim PET is strictly correlated with final pathologic response, 
with better results compared with presurgical scan. In particular, ROC analysis showed that the 
decrease in SUV mean correctly distinguished responders from nonresponders with an accuracy 
of 100%, whereas the decrease in SUV max yielded an accuracy of 97%.  
Janssen et al [2010] prospectively evaluated 30 patients referred for preoperative CRT who 
underwent sequential PET-CT imaging at four time points: prior to therapy, at day 8 and 15 
during CRT, and shortly before surgery. Tumor metabolic treatment responses were correlated 
with the pathological responses by evaluation of the TRG and the pathological ypT stage of the 
resected specimen. They showed that the response index (RI) for the SUV max on day 15 was 
the best predictive factor for the pathological response (AUC = 0.87) compared to the RI on 
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day 8 (AUC = 0.78) or the RI of presurgical PET imaging (AUC = 0.66). A cutoff value of 43% for 
the reduction of SUV max resulted in a sensitivity of 77% and a specificity of 93%. As such, an 
accurate PET-based prediction of the pathological treatment response is feasible already after 2 
weeks of CRT. This could help to select patients to be considered for less invasive surgical 
interventions or even a deferral from surgery. Similarly, early modifications of the treatment 
protocol are possible, which might result in an improved clinical outcome. 
 
4. DETECTION OF RECURRENT DISEASE 
 
Eighty percent of patients with colorectal cancer present with local disease amenable to surgery 
with curative intent [Jessup et al, 1997]. Of these, around 40% will develop recurrent cancer, 
mainly within the first 3 years after treatment [Abir et al, 2006; Arriola et al, 2006; Desch et al, 
2005; Kraemer et al, 2001].  
Pelvic recurrence remains a significant dilemma with rectal cancer, occurring in 3% to 47% of 
patients [Abulafi and Williams, 1994; Sagar and Pemberton, 1996; Titu et al, 2006].  
Relapse after initial surgery of CRC is responsible not only for significant morbidity and 
mortality, but also for impaired quality of life [Beets-Tan and Beets, 2004; Camilleri-Brennan and 
Steele, 2001; Miller, 1998]. Only between 20% and 30% of patients with local relapse detected 
during follow-up have tumors that are deemed to be resectable at the time of diagnosis 
[Goldberg et al, 1998]. Aggressive surgical approaches for colorectal cancer recurrence confined 
to a single organ are associated with a 5-year survival rate of up to 30% in selected patient 
populations [Abir et al, 2006; Arriola et al, 2006; Huguier et al, 2001; Titu et al, 2006]. 
Local recurrence is defined as clinical, radiologic, and/or pathologic determination of rectal 
cancer recurrence in the prior pelvic treatment field [Guillem et al, 2005]. Local relapse can be 
further divided into extraluminal recurrence (in which tumor regrowth occurs in and around the 
tumor bed, including the perirectal fat and the lymph nodes) and intramural recurrence (in which 
the tumor regrowth involves the region of the bowel anastomosis) [Abulafi and Williams, 1994]. 
The majority of local recurrences originate within the tumor bed, which emphasizes the 
importance of visualization of the perirectal tissues as part of postoperative follow-up [Titu et al, 
2006]. To augment the likelihood of cure it is therefore fundamental to diagnose local 
recurrences when still in an early stage. To guide salvage surgery, an anatomically correct 
description of the location and extent of relapse is essential. 
In general, diagnostic imaging for postoperative surveillance of rectal cancer should have the 
potential to differentiate between scar and extraluminal recurrence, as well as to identify 
anastomotic recurrence. In addition to CEA monitoring and endoscopy, CT, MRI, and PET are 
used as diagnostic imaging modalities for the detection of local relapse of rectal cancer. 
Nevertheless, the role of diagnostic imaging for routine follow-up of rectal cancer patients 
remains controversial because no single strategy for postoperative surveillance has been 
unequivocally shown to improve survival or cure rate [Guillem et al, 2005; Giordano et al, 2006; 
Longo and Johnson, 2002]. Moreover, the alteration of the pelvic anatomy associated with 
previous surgery and CRT remains a diagnostic challenge for all imaging strategies in detecting 
recurrence. 
As such, it is still unclear whether imaging is beneficial during the surveillance of patients after 
rectal cancer surgery [Desch et al, 2005; Schaefer et al, 2007; Glimelius et al, 2010, Titu et al, 
2006] and trials to establish the role of imaging are ongoing. However, if during follow-up a 
patient is suspected of having a local recurrence based on clinical symptoms and/or rising CEA 
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levels, CT is usually the imaging investigation to be performed in order to confirm or rule out 
the presence of a local or distant relapse [Desch et al, 2005; Schaefer et al, 2007; Valentini et al, 
2009]. A pelvic mass that enlarges on consecutive post-operative CT studies is highly suspicious 
for a local recurrence, although the diagnosis is not always easy to make [Takeuchi et al, 1999; 
Flamen et al, 1999]. 
However, few data exist elucidating the role of MD-CT for staging recurrent rectal cancer 
[Stueckle et al, 2005; Stueckle et al, 2006]. In a study with 83 patients, the sensitivity and 
specificity of MD-CT for diagnosing pelvic recurrence in the second postoperative examination 
was 82% and 97%, respectively, if multiplanar reconstructions were routinely performed 
[Stueckle et al, 2005].  
On the contrary, a study by Blomqvist et al [1996] in which twenty-five patients were enrolled, 
showed that MRI was the most effective imaging modality, with an accuracy of 87.5% compared 
with CT, which correctly diagnosed recurrent cancer in 76%. In another comparative study, 
Pema et al [1994] analyzed the importance of CT and MRI in diagnosing recurrent rectal cancer. 
Eighteen patients were included in this small study: MRI was the superior imaging method with a 
sensitivity of 91%, a specificity of 100%, and an overall accuracy of 95%, while CT reached values 
of 82%, 50%, and 68%, respectively. 
Sometimes the CT findings are equivocal and in those cases PET / PET-CT have proven 
beneficial in identifying local tumor re-growth [Flamen et al, 1999; Even-Sapir et al, 2004]. PET 
may help detecting pelvic recurrence in rectal cancer patients [Akhurst and Larson, 1999], with 
reported accuracies ranging from 74% to 96% [Schaefer and Langer, 2007]. In a retrospective 
study, Moore et al [2003] investigated the impact of PET for the detection of pelvic recurrence 
of 60 previously irradiated rectal cancer patients. This imaging technique correctly identified 16 
of the 19 documented recurrences, with a sensitivity, specificity, overall accuracy, PPV, and NPV 
of 84%, 88%, 87%, 76% and 92%, respectively. Even-Sapir et al [2004] assessed the role of PET-
CT in the detection of local recurrence of rectal cancer. Sixty-two patients underwent PET-CT 
examination, which was found to be more sensitive and specific than PET alone. PET-CT 
correctly depicted 23 of the 24 pelvic recurrences, and allowed to differentiate benign lesions 
from pre-sacral recurrences with a sensitivity of 100% and a specificity of 96%, despite a 
histological diagnosis being possible in only 30 of 81 analyzed lesions.  
Unfortunately, PET still has some limitations. The detectability of tumor depends on tumor size 
and FDG uptake [Fukunaga et al, 2004], and as such PET cannot recognize small volume disease 
due to its well known limitation in spatial resolution of around 4 – 6 mm [von Schulthess et al, 
2006]. PET has demonstrated low sensitivity for lymph node staging in rectal cancer [von 
Schulthess et al, 2006]. Mucinous adenocarcinomas display poor radiotracer uptake [Kamel et al, 
2004]. Radiation-induced inflammation in the first 12 months after RT reduces specificity, 
whereas sensitivity is limited in patients receiving chemotherapy because tumor tissue might not 
be metabolically active [Moore et al, 2003]. Additionally, physiological uptake in other pelvic 
organs (bladder, small bowel loops, seminal vesicles, and uterus) is associated with false-positive 
interpretations [Even-Sapir et al, 2004]. Due to problems with costs and availability, some 
authors suggest that PET imaging should be reserved for patients with increasing CEA levels and 
an otherwise normal diagnostic work-up [Abir et al, 2006]. 
As mentioned above in some studies comparing it to CT in this setting, MRI has proven to be 
helpful for assessing the resectability of a diagnosed local recurrence of rectal cancer [Dresen et 
al, 2010], and it is thought to be one of the leading imaging modalities for detection of a pelvic 
recurrence of rectal cancer [Stoker et al, 2000; Markus et al, 1997; Torricelli et al, 2003; Dicle et 
al, 1999], due to its excellent soft-tissue resolution and detailed anatomic information. The 
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distinction of recurrent cancer within a pre-sacral scar is more accurate compared with CT, 
based on differences in signal intensity between tumor and fibrosis [Dicle et al, 1999]. The main 
problem for MRI is the detection of a small growing tumor in an area of fibrotic scar tissue 
[Dresen et al, 2009; Kuo et al, 2005; Barbaro et al, 2010].  
DWI-MRI is a promising technique for the detection of small tumor volumes whose benefit has 
been shown also in pelvic tumors [Koh and Collins, 2007; Namimoto et al, 2009; Rao et al, 
2008]. As an addition to standard anatomical MRI, DWI could increase the diagnostic 
performance for detection of locorregional tumor recurrences [Nishie et al, 2008] (Figure II.22). 
 
 
Figure II.22. Axial T2-weighted (a, b) and, b1000 DW (c, d) images of a patient who had previously undergone rectal surgery. On 
T2-weighted MRI (a, b) there is an area of intermediate signal intensity within the rectal wall. On DWI (c, d), there is an area of 
high signal intensity corresponding to viable tumor, confirming the intramural recurrence, which was histologically proven after 
surgical excision. 
 
Lambregts et al [2011d] evaluated the accuracy of standard MRI, DWI and fusion images for the 
diagnosis of locally recurrent rectal cancer in patients with a clinical suspicion of recurrence. 
Two readers evaluated the images: reader 1 achieved an AUC of 0.99, sensitivity 100% and 
specificity 83% on standard MRI versus 0.98, 100% and 91% after addition of DWI (P = 0.78). For 
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reader 2 these values were 0.87, 84% and 74% on standard MRI and 0.91, 89% and 83% with 
DWI (P = 0.09). Fusion images did not significantly improve the performance. Interobserver 
agreement was κ=0.69 for standard MRI, κ=0.82 for standard MRI + DWI and κ=0.84 for the 
fusion images. The benefit of DWI was considered to be potentially more important for the 
detection of smaller tumors which are more difficult to detect within the fibrotic scar tissue. 
Other authors also showed that mainly anastomotic recurrences—which tend to be smaller in 
size—are missed with imaging, again suggesting that the benefit from additional functional 
imaging may be higher in the detection of these small tumors [Syk et al, 2008]. Interestingly, 
adding DWI to conventional imaging improved the interobserver agreement and reduced the 
number of false positives. DWI thus seems to increase the confidence of radiologists in ruling 
out the presence of a recurrence. 
Prior studies demonstrated that standard MRI generally tends to overestimate the presence of 
tumor within areas of fibrotic postoperative scar tissue [Dresen et al, 2009; Kuo et al, 2005; 
Barbaro et al, 2010; De Lange et al, 1989]. When the signal intensities of areas suspected for 
local tumor recurrence on T2-w MRI were analysed, authors reported equally low signal 
intensities for areas of desmoplastic reaction containing tumor and areas of desmoplasia only 
[De Lange et al, 1989]. Also in these cases, the combination of the morphological information 
from MRI and the functional information from DWI can be beneficial in the diagnosis of 
recurrent tumor. Fibrotic areas typically possess low cellular density and a large interstitial 
space, which results in low signal intensity on high b-value DW images. Conversely, tumoral 
tissue has a relatively high cellular density, which will result in high signal on DWI [Vandecaveye 
et al, 2007].  
Some authors have suggested the use of DCE-MRI sequences for a better diagnosis of recurrent 
tumor [Kinkel et al, 1996; Torricelli et al, 2003]. However, their value is somewhat conflicting as 
other reports have shown little improvement for DCE-MRI in comparison to standard 
morphological MRI [Blomqvist et al, 1998]. 
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Chapter III 
Clinical study: Diffusion-weighted magnetic resonance 
imaging in rectal cancer: apparent diffusion coefficient 
as a potential non-invasive marker of tumor 
aggressiveness 
 
1. INTRODUCTION 
 
The prognosis of rectal cancer depends on several factors, some of which are traditionally 
assessed by histopathological examination of the surgical specimen. These include the degree of 
tumor invasion into and beyond the bowel wall [Jass and Love, 1989; Willett et al, 1999], the 
number of lymph nodes involved by tumor [Wolmark et al, 1986; Tang et al, 1995], and 
involvement of the mesorectal fascia (MRF) [Adam et al, 1994], which can also be assessed pre-
operatively by magnetic resonance imaging (MRI) (Beets-Tan et al. 2001a, Brown et al. 2003a). 
Other factors with proven prognostic importance include the plasmatic level of 
carcinoembryonic antigen (CEA) as well as histological factors such as the tumor differentiation 
grade or the presence of lymphangiovascular invasion (LVI) [Huh et al, 2010; Gu et al, 2010; Du 
et al, 2009].  
The current trends in the management of rectal cancer point towards a more widespread 
acceptance of neoadjuvant therapies. These create an increasing need for preoperative imaging 
methods to non-invasively select high-risk patients who could benefit from the more aggressive 
multimodality treatment approaches [Barrett, 1998; Colorectal Cancer Collaborative Group, 
2001]. Detailed information on the patient’s individual tumor profile should allow optimization of 
therapy and is also relevant in terms of prognosis, by providing a way to determine the risk for 
local and distant recurrence [Kremser et al, 2003].At present, the use of diffusion-weighted 
imaging (DWI) incorporated into a standard MR protocol is gradually increasing because of its 
proven benefit not only for tumor detection/characterization but also for monitoring treatment 
response [Koh and Padhani, 2006; Koh and Collins, 2007; Patterson et al, 2008; Padhani et al, 
2009]. Diffusion-weighted imaging measures water diffusion characteristics, which are dependent 
on multiple factors such as cell density, vascularity, viscosity of extracellular fluid and cell 
membrane integrity [deSouza et al, 2008]. By quantifying these properties and expressing them 
as an apparent diffusion coefficient (ADC), DWI could potentially be used as an imaging 
biomarker to better select patients with poor prognosis who will truly benefit from a more 
aggressive neoadjuvant treatment [Lambrecht et al, 2010]. 
To date the value of ADC as a quantitative biomarker in patients with rectal cancer is not clear 
yet. Data are scarce and most published data on the value of DW-MRI for prediction of 
response to chemoradiation are conflicting [Kremser et al, 2003; Lambrecht et al, 2010; Kim et 
al, 2011; Sun et al, 2010; DeVries et al, 2003; Dzik-Jurasz et al, 2002]. We hypothesize that pre-
treatment tumor ADC values may reflect the tumor profile of aggressiveness.   
As the aggressiveness of rectal tumors is expressed by several factors, including T stage, N stage, 
involvement of the MRF, CEA levels, differentiation grade of the tumor and the presence of LVI, 
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[Jass and Love, 1989; Willett et al, 1999; Wolmark et al, 1986; Tang et al, 1995; Adam et al, 
1994; Huh et al, 2010, Gu et al, 2010; Beets-Tan et al, 2001a; Brown et al, 2003a; Wieder et al, 
2007; Ho et al, 2008; Lahaye et al, 2005] we aim to assess the value of DW-MRI as expressed by 
the quantified ADC values as a potential non-invasive imaging biomarker of tumor aggressiveness 
in rectal cancer.  
 
2. MATERIALS AND METHODS 
 
2.1. Patients 
 
Between October 2007 and November 2010, 86 consecutive patients were considered for 
inclusion in this retrospective study. Inclusion criteria were 1) histologically (biopsy) proven 
rectal carcinoma, 2) treatment by surgical resection with or without neoadjuvant therapy, 3) 
availability of pathological reports of surgical specimens mentioning tumor differentiation grade, 
and 4) availability of primary staging MRI including DWI. Patients with mucinous appearing 
tumors on the primary staging MRI (completely hyperintense on T2-weighted images without 
any solid tumor parts) were excluded, since they are known to have low cellular density, 
exhibiting high ADC values and as such potentially introducing a bias in the study results 
[Woodhams et al, 2009]. 
Clinical and imaging data were retrieved from a patient database. The study data were retrieved 
from a previous imaging study, which received approval from the local institutional ethical 
committee, and for which all patients provided written informed consent. Thirty-six patients 
were excluded: 16 did not receive surgery, 5 had predominantly mucinous tumors on the 
histological evaluation of the surgical specimen and in 15 patients, the histological differentiation 
grade could not be derived from the pathological reports (including 9 complete responders in 
whom no residual tumor could be found). The final study population consisted of the remaining 
50 patients (37 male, 13 female). Median age was 70 years (range: 49–88). Neoadjuvant 
treatment consisted either of short-course radiation therapy (RT) (5x5 Gy) or long-course 
chemoradiation therapy (CRT) (28x1.8 Gy on weekdays with concomitant 2x825 mg/m2/d 
capecitabine). 
 
2.2. MR Imaging 
 
The primary staging MRI was performed before the neoadjuvant and surgical therapies. Patients 
were imaged in a 1.5-T MR magnet (Intera; Philips Medical Systems, Best, The Netherlands), 
using a phased-array body coil. The standard imaging protocol consisted of standard T2-
weighted (T2W) fast spin echo in three orthogonal directions, which were used for clinical 
staging (TR/TE: 3427/150 msec; Flip angle: 90°; Echo train length: 25; NSA: 6; Acquisition voxel 
size: 0.78×1.14×5.00 mm; Number of slices: 22; Acquisition time: 5’08”). In addition, axial 
diffusion-weighted sequence with background body signal suppression (DWIBS, b-values: 0, 500, 
1000 s/mm2; TR/TE: 4829/70 msec; EPI factor: 53, NSA: 4, Acquisition voxel size: 
2.50×3.11×5.00 mm; Number of slices: 50 slices; Acquisition time: 10’37”) was acquired. Nodal 
evaluation was performed on an axial 3D T1-weighted gradient-echo sequence (TR/TE: 9.8/4.6 
msec; Flip angle: 15°; NSA: 1; Acquisition voxel size: 1.15×1.15×1.00 mm; Number of slices: 200; 
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Acquisition time: 6’30”), acquired after intravenous administration of gadofosveset trisodium 
(Ablavar™, Lantheus Medical Imaging, Billerica, MA, USA). All axial sequences were angled in 
identical planes, perpendicular to the tumor axis as identified on sagittal MRI. The T2W coronal 
sequence was angled parallel to the tumor axis. Patients did not receive bowel preparation, anti-
spasmodic medication or rectal distention before the MR examination.  
Apparent Diffusion Coefficient maps in greyscale were automatically generated at the operating 
system, using a mono-exponential decay model including all three b-values. 
 
2.3. ADC Evaluation 
 
The MR images were analysed by a radiological PhD fellow with 3 years of specific experience in 
reading rectal MRI examinations who was blinded to the clinical patient data and pathology 
reports. 
Mean ADC was calculated from a sample of three round/oval-shaped ROIs that were manually 
placed within solid tumour parts (as identified as focal masses showing intermediate signal 
intensity on the anatomical T2-weighted images) of three independent tumour-containing slices. 
The size and position of the ROIs was chosen to include as much of the solid tumor area as 
possible (Figure III.1).  
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Figure III.1. Example of manual placement of an oval-shaped ROI for measurement of the ADC values for each tumor on the ADC 
map (a). High b-value (b = 1000 s / mm2) DWI (b) and T2W (c) images provided respectively functional and anatomical 
reference. 
 
2.4. Prognostic Factors 
 
Clinical, radiological and histological prognostic factors were derived from the clinical patient 
database. The clinical factor was the plasmatic CEA level (ng/mL) at the time of diagnosis. The 
following parameters were retrieved from MRI at primary staging: the mrT stage (mrT1-2, T3, 
T4), the mrN stage (mrN0, N1, N2) – both reported according to the Sixth American Joint 
Committee on Cancer TNM staging system – and the MRF status at MRI (free or involved). 
Histological evaluation of the surgical resection specimen was the reference standard for the 
histological parameters: tumor differentiation grade and LVI. Differentiation grade of the tumor 
was scored by the pathologist according to the following grades, used in our institution: 0) 
poorly differentiated; 1) poorly to moderately differentiated; 2) moderately differentiated; 3) 
moderately to well differentiated; 4) well differentiated. LVI was reported as absent or present. 
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For T3 tumors showing extramural growth, the distance in millimeters from the outermost part 
of the tumor to the MRF was also measured on the primary staging MRI. 
 
2.5. Statistical Analysis 
 
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, 
version 17.0, Inc., Chicago, IL, USA).  
Student t-tests (independent-samples t-test) were used to assess differences between means of 
the following groups: CEA <5 ng/mL vs. ≥5 ng/mL (threshold used in our institution); mrT1-2 
(tumor limited to the bowel wall) vs. mrT3-4 (tumor beyond bowel wall); mrN0 vs. mrN1-2 
(N+); MRF-free vs. MRF-invaded; and LVI absent vs. LVI present. A one-way analysis of variance 
(ANOVA) was used to test differences in ADC values between the 5 pre-defined differentiation 
grade groups, followed by post-hoc Tuckey’s test.  
Correlation between pre-treatment ADC values and the distance from the outermost part of 
the tumor to the MRF at primary staging MRI was investigated with determination of the 
Pearson correlation coefficient.  
For all the above mentioned analyses, a p value of less than 0.05 was considered statistically 
significant.  
 
3. RESULTS 
 
3.1. Treatment Characteristics  
 
Three patients underwent immediate surgery, whereas the remaining 47 patients underwent 
surgery after neoadjuvant treatment consisting either of a short-course of radiation therapy 
(n=28) or a long-course chemoradiation therapy (n=19). Surgery consisted of a low anterior 
resection (n=39), abdomino-perineal resection (n=9), extended resection (n=1) or Hartmann 
resection (n=1).  
The median time interval between the primary staging MRI and surgery was 59 days (range: 7-
281): 52 days for the surgery alone group, 43 days for the patients who received short-course 
radiation therapy and 135 days for the patients who undergone long-course chemoradiation 
therapy.  
 
3.2. Clinical and Radiological Findings  
 
At the time of diagnosis, 29 patients had CEA levels lower than 5 ng/mL and 16 patients had 
CEA levels equal to or above 5 ng/mL. In 5 patients this value was not available at baseline. 
Regarding the MRI-based findings, 11 patients had tumors limited to the rectal wall (T1 or T2) 
while the remaining 39 were considered to be T3 tumors. Seventeen patients were staged as 
N0, while 33 had positive nodal disease (N1 or N2). The MRF was free in 36 patients and 
involved by tumor in the remaining 14.  
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3.3. Histopathological Findings 
 
From the analysis of the surgical specimens, 5 patients had poorly differentiated, 9 poorly to 
moderately differentiated, 31 moderately differentiated, 3 moderately to well differentiated and 
2 well differentiated tumors. In 28 patients LVI invasion was absent and in 10 it was present. In 
the remaining 12 patients this information could not be retrieved from the pathological reports. 
 
3.4. Correlation between ADC and Prognostic Factors 
 
The mean tumor ADC for the whole patient population was 1.069±0.162 x10-3 mm2/s.  
Table III.1 presents the differences in pre-treatment tumor ADC values between the different 
subgroups.  
 
 
Table III.1. Correlations between pretreatment ADC values and clinical, radiological, and pathological prognostic factors. 
 
Mean ADCs were significantly different for MRF-free vs. MRF-invaded (p=0.013), mrN0 vs. 
mrN+ (p=0.011), and for the different tumor differentiation grades at histology (p=0.025), with 
lower ADC values for tumors with involved MRFs, nodal-positive disease and for cancers of less 
differentiated grades (Figure III.2).  
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Figure III.2. ADC measurement in tumors of different aggressiveness. In a less aggressive lesion (a, ADC map; b, b = 1000 s /mm2 
image; c, T2W image), which is limited to the bowel wall, without mesorrectal lymph nodes and moderately to well differentiated, 
the ADC value (1.07 x 10-3 mm2/s) is higher than in a more aggressive neoplasm (d, ADC map; e, b = 1000 s /mm2 image; f, 
T2W image), staged as T3N2, with involved MRF and moderately to poorly differentiated (ADC value = 0.94 x 10-3 mm2/s). 
 
The relationship between ADC values and the different histological tumor differentiation grades 
is given in Figure III.3.  
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Figure III.3. Comparison of mean ADC values of tumors according to the histological differentiation grade. The whiskers represent 
the standard deviation. Tuckey’s post hoc testing showed that the mean ADCs between poor to moderately differentiated and well 
differentiated tumors differ significantly (P = 0.047). The relatively high ADC value of the poorly differentiated tumors could partly 
be related to the small number of patients in this subgroup. Another explanation could be that they have more necrosis at a 
cellular microscopical level resulting in higher ADC values. 
 
The mean ADC was different between the sub-groups based on the T stage at primary MRI, 
CEA levels and LVI at histology, with poor prognostic factors (lesions growing beyond the rectal 
wall, CEA levels ≥ 5 ng/mL, and tumors with LVI) showing lower ADCs, but these differences 
were not statistically significant. 
A significant positive correlation (r=0.374, p=0.019) between ADC values and the distance from 
the tumor to the MRF was found (Figure III.4). 
 
 
Figure III.4. Correlation between ADC values and pretreatment distance from tumor to MRF. 
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4. DISCUSSION 
 
The goal of the present work was to assess the value of DW-MRI as a potential non-invasive 
imaging biomarker of tumor aggressiveness in rectal cancer. The results of our study 
demonstrate statistically significant correlations between ADC values and the clinical MRF status 
and nodal status on MR imaging and the tumor differentiation grade at histology. There was no 
significant correlation between ADC and the T stage at primary MRI, pre-treatment CEA levels, 
or the presence of LVI at histology. 
To the best of our knowledge, a correlation between clinical pre-operative prognostic factors 
and ADC values in rectal cancer has not been the focus of previous studies. In our study pre-
treatment mean ADC was significantly lower for tumors invading MRF or tumors with positive 
nodal disease. This is an interesting finding as it is proven that both MRF involvement and 
positive lymph nodes are powerful predictors of a local recurrence and distant metastases. The 
presence of any correlation between ADC and MRF or nodal status therefore suggests that 
ADC on itself correlates with prognosis. This could be explained by the fact that ADC values 
are indirectly derived from a tumor’s cellular microarchitecture and may thus reflect the 
aggressiveness of the tumor tissue profile. This is further supported by the finding that tumors 
that were less well differentiated showed relatively low ADCs, again suggesting that low ADC 
values are associated with an unfavorable tumor profile. A recent study showed a similar trend 
towards low ADC values for poorly-differentiated tumors [Gu et al, 2011].  
Although not statistically significant, there was also a trend towards lower ADC values for 
patients with tumors growing beyond the rectal wall (T3-4) as compared to tumors that were 
restricted to the bowel wall (T1-2). The lack of significance may partly be due to the relatively 
small patient population. Another reason could be that the assumption of the subgroups T1-2 
and T3-4 having different prognosis (good vs. bad) may not be correct. There is a huge variability 
in prognosis within the group of T3 tumors: whereas large, bulky T3 tumors are associated with 
a poorer prognostic outcome and would behave more closely like T4 tumors, the smaller 
(borderline) T3 tumors are known to have a better prognosis, behaving more closely like T2 
tumors. A worsening of prognosis that is associated with a gradual increase of the depth of 
tumor extension into the surrounding mesorectal fat is described [Wieder et al, 2007]. This is 
also supported by our findings that showed a significant correlation between ADC and the 
distance from the tumor to the MRF with lower ADC values associated with a shorter distance 
between the outermost part of the tumor and the fascia. 
Previous studies have investigated the value of pre-treatment tumor ADC as a prognostic factor 
in terms of prediction of response to chemoradiation in the specific subgroup of patients with 
locally advanced rectal cancer. Results are conflicting, with some authors demonstrating 
significantly lower pre-treatment ADC values for the good responders as compared to the non-
responders, which suggests that pre-treatment ADC can be beneficial to predict treatment 
response [Lambrecht et al, 2010; Sun et al, 2010; Dzik-Jurasz et al, 2002]. Others, however, 
reported that pre-treatment ADC values were not statistically different for responders and non-
responders and as such may be limited in predicting treatment outcome [DeVries et al, 2003; 
Kim et al, 2011; Heo et al, 2010; Kim et al, 2011]. As the extent of response after 
chemoradiation may also be dependent on the tumor profile, it therefore seems logical to think 
that initial ADC values may be correlated both with response and the overall prognostic tumor 
profile as assessed in this current study. The findings of our study and the above mentioned 
reports may thus be related to each other. However, the assessment of treatment response was 
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not the focus of our study, and furthermore, the patients undergoing neoadjuvant 
chemoradiation constituted only a small subgroup (n=19) of the patient population, precluding 
any meaningful subanalyses.  
Our study has some limitations. First, our ADC measurements were obtained by measuring 3 
sample ROIs, which may not be fully representative for the overall tumor profile [Roth et al, 
2004]. However, this approach was chosen since outlining of the whole tumor volume is very 
time-consuming and difficult to perform in clinical practice. We aimed to reproduce what 
happens in the clinical daily work, where time constraints frequently imply that a simpler and 
quicker way to obtain ADC values will be used. Measurements were obtained by one 
experienced reader. We acknowledge that this does not allow for evaluation of potential 
interobserver variations. Second, we chose to correlate ADC with factors derived from the 
primary clinical staging MRI since we wanted to study the correlation between ADC and the 
primary tumor profile, i.e. before it was affected by any therapeutic interventions. Hence, we did 
not use the final pathological T-stage, N-stage and MRF for correlation with ADC, as the 
majority of patients had undergone chemoradiation therapy prior to surgery, in which setting the 
T and N stage at histology is no longer representative of the initial tumor profile. After 
chemoradiation treatment, histopathology is an indicator of treatment response and the 
prognostic relevance of the definite histological stage seems to be significant mainly in patients 
with a pathologically complete response [Garcia-Aguilar et al, 2003]. Third, although MRI is 
known to be a reliable modality for rectal cancer staging, its assessment is observer-dependent 
and under- or overstaging may have occurred. Nevertheless, for the most relevant prognostic 
factors for which the association with ADC was significant (MRF and nodal stage), the MRI 
assessment can be considered accurate to serve as the standard reference: it is known from 
different validation studies that MRI is highly (>90%) accurate for preoperative assessment of the 
MRF and reproducible in general hands [Beets-Tan et al, 2001a; Brown et al, 2003a; Ho et al, 
2008; Wieder et al, 2007]. Moreover, the nodal stage on MRI was determined by using a lymph 
node specific contrast agent (gadofosveset trisodium: GDF). This GDF-enhanced MRI approach 
was shown to be highly accurate with AUCs ranging between 0.94 and 0.98 in a recent 
publication [Lambregts et al, 2011a]. Finally, it would have been clinically interesting to assess the 
aggressiveness profile of tumors by means of outcome parameters such as disease-free or 
overall survival. However, this would require a larger patient cohort and a longer follow-up 
period which was beyond the scope of our current study. 
 
5. CONCLUSION 
 
In conclusion, ADC values of rectal cancers significantly correlate with prognostic factors 
including the MRF status, the nodal stage and the histological differentiation grade. There is a 
tendency towards lower ADC values in tumors with involvement of the MRF, node-positive 
tumors, poorly differentiated neoplasms, lesions growing beyond the rectal wall, CEA levels 
higher or equal to than 5 ng/mL, and tumors with LVI, which are the cancers with poorer 
prognosis. Our study suggests that ADC has the potential to become an imaging biomarker of 
tumor biological profile. 
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Chapter IV 
Clinical study: Rectal cancer: assessment of complete 
response to preoperative combined radiation therapy 
with chemotherapy—conventional MR volumetry 
versus diffusion-weighted MR imaging 
 
1. INTRODUCTION 
 
The treatment of locally advanced rectal cancer (LARC) has shifted in recent years from a 
primarily surgical approach with adjuvant radiation therapy toward preoperative combined 
radiation therapy with chemotherapy (CRT), which results in improved local control and 
reduced acute and late toxic effects [Sauer et al, 2004]. Moreover, the use of preoperative CRT 
induces downsizing and downstaging of the primary tumor, yielding a pathologic complete 
response (CR) (pCR) in up to 24% of patients. A pCR is known to be associated with a favorable 
oncologic outcome, in regard to both recurrence and survival [Maas et al, 2010]. Habr-Gama et 
al [2006] reported on 99 patients with a clinical CR who were treated with observation alone 
(“wait-and-see”): Compared with patients who had residual tumor and were referred to surgery, 
the 5-year overall and disease-free survival rates were favorable for the observation group. 
Although still controversial, the trend in treatment is now toward a more conservative policy 
for patients identified as complete responders after CRT [Bujko et al, 2007; O’Neill et al, 2007]. 
Traditionally, a pCR is determined with histopathologic examination after surgery. However, if 
the determination of a CR before surgery would influence the subsequent treatment choice, an 
accurate clinical assessment of response becomes essential. 
Currently used methods, such as digital examination and endoscopy and/or biopsy are good but 
not infallible. The role of magnetic resonance (MR) imaging in the primary staging of rectal 
cancer is well established, and it is now part of the standard work-up in many countries. 
However, its role in restaging after preoperative CRT is not yet clear, partly because to date 
restaging by using imaging has not influenced the treatment strategy. 
MR imaging, like other morphologic imaging techniques (endorectal ultrasonography and 
computed tomography) is hampered by interpretation difficulties in assessing the presence of 
residual tumor within areas of radiation-induced fibrosis [Chen et al, 2005; Huh et al, 2008; 
Barbaro et al, 2010)]. Studies are therefore focusing on the potential added benefit of functional 
and/or quantitative methods of MR image evaluation. One of these, MR volumetry, was reported 
to correlate well with downstaging of rectal cancer: A tumor volume reduction rate of around 
70%–75% or higher allowed identification of the patients in whom the tumors were downstaged 
[Barbaro et al, 2009; Dresen et al, 2009)]. Furthermore, a significant association with pCR was 
reported for patients with a volume reduction rate higher than 75% ([Kang et al, 2010)]. 
Recently, diffusion-weighted (DW) MR imaging after CRT was shown to be more valuable than 
morphologic MR imaging for the differentiation between a pCR and residual tumor, because on 
DW images, viable tumor remnants are more easily recognized, as they appear hyperintense 
compared with the low signal intensity (SI) of the surrounding nonneoplastic tissue ([Kim et al, 
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2009; Lambregts et al, 2011c)]. Hence, it can be hypothesized that volumetry of the tumor that 
is based on SI characteristics on DW images may be more accurate than conventional MR 
volumetry to distinguish between complete and noncomplete responders. In addition, promising 
results have been shown for quantitative DW imaging evaluation by measuring the apparent 
diffusion coefficient (ADC) for the evaluation of treatment response to CRT in patients with 
rectal cancer [Dzik-Jurasz et al, 2002; Sun et al, 2010; DeVries et al, 2003; Kremser et al, 2003; 
Hein et al, 2003; Kim et al, 2011; Roth et al, 2004]). 
With this study, we aim to determine the diagnostic performance of DW imaging for the 
assessment of a CR after CRT in patients with LARC by means of volumetric SI measurements 
and quantitative ADC measurements and to compare the performance of DW imaging with 
volumetry on standard T2-weighted MR images. 
 
2. MATERIAL AND METHODS 
 
2.1. Patients 
 
Eighty-six consecutive patients diagnosed with LARC at Maastricht University Medical Center 
(Maastricht, the Netherlands) between June 2006 and May 2010 were considered for inclusion in 
this retrospective study. Inclusion criteria consisted of (a) histopathologically (biopsy-) proved 
rectal adenocarcinoma; (b) locally advanced disease (staged on MR images as cT3–4 and/ or N-
category positive); (c) neoadjuvant treatment consisting of a long course of preoperative CRT 
(50.4 Gy radiation plus 2 3 825 mg/m 2 /d capecitabine [Xeloda; Hoffmann-La Roche, Basel, 
Switzerland]); and (d) availability of pre- and post-CRT MR imaging results, including DW imaging 
results. Exclusion criteria were (a) nonresectable and/or metastatic disease and (b) insufficient 
MR image quality (eg, owing to metal implants or movement artifacts). Thirty-six patients were 
excluded for the following reasons: severe susceptibility artifacts on DW images owing to metal 
implants (n = 2), neoadjuvant treatment consisting of a short course of 5 Gy radiation on 5 
consecutive days plus chemotherapy (n = 3), patient death during neoadjuvant treatment (n = 2), 
ineligibility to undergo surgery as a result of older age or comorbidity (n = 1), unresectable 
and/or metastatic disease (n = 9), or pre-CRT MR imaging performed without DW imaging (n = 
19). This left a total of 50 patients (median age, 71.5 years; range, 51–90 years) who constituted 
the final study population. Thirty-six patients were men (median age, 70.5 years; range, 55–90 
years) and 14 were women (median age, 76 years; range, 51–82 years). Clinical and imaging data 
were retrieved from a patient database originating from a previous imaging study approved by 
the local institutional ethical committee, for which all patients provided written informed 
consent [Lambregts et al, 2011a]. 
 
2.2. MR Imaging 
 
MR imaging was performed at 1.5 T (Intera; Philips Medical Systems, Best, the Netherlands) by 
using a phased-array body coil. All patients underwent pretreatment MR imaging for primary 
tumor staging and a second restaging MR imaging examination for response evaluation 6–8 
weeks after completion of CRT. 
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The imaging protocol consisted of the following: (a) standard two-dimensional T2-weighted fast 
spin-echo sequences in three orthogonal directions (sagittal, coronal, axial) (repetition time 
msec/ echo time msec, 3427/150; flip angle, 90°; echo train length, 25; number of signals 
acquired, six; acquisition voxel size, 0.78 x 1.14 x 5.00 mm; sections, 22; acquisition time, 5.08 
minutes) and (b) an axial DW sequence with background body signal suppression [Takahara et al, 
2004] and b values of 0, 500, 1000 s/mm2 (4829/70; echo-planar imaging factor, 53; number of 
signals acquired, four; acquisition voxel size, 2.50 x 3.11 x 5.00 mm; number of sections, 50; and 
acquisition time, 10.37 minutes). The axial T2-weighted and DW imaging sequences were used 
for volumetric analyses and were angled in identical planes, perpendicular to the tumor axis as 
defi ned on sagittal T2-weighted MR images. The coronal T2-weighted sequence was angled 
parallel to the tumor axis. Patients did not receive bowel preparation, antispasmodic medication, 
or rectal distention before any of the MR examinations. 
 
2.3. Volumetric Image Evaluation 
 
The MR images were evaluated on a picture archiving and communication system and were 
independently analyzed by two observers, with 5 (L.C.S.) and 3 (D.M.J.L.) years of specific 
expertise in reading pelvic MR images. The observers were blinded to each other’s results, the 
clinical patient data, and pathology reports. The readers calculated tumor volumes by manually 
tracing the tumor boundaries on the axial images and placing free-hand regions-of-interest 
(ROIs), which provided the sectional area of the lesion for each tumor-containing section ( Fig 
IV.1 ).  
 
 
Figure IV.1. Examples of manual tracing of free-hand ROIs for calculation of the sectional area of tumor in each section performed 
on pre-CRT T2-weighted ( a ) and DW ( b ) MR images and on post-CRT T2-weighted ( d ) and DW ( e ) MR images. ROIs were 
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copied from the diffusion images with b = 1000 s/mm2 to the corresponding pre-CRT ( c ) and post-CRT ( f ) ADC maps to 
calculate mean tumor ADC values. Sectional areas were multiplied by section thickness to determine the tumor volume. 
 
Whole-tumor volume was then calculated by multiplying each cross-sectional area by section 
thickness. The DW and T2-weighted MR images were analyzed independently and in random 
order, with a 1-week interval between the two reading sessions. On the T2-weighted images, 
tumor was defined as areas of isointense signal as compared with the relatively lower 
hypointense signal of the normal adjacent muscular rectal wall. 
On post-CRT T2-weighted MR images, areas of markedly low SI at the location of the primary 
tumor bed were interpreted as fibrosis. As the risk for residual tumor in these fibrotic areas is 
known to be ± 50%, they were also included in the volumetric measurements [Vliegen et al, 
2008b]. On the DW images, measurements were performed on high– b value (1000 s/mm2) 
images and were based on a visual analysis. 
Areas of high SI, compared with the normal bowel wall or background of lower SI tissue, were 
considered as tumor. For both data sets (T2 weighted and DW), the readers determined (a) 
pre-CRT tumor volume; (b) post-CRT tumor volume; and (c) the tumor volume reduction ratio 
( ∆ volume), which was calculated as follows: (TV pre - TV post ) x 100/TV pre , where TV pre is pre-
CRT tumor volume and TV post is post-CRT tumor volume. 
 
2.4. Measurement of the ADC 
 
The diffusion images were exported in Digital Imaging and Communications in Medicine format 
to an off-line MR workstation, on which ADC maps in gray scale were automatically generated 
by using a monoexponential decay model including all three b values (0, 500, and 1000 s/mm2). 
ROIs covering the whole tumor volume (as described above) were reproduced on the MR 
operating system on the diffusion images with b = 1000 s/mm2 by two independent readers 
(D.M.J.L. and T.T.), who were blinded to each other’s results, the clinical patient data, and 
pathology reports. The ROIs were then copied from the images with b = 1000 sec/mm 2 to the 
ADC map to calculate mean pre- and post-CRT tumor ADCs ( Fig IV.1 ). When no remaining 
high SI could be visualized on the post-CRT diffusion images, three sample measurements were 
obtained of the rectal wall at the former location of the primary tumor ( Fig IV.2 ). 
 
 
Figure IV.2. Interpretation of a CR on T2-weighted and DW MR images. (a) Pre-CRT DW image shows that there is a tumor visible 
in the distal rectum (arrows). (b) Post-CRT T2-weighted MR image shows that a normalized rectal wall is visualized. (c) High- b -
value (1000 s/mm2 ) post-CRT DW MR image shows absence of residual tumor, which was based on a lack of hyperintense SI 
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areas of the bowel wall. To obtain post-CRT ADC measurements, three sample measurements (an example of which is indicated by 
the arrow) were taken from the normalized rectal wall at the location of the former tumor. 
 
In one patient, ADC measurements were not obtained, because his tumor had an entirely 
mucinous aspect (completely hyperintense in signal on T2-weighted MR images) without any 
solid tumor parts. These fully mucinous tumors are known to exhibit high ADC values, which 
would potentially lead to bias of the study results [Woodhams et al, 2009]. 
 
2.5. Standard of Reference 
 
Forty-two (84%) patients underwent total mesorectal excision. The surgical resection specimens 
were histopathologically examined by dedicated pathologists experienced in colorectal cancer 
staging. Specimens were examined according to the Sixth American Joint Committee on Cancer 
TNM staging system. The tumor regression grade (TRG) was evaluated according to the method 
of Mandard et al [1994]. The response of the primary tumor was graded as follows: pCR (T 
stage after therapy at histopathologic evaluation, ypT0; TRG 1, no residual tumor cells) or 
residual tumor (ypT1–4; TRG 2–5, varying from rare residual cancer cells to a solid residual 
tumor mass). 
Eight (16%) patients did not undergo surgery because of strong clinical evidence of a CR 
(repeated negative findings at sigmoidoscopy and biopsy after CRT). These patients underwent 
intensive 3-monthly follow-up, with a median local and distant recurrence-free follow-up period 
of 17 months, which was considered a surrogate end point for a CR. 
 
2.6. Statistical Analysis 
 
Statistical analyses were performed by using software (SPSS, version 16.0; SPSS, Chicago, Ill). 
Interobserver variability for the three readings (T2-weighted MR volumetry, DW MR volumetry, 
and ADC), as well as the correlation between the volume measurements on T2-weighted and 
DW images were analyzed by calculating the intraclass correlation coefficient (ICC) for single 
measurements (0–0.20, poor correlation; 0.21–0.40, fair correlation; 0.41–0.60, moderate 
correlation; 0.61–0.80, good correlation; and 0.81–1.00, excellent correlation). 
Volumes and ADCs were averaged between the two observers for further analysis. A Student t 
test was used to compare the mean ADCs between the complete responders and noncomplete 
responders. As the tumor volumes were not normally distributed, a Mann-Whitney U test was 
used to compare the tumor volumes between the complete responder and noncomplete 
responder groups. A Wilcoxon signed-rank test was used to compare pre- and post-CRT 
volumes, and a paired-samples t test was used to compare the pre- and post-CRT ADC 
measurements. Receiver operating characteristic (ROC) curves were generated to evaluate the 
diagnostic performance in detecting a CR for (a) T2-weighted MR volumetry, (b) DW MR 
volumetry, and (c) ADC. Corresponding areas under the ROC curve (AUCs), sensitivities, 
specificities, positive predictive values, and negative predictive values were calculated. For these 
analyses, cutoff values were determined according to the point nearest to the upper left corner 
in the ROC curves. Differences in diagnostic performance were analyzed by comparing the ROC 
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curves according to the method described by DeLong et al [1988]. A difference with a P value of 
less than .05 was considered significant. 
 
3. RESULTS 
 
3.1. Patient and Treatment Characteristics 
 
Twenty-four patients underwent a low anterior resection, 12 underwent an abdominoperineal 
resection, and six underwent an extended resection. Histopathologic analysis of the surgical 
specimen yielded the following fi ndings: Six patients had ypT0, four had ypT1, 13 had ypT2, 18 
had ypT3, and one had ypT4 tumor. Six patients had mucinous type adenocarcinoma. The 
median time between the restaging MR imaging and surgery was 20 days (range, 4–197 days). 
Together with the eight nonsurgically treated patients, the total number of patients with a CR 
corresponded to 14 (28%).  
 
3.2. Interobserver Agreement 
 
The interobserver agreement (ICC) for the T2-weighted MR volume measurements was 0.93 on 
pre-CRT MR images and 0.79 on post-CRT MR images. For the DW MR volume measurements, 
ICCs were 0.96 on pre-CRT MR images versus 0.75 on post-CRT MR images. For the ADC 
measurements, ICCs were 0.91 on pre-CRT MR images versus 0.61 on post-CRT MR images. 
Figure IV.3 illustrates the effect of interobserver variations on the volumetric DW MR and ADC 
measurements. 
 
 
Figure IV.3. Post-CRT images in 79-year-old female patient with a ypT3 residual tumor. (a) T2-weighted MR image shows persistent 
wall thickening suggestive of residual tumor (intermediate SI = arrowheads) and fibrosis (low SI = arrow). (b) DW MR image 
shows a small focus of hyperintensity in the bowel wall. To delineate the tumor volume, the ROI was placed as shown by observers 
1 (arrow, also on c ) and 2 (arrowhead, also on c ). The two ROIs resulted in comparable tumor areas (0.48 vs 0.46 cm2 ). (c) 
ADC map derived from the DW images shows that corresponding ADC values were 1.21 versus 1.36 x 10-3 mm2/s for the ROIs 
placed by the two respective observers. The difference in ADC between the two observers (0.15 x 10-3 mm2/s) for this single 
measurement was thus larger than the overall difference in mean tumor ADC observed between the complete responder and 
noncomplete responder groups, which was 0.07 x 10-3 mm2/s for the post-CRT measurements. This example illustrates that small 
variations in ROI size and/or placement may result in nonnegligible variations in ADC that may substantially influence study results. 
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3.3. T2-weighted versus DW MR Volumetry 
 
The median tumor volumes from T2-weighted MR and DW MR images (mean of two observers) 
for the whole patient group and for the complete responder versus noncomplete responder 
groups are displayed in Table IV.1.  
 
 
Table IV.1. Median volumes and mean ADC values. 
 
Median tumor volumes decreased from 21.8 to 5.5 cm3 on T2-weighted MR images ( P < 0.001) 
and from 18.0 to 1.0 cm3 on DW MR images ( P < 0.001). There were no significant differences 
in pre-CRT volumes between the complete responder and noncomplete responder groups on 
neither T2-weighted MR images (20.6 vs 24.3 cm3, P = 0.46) nor DW MR images (11.9 vs 18.9 
cm3, P = 0.16). The post-CRT volumes were significantly smaller for the complete responder 
group compared with the noncomplete responder group, both on T2-weighted MR images (1.2 
vs 5.6 cm3, P = 0.03) and DW MR images (0.03 vs 1.5 cm3, P < 0.001). The ∆ volume was 
significantly larger for the complete responder group than it was for the noncomplete responder 
group, both on T2-weighted MR images ( - 92.2 vs - 78.1%, P < 0.001) and DW MR images ( - 
99.7 vs - 90.2%, P < 0.001). The correlation (ICC) between the volume measurements derived 
from T2-weighted and DW MR images was 0.97 for the pre-CRT measurements and 0.25 for 
post-CRT measurements.  
 
3.4. Tumor ADC Values 
 
The mean tumor ADC values for the whole patient group and for the complete responder 
versus noncomplete responder groups are displayed in Table IV.1.  
Mean tumor ADC for the two observers increased from 1.09 x 10 - 3 mm 2 /sec on pre-CRT MR 
images to 1.43 x 10 - 3 mm 2 /sec on post-CRT MR images ( P < 0.001 ). There were no 
significant differences in pre-CRT, post-CRT, or _ ADC between the complete responder and 
noncomplete responder groups ( P = 0.61, 0.48 and 0.96, respectively). 
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3.5. Diagnostic Performance for Assessment of CR 
 
The ROC curves used to compare the diagnostic performance of the pre-CRT, post-CRT, and ∆ 
measurements of T2-weighted MR volumetry, DW MR volumetry, and ADC for assessment of a 
CR are shown in Figure IV.4.  
 
 
Figure IV.4. Comparison of ROC curves displaying the diagnostic performance for pre-and post-CRT volumes and ∆ volume (Delta) 
on T2- and DW MR images and ADC in the assessment of a CR. Numbers = AUC values for each sequence, numbers in 
parentheses = 95% confidence intervals, * = significant difference in AUC compared with T2-weighted MR volumetry, and ^ = 
significant difference in AUC compared with ADC. 
 
Corresponding accuracy data are provided in Table IV.2. 
 
 
Table IV.2. Diagnostic performance for volume measurements from T2-weighted and DW MR Images and ADC in detection of a CR. 
 
The pre-CRT measurements resulted in AUCs of 0.57, 0.63, and 0.55 for T2-weighted MR 
volumetry, DW MR volumetry, and ADC, respectively, which were not significantly different 
from each other ( P = 0.15–0.85). For the post-CRT measurements, AUCs were 0.70 for T2-
weighted MR volumetry, 0.93 for DWMR volumetry, and 0.54 for ADC. The results for DW MR 
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volumetry were significantly better compared with either T2-weighted MR volumetry or ADC ( 
P = 0.02 and P < 0.001, respectively). The ∆ volumes of T2-weighted MR (AUC, 0.84) and DW 
MR (AUC, 0.92) were significantly better than ∆ ADC (AUC, 0.51; P = 0.003 and P < 0.001, 
respectively). 
The difference in AUC between the ∆ volumes from T2-weighted and DW MR was not 
significant ( P = 0.42). The performance of post-CRT DW MR volumetry was equally accurate as 
the ∆ volumes from T2-weighted ( P = 0.31) and DW ( P = 0.65) MR. 
 
3.6. Interpretation Errors on DW MR Images 
 
Eleven of the 14 complete responders could be detected on the basis of the absence of high SI 
on DW MR images. The three false-negative findings on DW MR images were caused by the 
following reasons: In one patient, high SI caused by a collapsed rectal wall at the location of the 
primary tumor was erroneously interpreted as residual tumor. In the other two patients, DW 
MR images showed small areas of high SI at the location of the primary tumor, while 
histopathologic findings indicated mainly fibrosis, necrosis, and inflammation without any residual 
tumor cells (Fig. IV.5). 
 
 
Figure IV.5. (a) Post-CRT T2-weighted and (b) DW MR images in 71-year-old male patient with a CR in whom the presence of 
residual tumor was overestimated by both observers on both images. T2-weighted MR image demonstrates a persistent wall 
thickening with predominant low SI owing to fibrosis (arrowhead), but also with some areas of intermediate SI interpreted as 
residual tumor (arrows). On b, hyperintense areas (arrows) were interpreted as residual tumor within the bowel wall. 
Histopathologic examination revealed no viable neoplastic tissue (ypT0), although some nonneoplastic epithelial tissue of unknown 
origin was found within the muscular layer, which may explain the difficulties in interpreting the images. 
 
4. DISCUSSION 
 
The goal of our study was to evaluate the diagnostic performance of DW MR imaging for the 
assessment of a complete tumor response in patients with LARC and to compare it with tumor 
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volume measurements on conventional T2-weighted MR images. For this purpose, DW MR 
images were evaluated in twofold: (a) by volume measurements of high SI areas on diffusion 
images with b = 1000 sec/mm2 and (b) by measurement of tumor ADC values. The results of our 
study demonstrate that post-CRT DW MR volumetry provides high diagnostic performance 
(AUC, 0.93) for the assessment of a CR and is significantly more accurate than is post-CRT T2-
weighted MR volumetry (AUC, 0.70) or post-CRT ADC (AUC, 0.54). The post-CRT DW MR 
volumetry was equal in performance to volume reduction measurements ( ∆ volume) of both 
T2-weighted and DW MR (AUC, 0.84 and 0.92, respectively). Pre-CRT DW MR and T2-
weighted MR volumetry, as well as ADC, were not reliable to identify a CR, with AUCs ranging 
between 0.51 and 0.63. 
Previously published data addressed the value of rectal tumor volumetry on standard T2-
weighted MR images for the assessment of response after CRT and showed conflicting results. 
Kang et al [2010] reported a significant association with pCR for patients with a tumor volume 
reduction rate of more than 75%. Kim et al [2005] could not confirm these findings and showed 
no difference in the tumor volume reduction rates between patients with pCR and those with 
residual disease. The findings of our study showed that volume reduction measurements 
performed either on T2-weighted MR images or diffusion images with b = 1000 sec/mm2 can be 
used to assess a CR, with an overall accuracy of 88% for both techniques. Of interest, however, 
was our finding that tumor volumetry performed on post-CRT DW MR images only was equal 
in performance to the tumor volume reduction measurements on T2-weighted and DW MR 
images, suggesting that evaluation of pre-CRT images may not even be necessary. The latter is 
further supported by the fact that, in our study, pretreatment measurements were not reliable 
for the assessment of a CR. Another interesting finding was that volumetry on post-CRT DW 
MR images was significantly more accurate than that on post-CRT T2-weighted MR images for 
assessing a CR. Apparently, the tumor volumes measured on the basis of the presence (or 
absence) of high-SI areas on DW MR images better represented the actual presence of residual 
tumor. On morphologic post-CRT MR images, it is more difficult to measure volumes because it 
is difficult to define which of the fibrotic areas are still suspicious for tumor and should be 
included in the volume measurements and which should not. We experienced that those 
difficulties were less pronounced on DW MR images and that, on DW MR images, the 
delineation of residual tumor was more clear-cut. This was also reflected in the poor correlation 
(ICC, 0.25) between the post-CRT tumor volumes measured on T2-weighted and DW MR 
images. 
Given the high diagnostic performance of post-CRT DW MR volumetry on the basis of signal 
perception on images with b = 1000 sec/mm2, it could be hypothesized that a visual evaluation of 
whether or not a high SI suggestive of residual tumor is remaining will be sufficient, and 
volumetric measurements are not even required. Such a visual approach would also be more 
practical and far less time consuming. Previous authors [Kim et al, 2009; Lambregts et al, 2011c] 
have already shown good results for a visual analysis of DW MR images. In these reports, the 
value of adding DW MR imaging to standard MR imaging was assessed by evaluating the DW and 
T2-weighted MR images side by side and comparing findings of this evaluation with those on T2-
weighted MR images only. Kim et al [2009] reported an AUC of 0.82–0.88 for the combined 
reading of standard MR images plus DW MR images, results comparable to those of Lambregts 
et al [2011c] who reported AUCs ranging between 0.78 and 0.80 for three independent readers. 
In our study, we found an even higher AUC (0.93) for the assessment of a CR with DW MR 
imaging. A possible explanation could be that, in our study, we evaluated the DW MR images 
independently from T2-weighted MR images and with objective volume measurements, whereas 
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in the above-mentioned works, T2-weighted and DW MR images were read side by side and by 
means of subjective interpretation. For example, if a radiologist has already determined a strong 
suspicion of residual tumor on the basis of the T2-weighted MR image morphologic findings, he 
or she will not be eager to alter the diagnosis even if the DW MR image would show the 
contrary. This factor, together with the knowledge that, in oncology, one should better err on 
the “safe” side and, in case of doubt, should best diagnose a patient as having residual disease 
than to potentially incorrectly categorize that patient as having a CR, might have incorporated 
some bias in the evaluation of DW MR images in published literature. 
In our study, this bias was eliminated, since the definition of a pCR on a DW MR image was 
solely based on the absolute absence of hyperintense areas within the rectal wall and the DW 
MR images were evaluated independently from the T2-weighted images. 
Despite our favorable results for DW MR imaging, we acknowledge that it remains difficult to 
differentiate between patients with a CR (TRG 1) and patients with small microscopic clusters of 
residual tumor (TRG 2). Furthermore, it is difficult to obtain a precise correlation between DW 
MR imaging findings and the underlying histopathologic findings at a microscopic level. Further 
studies are required to address this issue. 
In our study, we failed to demonstrate a benefit for pre-CRT ADC, post-CRT ADC, or ∆ ADC 
measurements to differentiate between patients with a CR and residual tumor. A possible 
explanation could be that ADC measurements are more subject to measuring errors, because of 
the inherently low discriminatory power and lesion conspicuity on ADC images. Even subtle 
variations in ROI size and ROI positioning between two readers may result in substantial 
variations in ADC. 
We believe that this phenomenon significantly contributed to the low performance of ADC in 
our study to precisely distinguish between complete and noncomplete responders. This factor is 
less an issue when the response groups are more roughly categorized in “responding” and 
“nonresponding” patient groups, as was done by a number of previous authors [Hein et al, 2003; 
Sun et al, 2010; DeVries et al, 2003; Kremser et al, 2003; Dzik-Jurasz et al, 2002]. Obviously, 
such large subcategories will require less precise discrimination methods and is the reason why 
we believe that these published data have shown more favorable results for ADC. 
There were some limitations to our study design. First, eight of 14 complete responders were 
classified in a group with a wait-and-see approach and histopathologic findings were only 
available from the biopsy specimen. It should be stressed, however, that these patients are 
classified in a group with a very strict follow-up protocol, including regular (3-monthly) clinical, 
endoscopic (with biopsy), and imaging examinations and that, to this date (at 17 months of 
follow-up), none have developed recurrent disease. A second issue is that a proportion of the 
included patients had relatively small tumors, which can be explained by the current trend in our 
institution to stratify an increasing number of small rectal cancers into the pre-CRT regimen. 
Finally, we acknowledge that, ideally, our study design should also have included an evaluation of 
intraobserver variability. This was, however, not practically feasible owing to the highly time-
consuming methods required to obtain the volumetric and ADC measurements. 
 
5. CONCLUSION 
 
In conclusion, post-CRT volumetry on DW MR images was significantly more accurate than was 
post-CRT volumetry on T2-weighted MR images to assess a CR after CRT in patients with 
LARC. 
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Post-CRT DW MR was equally as accurate as volume reduction ( ∆ volume) measurements on 
either DW or T2-weighted MR images. Pre-CRT volume measurements were not accurate. The 
above findings suggest that evaluation of post-CRT DW MR images can be sufficient and pre-
CRT images do not necessarily have to be evaluated. ADC measurements were not reliable for 
the assessment of a CR. 
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Chapter V 
Clinical study: Tumour ADC measurements in rectal 
cancer: effect of ROI methods on ADC values and 
interobserver variability 
 
1. INTRODUCTION 
 
At present, the standard treatment for patients with locally advanced rectal cancer consists of a 
long course of neoadjuvant chemoradiation treatment (CRT) followed by surgical resection. As 
surgery is routinely performed in each patient—regardless of the response to treatment—
response evaluation after CRT has so far not been a major issue. Nowadays there is, however, a 
trend towards minimally invasive treatments instead of standard surgery for well-responding 
patients [Habr-Gama e tal, 2006; Lezoche et al, 2008; Maas et al, 2010]. Accurate response 
assessment then becomes relevant, as it may directly influence treatment planning. 18F-
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) and MRI have been most 
extensively studied for response evaluation, but these techniques suffer from limitations in the 
interpretation of fibrotic scar tissue and inflammation [Barbaro et al, 2010; Capirci et al, 2004]. 
Diffusion-weighted MR Imaging (DWI) is a functional imaging technique that analyses differences 
in the extracellular movement of water protons to discriminate between tissues of varying 
cellularity [Bammer, 2003]. Different publications on DWI have shown its potentially beneficial 
role for the detection and characterisation of malignant tumours [Koh and Collins, 2007; Bruegel 
et al, 2008; Lim et al, 2009]. In addition, changes in tumour diffusion during and after treatment 
are indicative of tissue changes on a cellular level and may be used to evaluate treatment 
response [Patterson et al, 2008; Padhani et al, 2009]. Previous studies in a variety of tumour 
types have suggested that quantitative interpretation of the apparent diffusion coefficient (ADC) 
can be used as a biomarker for response to treatment [Theilmann et al, 2004; Cui et al, 2008; 
Koh et al, 2007; Jain et al, 2010]. For rectal cancer patients specifically, a benefit for treatment 
response evaluation by measuring tumour ADC values before [Dzik-Jurasz et al, 2002; Sun et al, 
2010; Roth et al, 2004; Lambrecht et al, 2010], during [Dzik-Jurasz et al, 2002; Sun et al, 2010; 
Roth et al, 2004; Kremser et al, 2003; Hein et al, 2003], and after chemoradiation treatment has 
been suggested [Kim et al, 2011; Kim et al, 2009]. Nevertheless—as also previously pointed out 
in a review by Patterson et al [2008]—there is no consensus yet on the true clinical value of 
ADC measurements for response assessment in rectal cancer. This is because the available 
literature consists of mainly small-scale studies with conflicting results. Moreover, in most 
studies, DWI evaluation was only performed by a single reader and ADC measurements by a 
variety of methods for region of interest (ROI) placement. Whereas some authors included the 
whole tumour volume [Sun et al, 2010; Roth et al, 2004; Lambrecht et al, 2010; Kim et al, 2011; 
Seierstad et al, 2007], others included only a single tumour slice [Dzik-Jurasz et al, 2002; Hein et 
al, 2003] or small tumour samples [Kim et al, 2009], which may contribute to the large variety in 
reported ADC results. It remains unclear whether ROIs for ADC measurements should ideally 
incorporate the entire tumour volume or only a representative tumour section. Furthermore, 
none of the studies focusing on rectal tumour ADC have addressed the issue of interobserver 
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variability, which is a non-negligible factor when considering the use of ADC as a potential 
marker for response in clinical practice. 
The purpose of the current study is to assess the influence of ROI size and positioning on 
interobserver variability and ADC values when measuring tumour ADC before and after 
chemoradiation treatment in patients with locally advanced rectal cancer. We aim to determine 
which method offers the most reproducible results in order to provide a reference for further 
studies. 
 
2. MATERIALS AND METHODS 
 
2.1. Patients 
 
This study retrospectively evaluated 46 patients who were treated for locally advanced rectal 
cancer between 2006 and 2010. Clinical patient data were retrieved from a patient database 
originating from a previous imaging study approved by the local institutional review board, for 
which the patients provided written informed consent. Thirty-four patients were male and 12 
were female. Median age was 70 years (range 49–88). Inclusion criteria consisted of [a] 
histologically (biopsy) proven rectal adenocarcinoma, [b] locally advanced disease, defined on 
primary staging T2-weighted MRI by an experienced gastrointestinal radiologist as tumour in the 
distal rectum (≤5 mm from the anorectal junction), threatened or involved circumferential 
resection margins (≤2 mm margin between the tumour and mesorectal fascia) and/or positive 
nodal stage (≥1 suspicious nodes, i.e. >5 mm in size and/or heterogeneous signal intensity and/or 
irregular border), [c] treatment consisting of a long course of preoperative CRT (50.4 Gy 
radiation+ 2 × 825 mg/m2/day capecitabine) followed by surgical resection and [d] availability of 
pre- and post-CRT MR imaging including DWI. Patients with non-resectable and/or metastatic 
disease were excluded. Mucinous tumours are known to have a very low cellular density and will 
therefore exhibit high ADC values [Woodhams et al, 2009]. As this may bias the study results, 
patients with predominantly mucinous appearing tumours (identified as predominantly high signal 
lesions on T2-weighted MRI) were also excluded. 
 
2.2. MR Imaging 
 
Patients did not receive bowel preparation or spasmolytics. Imaging was performed at 1.5T 
(Intera; Philips Medical Systems, Best, The Netherlands) using a phased array body coil. All 
patients underwent a pre-treatment MRI for primary tumour staging and a second, restaging MRI 
for response evaluation 6–8 weeks after completion of CRT. The imaging protocol consisted of 
standard 2D T2-weighted (T2W) fast spin-echo sequences (FSE) in three orthogonal directions 
and an axial DWI single-shot echo planar imaging sequence, according to the method of 
diffusion-weighted imaging with background body signal suppression (DWIBS), acquired with b-
values of 0, 500 and 1000 s/mm2 [Takahara et al, 2004]. The sequence parameters are displayed 
in Table V.1.  
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Table V.1. Sequence parameters. * DWIwas acquired with b values of 0, 500 and 1000 s/mm2 
 
The axial T2W and DWI sequences were angled in identical planes and were planned 
perpendicular to the tumour axis as defined on sagittal MRI. ADC maps in greyscale were 
automatically generated at the operating system, using a monoexponential decay model including 
all three b-values. 
 
2.3. Image evaluation 
 
The MR images were independently analysed by two radiological researchers (DMJL and TT), 
who performed tumour ADC measurements on the pre- and post-chemoradiation images. The 
readers were blinded to each other’s results, the clinical patient data and pathology reports. 
Mean tumour ADC was evaluated by manually drawing regions of interest (ROI) on the high b-
value (b1000) diffusion images and copying them to the corresponding ADC map (Fig. V.1).  
 
 
Fig. V.1. Axial T2-weighted image (a), b1000 diffusion image (b) and ADC map (c) of a male patient with a tumour in the rectum. 
For the whole-volume and single-slice methods, ADC was measured by drawing freehand ROIs along the high signal intensity border 
of the tumour on the b1000 images (b) to cover the entire tumour area. ROIs were copied to the ADC map (c) to calculate ADC. 
For the solid sample method, tumour ADC was measured by drawing three oval- or round-shaped ROIs within the most solid 
tumour areas. 
 
The mean ADC + standard deviation (SD) and the number of pixels per ROI was recorded for 
each individual measurement. On the pre-treatment b1000 diffusion images, tumour was defined 
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as a focal mass showing high signal intensity compared with the signal of the normal adjacent 
rectal wall and corresponding with the tumour (mass showing intermediate signal intensity) on 
the anatomical T2-weighted MRI. On the post-chemoradiation DWI, tumour was defined as 
focal areas of residual high signal on the b1000 images within the location of the primary tumour 
bed and/or corresponding with residual tumour on T2-weighted MRI (Fig. V.2).  
 
 
Fig. V.2. Axial pre- (a) and post-treatment (b) T2-weighted images of a male patient with a rectal tumour. After treatment, the 
tumour has undergone mainly fibrotic changes (arrowheads). On the corresponding b1000 diffusion image, an ROI was drawn along 
a well-defined area of high signal intensity within the fibrosis, suggestive of residual tumour. At histology, a residual ypT2 tumour 
was found. 
 
The pre-treatment images were at the readers’ disposal when analysing the post-treatment 
images, in order to compare and identify the location of the tumour. When no remaining high 
signal could be visualised on DWI, three sample measurements were obtained of the rectal wall 
at the former location of the primary tumour, of which an example is illustrated in Fig. V.3. 
 
 
Fig.V.3. Fig. 3 Axial T2-weighted images of a male patient with a rectal tumour before (a) and after (b) chemoradiation treatment. 
After CRT, the rectal wall has normalised (arrowheads). On the corresponding b1000 diffusion image (c), no high signal was 
observed and ROIs were placed within the rectal wall at the location of the primary tumour to measure post-treatment ADC. At 
histology, the patient had undergone a complete response. 
 
2.4. ROI protocols 
 
Mean tumour ADCs were measured according to three distinct ROI protocols: [a] ‘Whole-
volume’, [b] ‘Single-slice’ and [c] ‘Solid tumour samples’. For the whole -volume method, 
freehand ROIs were drawn along the border of the high signal of the tumour on the b1000 
images to cover the entire tumour area of each consecutive tumour-containing slice. Mean ADC 
(+SD) was obtained for each slice and ADC values were averaged to calculate the mean ADC of 
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the whole tumour volume. For the single-slice method, a single freehand ROI was drawn in the 
same way (along the border of the tumour), but only on a single slice containing the largest 
available tumour area. For the third method, mean ADC was calculated from a sample of three 
round/oval-shaped ROIs that were placed within the most solid tumour part (as identified on 
T2W-MRI) of three independent tumour-containing slices, which an example is illustrated in Fig. 
V.1. 
 
2.5. Statistical analyses 
 
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, 
version 16.0, Inc., Chicago, IL, USA). Interobserver variability for the tumour ADC 
measurements of the two readers for the pre- and post-CRT ADC measurements and for each 
individual ROI method was analysed according to the method of Bland and Altman and by 
calculating the intraclass correlation coefficient (0.00–0.20 poor, 0.21–0.40 fair, 0.41–0.60 
moderate, 0.61–0.80 good and 0.81–1.00 excellent correlation). ADCs were averaged between 
the two observers for further analyses. A paired samples t-test was used to compare [a] the pre- 
and post-treatment ADCs and [b] the tumour ADC values obtained by the three different ROI 
methods. For each patient, the average variance was calculated over the different slice 
measurements, weighted with the number of pixels. The mean SD for each patient was 
calculated as the square root of the variance. The variance (mean for the whole patient group) 
of the different ROI measurement methods and for the pre- and post-CRT measurements was 
compared using the F-statistics with the total number of slices as the degree of freedom. P values 
<0.05 were considered statistically significant. 
 
3. RESULTS 
 
3.1. Patient and treatment characteristics 
 
Twenty-seven patients underwent a low anterior resection, 15 an abdominoperineal resection 
and 4 more extended surgery. At histology 6 patients had a ypT0, 5 ypT1, 14 ypT2, 20 ypT3 and 
1 a ypT4 status. Thirty-three patients had a ypN0, 9 ypN1 and 4 ypN2 status. 
 
3.2. Effect of ROI methods 
 
The mean tumour ADCs, SDs and total ROI sizes are displayed in Table V.2 for the pre- and 
post-treatment measurements of each respective ROI protocol. 
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Table V.2. Influence of choice of regions of interest (ROIs). Note.-ADCs and ROI sizes were compared by means of a paired t-test. 
SDs were compared as variances by means of F-statistics * indicates a significant difference compared with whole-volume ROIs ** 
indicates a significant difference compared with single-slice ROIs 
 
Mean pre-treatment tumour ADC was significantly lower when measured by means of small 
sample ROIs, compared with the whole-volume (P  < 0.001) or single-slice protocol (P  < 
0.001), respectively. For the post-CRT measurements there were no significant differences in 
tumour ADC between the whole-volume ROIs compared with the single-slice (P = 0.07) or 
small sample ROIs (P = 0.08), respectively, but the single-slice ROIs resulted in significantly 
higher ADCs compared with the small sample ROIs (P = 0.002). For the pre-CRT 
measurements, the variance (SD) of the small sample ROI measurements was significantly 
smaller than for the whole-volume ROIs (P  <  0.001) and single-slice ROIs (P  =  0.03), 
respectively. For the post-CRT measurements, the variance of the small sample ROIs was also 
smaller than that of the whole-volume ROIs (P =  0.003) and single-slice ROIs, although the 
latter difference was not statistically significant (P  = 0.06). There were no significant differences 
in tumour ADC or variance between the whole-volume and single-slice approaches. 
 
3.3. Interobserver variability 
 
Intraclass correlation coefficients between the two readers are provided in Table V.3 for the 
three ROI protocols.  
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Table V.3. Interobserver variability (measured as the intraclass correlation coefficient*) for the different ROI protocols. 
 
The interobserver reproducibility was excellent (ICC 0.91) for the pre-CRT whole-volume ADC 
measurements, and good (ICC 0.66) for the post-CRT measurements. For the single-slice and 
solid sample ROIs, the ICCs ranged from 0.42 to 0.65. Figure V.4 displays the Bland-Altman plots 
for the whole-volume measurements performed pre- and post-CRT. 
 
 
Fig. V.4. Interobserver reproducibility for the whole-volume tumour ADC measurements performed pre- and post-chemoradiation 
treatment. Bland-Altman plots of the mean ADC of the two observers (x-axis) against the difference in ADC between the two 
observers (y-axis). The continuous lines represent the mean absolute difference (bias) in ADC between the two observers; the 
dashed lines represent the 95% confidence intervals of the mean differences (limits of agreement). 
 
4. DISCUSSION 
 
The results of this study show that, when measuring ADC in patients with locally advanced 
rectal cancer, tumour ADC values and interobserver variability are highly dependent on 
methods of ROI analysis. ADC measurements obtained from the whole tumour volume are 
more reproducible than those obtained from single-slice or small sample measurements. In 
specific pre-treatment whole-volume ADC measurements result in excellent interobserver 
reproducibility. 
The number and size of the ROIs affected the interobserver agreement. When comparing the 
different ROI protocols, the single-slice and sample ROIs resulted in considerably poorer 
interobserver agreement (ICC 0.42–0.65) than the whole-volume ROIs (ICC 0.66–0.91), 
indicating that analysing a larger number of pixels results in more reproducible ADC values. 
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Interobserver agreement for the whole-volume ADC measurements before treatment was 
excellent (ICC 0.91), but results after treatment were poorer (ICC 0.66). After chemoradiation, 
rectal tumours have often undergone massive fibrotic changes and defining a region of tumour 
residue within the fibrosis may be more difficult (Fig. V.5).  
 
 
Fig. V.5. Axial T2-weighted images of a male patient with a rectal tumour before (a) and after (b) chemoradiation treatment. An 
ill-defined residual area of hypointense signal intensity, indicative of fibrosis, is visible after CRT (arrowheads). On the corresponding 
diffusion image (c) there is still an area of high signal intensity, suggestive of residual tumour (arrows). Because of its irregular 
aspect and ill-defined borders, however, it is difficult to delineate an ROI, explaining the relatively poor interobserver agreement 
for the post-CRT ADC measurements. At histology, a ypT1 residual tumour was found. 
 
In cases where the tumour has completely regressed and the bowel wall has normalised or 
become fibrotically thickened, it can be even more challenging to correctly define an ROI (Fig. 
3). After CRT, ADC measurements thus seem to be more affected by the interpretation skills of 
the reader than before CRT, when the tumour is generally better defined. 
The choice of ROIs also significantly influenced the tumour ADC values. On pre-CRT MRI, the 
whole-volume and single-slice ROIs resulted in significantly higher tumour ADC values than the 
small sample ROIs. The small sample ROIs only included the most viable solid tumour parts, 
which may explain the lower ADC values. In this setting, areas of necrosis are likely to be 
excluded from the ADC measurements, while the presence of necrosis before onset of 
treatment is in fact believed to be an important indicator when aiming at evaluating response. A 
previous study of Roth and co-authors showed that whole-volume tumour ADC measurements 
were a better predictor of response than ROIs chosen only from viable regions of the tumour 
[Roth et al, 2004]. Although the focus in their study was on perfusion CT in patients with 
colorectal cancer Goh et al [2008a] also found that, when obtaining pharmacokinetic parameters 
by applying different ROI sizes and positions, whole tumour volume measurements were the 
most reliable. The above-described phenomenon may also explain why the whole-volume ADC 
measurements resulted in a larger variance and higher standard deviations, which is likely to 
reflect the heterogeneous nature of the tumour, including solid foci, as well as areas of necrosis 
and fibrosis. Altogether these findings suggest that whole-volume measurements might be a 
better indicator of tumour viability and may therefore be more suitable for assessment of 
response. Furthermore, as was also stressed by Goh et al [2008a], if variations in ROI 
substantially influence the measurements, efforts should be made to standardize their application 
for clinical use. Interestingly, we observed no significant differences in tumour ADC or SD 
between the whole-volume measurements and the single-slice approach, suggesting that the 
latter may also be used as a less time-consuming alternative. However, one should keep in mind 
that the single-slice method was subject to a much larger interobserver variability and whole-
volume measurements thus remain the single most reliable method. 
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Our study is limited because of its retrospective nature and the relatively small patient numbers. 
Furthermore, it was sometimes difficult to position regions of interests due to susceptibility 
artefacts occurring around air-tissue interfaces. This was especially challenging after 
chemoradiation, in cases where only a limited or no residual tumour could be identified on 
DWI. Susceptibility artefacts might be minimised by applying rectal wall distension with 
intraluminal filling, which we have not done in the current study. The specific focus of this study 
was to determine the effect of ROI size and positioning on tumor ADC evaluation and not to 
assess the relation between ADC and response, as various previous authors have done [Dzik-
Jurasz et al, 2002; Sun et al, 2010; Roth et al, 2004; Lambrecht et al, 2010; Kremser et al, 2003; 
Hein et al, 2003; Kim et al, 2011; Kim et al, 2009; Seierstad et al, 2007]. As such, we chose not 
to include a correlation between ADC and histopathological parameters of response. 
 
5. CONCLUSION 
 
In conclusion, variations in ROI size and positioning have a significant effect on tumour ADC 
values and interobserver variability. The most reproducible results are obtained when measuring 
ADC of the whole tumour volume. Interobserver variability is larger after chemoradiation 
treatment than before. These issues should be taken into account when considering the use of 
ADC as a potential biomarker for response in clinical practice. 
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Chapter VI 
Clinical study: Usefulness of perfusion CT to assess 
response to neoadjuvant combined chemoradiotherapy 
in patients with locally advanced rectal cancer 
 
1. INTRODUCTION 
 
The multidisciplinary management of rectal cancer patients has been witnessing a progressive 
change in the therapeutic approach of locally advanced tumors towards preoperative 
chemoradiation therapy (CRT), which is useful for tumor downsizing and downstaging, 
facilitating curative resection, decreasing the local recurrence rate and improving patient survival 
[Pahlman et al, 1995; Kaminsky-Forrett et al, 1998; Mohiuddin et al, 2000; Medich et al, 2001; 
Janjan et al, 2001; Valentini et al, 2002; Theodoropoulos et al, 2002]. Tumor downstaging may 
lead to a partial or complete tumor regression, but in many cases, even if the tumor cell density 
is significantly decreased the pathologic stage remains the same. The histological tumor response 
to the preoperative treatment can be assessed by the tumor regression grade (TRG), which may 
be determined according to different grading systems. One of them, proposed by Dworak et al, 
was specifically designed for application in rectal cancer [Dworak et al, 1997]. 
Predicting which tumors will respond well to this therapeutic approach remains a challenge since 
morphological imaging criteria are unreliable in this regard [Chen et al, 2005; Huh et al, 2008; 
Barbaro et al, 2010]. As it is becoming increasingly important that preoperative imaging may 
non-invasively select high-risk patients who could truly benefit from more aggressive 
multimodality treatment approaches in the preoperative setting [Barrett, 1998; Colorectal 
Cancer Collaborative Group, 2001], there is a growing interest on functional imaging techniques 
that can help monitor treatment effects. Both magnetic resonance imaging (MRI) and computed 
tomography (CT) have shown potential to act as functional biomarkers [Brasch et al, 2000, 
Harvey et al, 1999, Miles et al, 2000; Dugdale et al, 1999]. Perfusion CT is able to assess vascular 
physiology within tumors retrieving information about tumor blood flow (BF), blood volume 
(BV), mean transit time (MTT), and vascular permeability–surface area product (PS) [Goh et al, 
2008b, Kambadakone et al, 2009; Kan et al, 2005]. These parameters reflect vascular changes 
occurring in neoplastic tissue, ultimately related to the angiogenic process: BF reflects vascular 
supply to the lesion, BV reflects functional vascular volume, MTT reflects the time of blood 
through the tumor bed under the influence of vascular density, morphology and shunting, as well 
as interstitial pressure, and PS reflects leakiness of the microvasculature [Bellomi et al, 2007, 
Goh et al, 2009a].  
Two landmark articles have evaluated perfusion CT in the context of rectal cancer assessment 
prior to CRT, with good response defined as tumor downstaging [Bellomi et al, 2007; Sahani et 
al, 2005], but to our knowledge there are no published data about its use as a biomarker for 
treatment monitoring using TRG as endpoint of response to CRT. Thus the purpose of this 
study was to prospectively evaluate perfusion CT to assess tumor vascularity changes in locally 
advanced rectal cancer after neoadjuvant CRT and to analyze the correlation between baseline 
perfusion parameters and tumor response to CRT, as defined by the TRG. 
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2. MATERIALS AND METHODS 
 
2.1. Patients 
 
Between November 2007 and September 2010, 26 consecutive patients met the inclusion 
criteria of this prospective study, consisting of: 1) histologically (biopsy) proven non-mucinous 
rectal carcinoma; 2) locally advanced disease (staged by MRI as T3–4 and/or N positive); and 3) 
neoadjuvant treatment consisting of long-course CRT followed by surgical resection of the 
tumor. Patients with a history of allergy to iodinated contrast agents were excluded, as were 
patients locally non-resectable tumors and/or metastatic disease. These tumors were excluded 
based on: 1) the assumption that it would be impossible to foresee their downstaging and 
downsizing after CRT, thus precluding surgery within the time frame defined in the study design, 
therefore introducing heterogeneity in the study population and 2) the fact that metastatic 
tumors would not receive the same combined CRT prior to an eventual surgical excision. The 
study received approval from the local institutional ethical review board, and after the procedure 
had been fully explained, all patients provided written informed consent. Six patients were 
excluded: 2 died before surgery, in 3 the CRT protocol was interrupted due to complications 
and one developed metastatic disease during CRT, forcing a change in the therapeutic regimen. 
The final study population consisted of 20 patients (12 male, 8 female; median age: 57 years, 
range: 42–78), staged at baseline MRI as follows: T3N0 (n=1), T3N1 (n=13), T3N2 (n=5) and 
T4N1 (n=1). 
 
2.2. Treatment 
 
All patients were submitted to 3D-conformal radiotherapy with a total dose of 5040 cGy, 
delivered in 180 cGy fractions, 5 fractions a week, over a period of 5.5 weeks. 
Chemotherapeutic agents used concomitantly during the radiotherapy were oral capecitabine 
(1650 mg/m2/day, in 2 divided doses) or oral tegafur-uracil (UFT) + calcium follinate (300 
mg/m2/day + 90 mg/day, in 3 divided doses on weekdays). Surgery was performed 6-8 weeks 
after completion of CRT in all patients. 
 
2.3. CT Technique 
 
All patients underwent baseline perfusion CT the week before the beginning of therapy. Of 
these, 11 were submitted to a second perfusion CT study, within 2 weeks before surgery 
(median days after baseline examination: 81; range: 74-96). Regarding the remaining nine 
patients, one was unavailable for follow-up, two were excluded owing to technical problems 
(related to peristalsis in the rectum, introducing motion artifacts that may have interfered with 
the perfusion measurements), and six refused the second examination. Immediately before 
imaging, patients received intravenous spasmolytic medication (1mL of hyoscine butylbromide). 
Patients did not receive oral contrast, bowel preparation or rectal distention before the CT 
examinations. They were imaged in the supine position, in a 64-section multi-detector CT 
scanner (Lightspeed 64, GE Healthcare Technologies, Waukesha, Wis, USA). A preliminary non-
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enhanced scan of the pelvic region (2.5-mm section thickness) was performed to localize the 
tumor. Then, a board-certified radiologist (with 8 years of experience in GI imaging) selected a 
40-mm scanning range for dynamic CT, chosen to include the maximum area of visible tumor. 
Dynamic study of the imaging volume, with an acquisition in cine mode, was performed as 
follows: 8 contiguous 2.5-mm reconstructed sections obtained at the same table position, 1-
second gantry rotation time, 120 kVp, 300 mA. Scanning was started 5 seconds after i.v. injection 
of 100 mL of non-ionic iodinated contrast agent (370 mg of iodine/mL), followed by 40 mL of 
saline solution, via a pump injector at a fixed rate of 4-5 mL/s through a 18–20-G catheter in the 
ante-cubital vein. A set of 8 images per second during 60 seconds was obtained, corresponding 
to a total of 480 images.  
 
2.4. Image and data analysis 
 
The image datasets were transferred to an image-processing workstation (Advantage Windows 
4.3; GE Healthcare Technologies, Waukesha, Wis, USA). Commercially available software (CT 
Perfusion 3.0; GE Healthcare Technologies, Waukesha, Wis, USA) was used to calculate 
perfusion parameters. This software uses a deconvolution algorithm and is based on a 
mathematical model [Johnson et al, 1966] that describes the distribution of iodinated contrast 
material in tissue. Assumptions made within the model [Sahani et al, 2005; Lee et al, 2003] 
include the following: a) the extracapillary interstitial space is a well-mixed and uniform 
compartment, and b) by considering the interstitial space as a well-stirred compartment, the 
concentration of solute within this space is a function of time. An adiabatic approximation of the 
mathematical model [StLawrence et al, 1998] is used in the perfusion software to yield perfusion 
parameters for a tissue region of interest (ROI). These parameters result from time–contrast 
enhancement curves of the tissue ROI and the tissue ROI's arterial input. Thus, the resultant 
perfusion parameters represent mean values for the tissue ROI over the time period of the 
time–contrast enhancement curves. 
CT perfusion analysis was independently performed by a board-certified radiologist (with 4 years 
of experience in perfusion CT studies) and a senior resident (with no previous experience in 
perfusion CT), both blinded to each other’s measurements, the pathology results and the 
patient’s clinical response to treatment. The arterial input was obtained by drawing a circular 
ROI (maximum of 10 pixels) placed in the external iliac artery. An arterial enhancement-time 
curve was automatically generated, as well as functional parametric maps, representing in a color 
scale pixel values of the following perfusion parameters: BF (in milliliters per 100 g of wet tissue 
per minute), BV (in milliliters per 100 g of wet tissue), MTT (in seconds) and PS (in milliliters per 
100 g of wet tissue per minute). In order to quantify the baseline perfusion parameters of a 
neoplasm, a free-hand ROI encompassing as much of the tumor area as possible (pre-CRT area 
range: 292- 1355 mm2; post-CRT area range: 193-1099 mm2) was drawn along the visible 
margins of the lesion at a single table position (where the solid tumor area was largest) and then 
automatically copied to each functional map (Fig. VI.1).  
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Figure VI.1. (a) Hand-drawn regions of interest (ROIs) along the visible margins of the tumor on axial images. (b) A time-
enhancement curve corresponding to the tumor ROI is also generated. Perfusion parameters are computed and values can be 
presented in a table or in each one of the functional parametric maps: (c) blood flow (BF); (d) blood volume (BV); (e) mean 
transit time (MTT); (f) permeability-surface area product (PS). 
 
For patients without visible tumor burden after CRT, a ROI was placed over the rectal wall, in 
the former location of the neoplasm. This methodology was chosen because it was 
demonstrated that even if no residual tumor burden is visible macroscopically, viable tumor cells 
persist in the tumor bed in 50% of the cases [Vliegen et al, 2008b]. The variation rate of each 
perfusion parameter after CRT was calculated as follows: ([Pre-CRT value] – [Post-CRT value]) 
x 100/(Pre-CRT value). 
 
2.5. Standard of reference  
 
For the histological examination of the surgical specimen, its circumferential resection plane was 
inked, and it was opened anteriorly and fixed in formalin for 24 h. The whole specimen was then 
sectioned transversely, every 0.3 cm. The extent of lateral spread in the mesorectum was 
assessed on each slice, and the shortest distance between the tumor or lymph node and the 
circumferential resection plane was measured. Specimens were assessed by a semi-quantitative 
determination of the TRG as proposed by Dworak et al [1997] as the standard of reference. 
According to the proposed grading system, the tumor response to CRT was defined as follows: 
grade 0: no regression; grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy; 
grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find); grade 3: very 
few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous 
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substance; grade 4: no tumor cells, only fibrotic mass (total regression or response). Tumor 
response after CRT was based on the presence of gross residual tumor: tumors with TRG 0-2 
scoring were non-responders, while neoplasms with TRG 3-4 scores were considered 
responders.  
 
2.6. Statistical analysis 
 
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, 
version 17.0, Inc., Chicago, IL, USA). Interobserver variability between measurements of the two 
readers for pre- and post-CRT perfusion parameters was analysed by calculating the intraclass 
correlation coefficient (ICC) (0–0.20, poor correlation; 0.21–0.40, fair correlation; 0.41–0.60, 
moderate correlation; 0.61–0.80, good correlation; and 0.81–1.00, excellent correlation). Values 
of perfusion parameters were averaged between the two observers for further analysis. Since 
most data were not normally distributed, nonparametric tests were used. The median BF, BV, 
MTT and PS on pre- and post-CRT examinations were compared by means of the Wilcoxon 
signed ranks test to investigate changes in the perfusion parameters after CRT. The Mann-
Whitney U test was used to compare the variation rates in the perfusion parameters after CRT 
in responders and non-responders and also to compare baseline ROI areas and median BF, BV, 
MTT and PS of responders and non-responders. For all the above mentioned analyses, a two-
tailed p value of less than 0.05 was considered statistically significant. Receiver operator 
characteristics (ROC) curves were generated to evaluate the diagnostic performance for 
baseline perfusion parameters in detecting a favorable response (TRG 3-4). Corresponding areas 
under the ROC curve (AUC), sensitivity, specificity, positive and negative predictive values (PPV, 
NPV) were calculated. For these analyses, cut-off values were determined according to the point 
nearest to the upper left corner in the ROC curves.  
 
3. RESULTS 
 
3.1. Treatment characteristics  
 
According to the above mentioned protocols, 10 patients were treated with capecitabine, while 
UFT was given to the remaining 10. Surgery consisted of low anterior resection (n=15), 
abdomino-perineal resection (n=4), or extended resection (n=1). The median interval between 
the baseline perfusion scan and surgery was 101 days (range: 73-112).  
 
3.2. Histopathological findings 
 
After histological analysis of the surgical specimens and application of the Dworak scoring 
system there were 15 non-responders (2 patients with TRG 0, 4 patients with TRG 1, 9 patients 
with TRG 2) and 5 responders (3 patients with TRG 3 and 2 patients with TRG 4). Regarding 
pathological staging, the results showed 2 patients with a ypT0N0, 1 a ypT1N0, 10 a ypT2N0, 4 
a ypT3N0, 1 a ypT3N1, 1 a ypT3N2 and 1 a ypT4N1 tumor. 
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3.3. Interobserver variability 
 
The correlation between pre-CRT measurements of both readers was excellent, with ICCs of 
0.86 (0.67-0.94), 0.83 (0.62-0.93), 0.92 (0.80-0.97) and 0.95 (0.87-0.98), respectively for the BF, 
BV, MTT and PS. As for post-CRT measurements, the correlation was good to excellent, with 
ICCs of 0.77 (0.32-0.94), 0.74 (0.51-0.88), 0.89 (0.63-0.97) and 0.75 (0.52-0.84), respectively for 
the same perfusion parameters mentioned above. Median differences between readers were the 
following: for BF, difference on pre-CRT images was 3.75 mL/100g/min and on post-CRT CT 
was 1,45 mL/100g/min; for pre-CRT BV was 0.10 mL/100g and on post-CRT CT was 0.33 
mL/100g; for MTT on pre-CRT scans was 0.55 s and on post-CRT images was 1.70 s; for pre-
CRT PS was 0.95 mL/100g/min and for post-CRT examinations was 1.01 mL/100g/min. 
 
3.4. ROI Areas 
 
The median baseline ROI area was not significantly different between tumors which responded 
well (495 mm2, range: 344-723 mm2) and poorly-responding lesions (625 mm2, range: 292-1355 
mm2) (P=0.257). 
 
3.5. Perfusion parameters for assessment of response 
 
Differences between medians of baseline perfusion parameters across all levels of TRG and in 
responders and non-responders are summarized in Table VI.1.  
 
 
Table VI.1. Baseline perfusion parameters across all levels of TRG and in responders and nonresponders to combined chemoradiation 
therapy. 
 
BF was significantly lower and MTT was significantly higher in responders than in non-
responders. No significant difference was found for BV and PS of responders and non-
responders. The AUCs for the perfusion parameters were the following: 0.88 for BF, 0.67 for 
BV, 0.92 for MTT and 0.63 for PS (Figure VI.2).  
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Figure VI.2. Comparison of receiver operating characteristic curves displaying the diagnostic performance for baseline measurements: 
(a) blood flow (BF); (b) blood volume (BV); (c) mean transit time (MTT); (d) permeability-surface area product (PS) in the 
evaluation of good response to chemoradiation therapy (tumor regression grades 3 and 4). AUC, area under the curve. 
 
Corresponding sensitivities, specificities, PPV and NPV are provided in Table VI.2.  
 
 
Table VI.2. Diagnostic performance of baseline perfusion measurements in detecting a good response to CRT. 
 
Figure VI.3 shows box-and-whisker plots for BF and MTT, with depiction of the threshold value 
for discrimination between responders and non-responders.  
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Figure VI.3. Box-and-whisker plots showing baseline blood flow (BF) and mean transit time (MTT) values of responders (tumor 
regression grade [TRG] 3-4) and nonresponders (TRG 0-2). Boxes stretch from lower quartile to upper quartile (25th to 75th 
percentile); median is shown as a line across each bar; whiskers show sample minimum and maximum; O denotes outliers; red 
horizontal lines represent thresholds. Using a threshold value of 59.25 mL/100 g/minute for BF it is possible to differentiate 
responders from nonresponders with a sensitivity of 80.0% and a specificity of 73.3%. Regarding MTT, a threshold of 9.52 seconds 
allows distinction between responders and nonresponders with a sensitivity of 100% and a specificity of 86.7%. 
 
When both are taken in combination, they yield a sensitivity of 80% (95% CI: 28-99) and a 
specificity of 66.7% (95% CI: 38-88) for characterization of response. 
 
3.6. Perfusion parameters before and after CRT 
 
In the 11 patients who underwent pre- and post-CRT perfusion CT, the median BF on pre-CRT 
images was 61.00 mL/100g/min (range: 20.10–86.60) and on post-CRT CT was 20.10 
mL/100g/min (range: 7.73–60.80) (P=0.003). For pre-CRT median BV was 4.84 mL/100g (range: 
3.05–5.23) versus 2.80 mL/100g (range: 1.64–4.26) for post-CRT CT (P=0.003). The median 
MTT on pre-CRT scans was 8.63 s (range: 4.88–22.50) and on post-CRT images was 15.90 s 
(range: 4.48–26.70) (P=0.006). For pre-CRT CT, median PS was 12.80 mL/100g/min (range: 
8.55–20.30) versus 9.51 mL/100g/min (range: 3.71–13.50) for post-CRT examination (P=0.008). 
Of these 11 patients, 4 were responders and 7 were non-responders. All responders and 4 non-
responders showed lower BF, BV and PS and a higher MTT after CRT (Fig. VI.4). 
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Figure VI.4. Good responder to chemoradiation therapy (CRT): apart from morphological changes between pre- (a) and posttherapy 
(d) with a clear lesion downsizing, perfusion computed tomography showed a decrease in blood flow (BF) from pretreatment study 
(b) to posttreatment examination (e). There is also an increase in mean transit time (MTT): (c) baseline; (f) post-CRT. The blood 
volume and the permeability-surface area product (data and parametric maps not shown) also decreased. 
 
Among non-responders, one showed higher BF and BV (Fig. VI.5), in other a higher PS was found 
and in a third the MTT was lower after CRT.  
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Figure VI.5. Poor responder to chemoradiation: absence of response to treatment was found with a lack of significant downsizing of 
the tumor between pre- (a) and posttherapy (d) images. Perfusion measurements revealed a decrease in the blood flow (BF): (b) 
baseline; (e) postchemoradiation therapy (CRT), and also in the mean transit time (MTT): (c) baseline; (f) post-CRT. The blood 
volume and the permeabilitysurface area product (data and parametric maps not shown) also decreased. 
 
Nevertheless, the median variation rates of the perfusion parameters after CRT were not 
significantly different in responders and non-responders: 58.0% versus 63.0% (P=0.85) for BF, 
29.1% versus 42.2% (P=0.70) for BV, 48.3% versus 84.2% (P=0.70) for MTT and 47.7% vs. 23.9% 
(P=0.13) for PS. 
Table VI.3 yields a detailed view of the perfusion measurements on a patient-by-patient basis. 
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Table VI.3. Perfusion measurements on a patient-by-patient basis. 
 
3.7. Radiation Dose 
 
The effective radiation dose to the patients ranged from 36.03 mSv to 36.13 mSv. Of this, the 
cine acquisition was responsible for 20.74 mSv, while the remaining effective dose was related to 
the non-enhanced scans. 
 
4. DISCUSSION 
 
The results of our study show that baseline BF and MTT were significantly different in 
responders and non-responders (BF was significantly lower and MTT significantly higher in 
responders) and were accurate for predicting a favorable tumor response to CRT, with an AUC 
of 0.88 and 0.92, respectively. Baseline BV and PS were not significantly different among 
responders and non-responders. Comparing the functional perfusion data at baseline with those 
obtained following CRT conclusion, there was a significant change in all perfusion parameters: 
BF, BV and PS decreased while the MTT increased, but these changes were not different in 
responders and non-responders.  
To our knowledge, assessing response to CRT as defined by the TRG has not been focused in 
previous studies of perfusion CT of rectal cancer. Former works addressed the diagnostic value 
of perfusion CT in evaluating response based on morphologic criteria of tumor downstaging 
[Bellomi et al, 2007; Sahani et al, 2005]. The use of these criteria as endpoint of response to 
CRT may be prone to under or overstaging and requires accurate baseline and post-CRT 
imaging examinations. However, our study assessed response to CRT based on the TRG, which 
is an objective criterion as standard of reference to evaluate response. Moreover, grade analysis 
is a better predictor of outcome after treatment than T downstaging [Bouzourene et al, 2002]. 
In patients with gross residual tumor (TRG 0–2), the risk of local and distant recurrence is 
increased and the disease-free survival is statistically poor [Losi et al, 2006]. 
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Confirming the findings of a previous study [Sahani et al, 2005], our results showed that baseline 
BF and MTT are different between responders and non-responders, being respectively 
significantly higher and significantly lower in poorly-responding patients. This can be theoretically 
explained by the presence of intratumoral arteriovenous shunts with a high perfusion rate and 
low exchange of oxygen [Brown et al, 1998)]. Such arteriovenous shunts were shown to 
account for up to 30% of total tumor flow of blood [Eddy, 1980; Peters et al, 1980; Wheeler et 
al, 1986] and in an animal study it was demonstrated that tumoral areas of high BF in perfusion 
CT images corresponded to sites of shunting of blood flow [Kan et al, 2005]. These shunts have 
low resistance to flow, resulting in increased BF and shorter MTT. BV, although not significantly 
different, is also higher in poor responders. It seems therefore logical that high perfusion values, 
which suggest a high rate of angiogenesis within the tumor, may point towards a poor therapy 
response and/or a worse prognosis. High perfusion could also be a result of intrinsic high 
angiogenic activity of tumor [Leek et al, 1999]. Interestingly, our results disagree with those 
from a previous study that showed baseline BF and BV in poor responders to be significantly 
lower and MTT significantly higher than in responders [Bellomi et al, 2007]. Reason(s) for these 
discrepancies with our results may reflect not only the use of a different endpoint to assess 
response, different patient selection criteria (we did not use endorectal US for initial staging) and 
also differences in the perfusion technique: a shorter scanning time (effective scan duration of 
about 30 seconds) may be too short to reliably assess PS [Goh et al, 2005a; Miles, 2003], and 
use of thicker sections of 10 mm may also influence quantitative perfusion data [Bellomi et al, 
2007]. Table VI.4 provides a comparison between the methods and findings of our study and 
those from the two above mentioned works. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI     Page 117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table VI.4. Comparison of findings from previous reports on perfusion CT of rectal cancer with results from the present study. 
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Both baseline BF and MTT showed respectively AUCs of 0.88 and 0.92 in determining a good 
response to CRT, thus being able to yield a diagnostically useful threshold value. Therefore, BF 
values below 59.25 mL/100g/min and MTT values over 9.52 s were found to have high accuracy 
for predicting a good response to CRT. Contrarily, baseline BV and PS could not accurately 
discriminate responders from non-responders. Again, explanation for poor response is probably 
related to the opening of a significant number of arteriovenous shunts rather than the acquisition 
of a new vascular supply. Shunting facilitates the passage of blood directly from the arterial to 
the venous beds bypassing the exchange capillaries, hence decreasing MTT [Chaplin et al, 1997]. 
This would result in a high perfusion rate with minimal or null exchange of nutrients (including 
oxygen), therefore preventing and limiting the action of chemotherapeutic drugs over the 
capillary bed, helping to explain an unfavorable response [DeVries et al, 2001]. We are aware, 
however, that this explanation, which is also based on findings from previous reports [Kan et al, 
2005; Sahani et al, 2005; Eddy, 1980, Peters et al, 1980, Wheeler et al, 1986, DeVries et al, 2001] 
is speculative, since it lacks pathologic confirmation. The previous studies on perfusion CT for 
monitoring CRT effects in rectal cancer showed significant changes in perfusion parameters after 
therapy. Sahani et al [2005] reported a significant decrease in BF and increase in MTT, whereas 
Bellomi et al [2007] showed a significantly lower BF, BV and PS after CRT. In agreement with 
those results, we demonstrated a significant change in perfusion parameters after CRT 
compared with the baseline scan: BF, BV and PS diminished, whereas MTT increased. This may 
reflect a decreased number of arteriovenous shunts (BF), a reduced volume of the vascular bed 
(BV) and a reduced leakage from neoplastic vessels (PS). The higher MTT is probably an 
expression of the sum of changes in the tumor vascular bed itself. However, the median 
variation rates of the perfusion parameters after CRT were not significantly different in 
responders and non-responders. Therefore, our results suggest that a baseline perfusion study 
alone could discriminate between responders and non-responders and a post-CRT is not 
warranted in order to achieve that goal. 
Our study has limitations. Results are based on a small patient cohort of a single centre and are 
therefore specific to the methods and software we used, and as such our thresholds may not 
necessarily apply to other patients. They should be regarded as preliminary data that may 
stimulate studies on larger populations, especially multicenter trials encompassing 
standardization of protocols for perfusion CT in this clinical setting.  
The use of a large (100 mL) dose of iodinated contrast is not recommended by some authors, 
who suggest that a smaller (<50 mL) bolus should be administered instead. Nevertheless, it was 
demonstrated that contrast volumes similar to those applied in clinical practice for 
abdominopelvic CT imaging are not detrimental to the accuracy of quantitative tumor vascular 
parameters measured at perfusion CT, with the advantage of obtaining simultaneously 
morphological (staging) data [Goh et al, 2009b]. Restrictions on the administration rates by the 
caliber of the iv cannula usually sited in clinical practice imply that rates above 5 mL/s are not 
commonly used [Goh et al, 2009b]. Moreover, the deconvolution method we applied can 
tolerate lower injection rates, such as less than 5 mL/s [Kambadakone et al, 2009]. The free-
hand drawing of a ROI in a single slice may not fully represent the overall tumor vascular profile 
and implicates a subjective judgment by the readers of where the tumor margin is located. 
Therefore, even subtle variations in ROI size and positioning between readers may result in 
substantial variations in perfusion parameters. However, observer variability is lower for this 
type of ROI analysis as shown in other studies [Goh et al, 2005b; Goh et al, 2008a] and in 
concordance with our results with good to excellent interobserver agreement. We did not test 
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reproducibility, due to the radiation burden and concerns of contrast-induced nephropathy. A 
potentially distinct efficacy of the different chemotherapeutic drugs with impact on the results 
should theoretically be considered. We did not assess baseline tumor volume, which may predict 
response to therapy [Kim et al, 2005], nor did we evaluate changes in tumor volume after 
therapy, since contrast-enhanced scans of the whole pelvis were not performed. A direct 
correlation with histological markers of angiogenesis, such as microvessel density, was not 
performed since it is not routinely performed in our institution. Furthermore, there are 
limitations in its routine use as a biomarker: it requires invasive tissue sampling, needs 
standardization, and suffers from random sampling errors since the entire tumor volume is not 
examined, which can hamper evaluation because of the heterogeneity of malignant neoplasms 
[Cuénod et al, 2006]. 
 
5. CONCLUSION 
 
In conclusion, baseline BF was significantly lower and MTT was significantly higher in responders 
than in non-responders and both parameters can accurately discriminate patients with a 
favorable response from the ones that fail to respond to preoperative CRT, potentially selecting 
high-risk patients with radio- and chemo-resistant tumors that may benefit from a more 
aggressive preoperative treatment approach. 
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Chapter VII 
Summary and conclusions 
 
1. SUMMARY 
 
The present thesis focuses on the study of rectal cancer, which is one of the most frequently 
diagnosed neoplasms in the Western World, and is also associated with a high mortality rate. 
Long-term survival is highly dependent on tumor stage at discovery: tumors at an advanced stage 
at diagnosis are associated with a poor outcome. Accordingly, tumor stage at diagnosis is a guide 
to treatment strategies. As such, while patients with early cancers usually may achieve cure 
through surgery alone, those with locally advanced cancers typically undergo preoperative 
therapy, which is useful for decreasing the tumor stage in order to facilitate curative resection, 
and to decrease the local recurrence rate. Therefore, the role of the radiologist is to identify 
tumors within these groups, so that a tailored treatment can be offered to each single patient in 
order to decrease the probability of local recurrence. 
In recent years, a paradigm shift toward less invasive treatments has been witnessed, including 
local excision by TEM or even a – still controversial – deferral from surgery in those patients 
achieving a complete response from the tumor following preoperative CRT. 
However, no imaging techniques currently allow an accurate prediction of which tumors will 
respond satisfactorily to this kind of treatment, and which cases develop a complete response. 
This is particularly true when using purely morphological imaging methods, and consequently 
there has been a growing interest in more ‘functional’ imaging techniques, such as DW-MRI or 
perfusion CT. 
Magnetic resonance imaging is widely used for the diagnosis and staging of tumors, whereby 
mainly morphometric macroscopic tissue information is usually obtained. For the assessment of 
viability and aggressiveness of the tumor or its response to therapy, a method that gives insights 
at a cellular level would be desirable. DW-MRI provides images whose signal intensity is 
sensitized to the random motion of free water molecules. The mobility of water molecules 
within a given voxel is determined by the microscopic cellular structure, i.e., the presence of 
barriers, such as cell membranes and macromolecules. Thus, DWI has been suggested as a tool 
to distinguish different tissue compartments based on their different cellular structure. As such, 
this method offers a theoretical possibility for the assessment of viability of the tumor or its 
response to therapy. 
Perfusion CT is a technology that allows measurement of tumor vascular physiology and 
construction of regional maps of tumor blood flow, blood volume, mean transit time, and 
vascular permeability–surface area product. This type of study can be repeated at different times 
to assess tumor response to temporal changes in tumor angiogenesis or anti-angiogenic therapy. 
The contribution of this study focuses mainly on the aforementioned ‘functional’ techniques. I 
attempted to bring a new insight into their use in the study of rectal cancer and also to give an 
own contribution to the consolidation of their routine application in everyday clinical practice. It 
was possible to demonstrate that both techniques, despite not being ready to fulfil that role yet, 
may be valuable in characterizing rectal tumors and may provide additional information about 
response and prognosis. 
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Diffusion-weighted imaging has the potential to become an imaging biomarker in these tumors, 
as lower ADCs are found in more aggressive tumors. DWI-based volumetry can help in 
predicting response to neoadjuvant therapy and assessing the presence of complete tumoral 
response. Perfusion CT can also aid in the prediction of response, as tumors with lower blood 
flow may respond more favourably to neoadjuvant combined chemoradiation therapy. 
 
2. CONCLUSIONS 
 
1. Significant correlations between ADC values and the clinical MRF status, and nodal status 
on MR imaging and the tumor differentiation grade at histology have been statistically 
demonstrated. There is a tendency towards lower ADC values in tumors with involvement of 
the MRF, node-positive tumors, poorly differentiated neoplasms, lesions growing beyond the 
rectal wall, CEA levels higher or equal to than 5 ng/mL, and tumors with LVI, which are the 
cancers with poorer prognosis. This study suggests that ADC has the potential to become an 
imaging biomarker of tumor biological profile. 
 
2. It was also proved that tumor volumetry performed on DW MR images after combined 
CRT assesses complete tumor response accurately, and is significantly more accurate than 
volumetry performed on post-CRT T2-w MR images. Tumor volume reduction measurements 
performed on either T2-w MR images or DW MR images are equally as accurate as 
measurements performed on post-CRT DW MR images in assessing a CR. Tumor volumes 
measured on either pre-CRT T2-w MR images or pre-CRT DW MR images are not accurate for 
the assessment of a CR. ADC measurements do not assess a CR accurately. This way, tumor 
volumetry performed on post-CRT DW MR images may be used for the clinical selection of 
rectal cancer patients with a CR after CRT who might be stratified for conservative, non-surgical 
follow-up treatment. 
 
3. When measuring ADC in patients with locally advanced rectal cancer, ADC values and 
interobserver variability are highly dependent on the methods of ROI analysis. The most 
reproducible results derive from ADC measurements of the whole tumor volume. Tumor ADC 
measurements are more reproducible before rather than after chemoradiation treatment. In 
specific, the ROI size and positioning influence tumor ADC measurements in rectal cancer, as 
well as interobserver variability of tumor ADC measurements. As such, variations caused by ROI 
size and positioning should be taken into account when using ADC as a biomarker for tumor 
response. 
 
4. A significant difference in perfusion parameters of rectal cancers in responders and non-
responders as determined by perfusion CT has been shown. In specific, BF was significantly 
lower and MTT significantly higher in responders, and both have proved to be accurate for 
predicting a favorable tumor response to CRT. Comparing the functional perfusion data at 
baseline with those obtained following CRT conclusion, there was a significant change in all 
perfusion parameters: BF, BV and PS decreased while the MTT increased, but these changes 
were not different in responders and non-responders. Therefore, perfusion CT may help to 
select high-risk patients with radio- and chemo-resistant tumors that may benefit from a more 
aggressive preoperative treatment approach. 
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SUMÁRIO 
 
Na presente tese focamo-nos no estudo do cancro do recto, que constitui uma das neoplasias 
mais frequentemente diagnosticadas nos países desenvolvidos, associada a uma elevada taxa de 
mortalidade. A sobrevivência dos pacientes encontra-se intimamente relacionada com o estádio 
do tumor aquando do diagnóstico: lesões num estádio mais avançado associam-se a um 
prognóstico mais sombrio. Por seu turno, o estadiamento tumoral constitui a base para a 
tomada de decisões terapêuticas e, desta forma, pacientes com tumores em estádios mais 
precoces podem ser curados através de cirurgia, enquanto que aqueles com tumores localmente 
avançados são via de regra submetidos a terapêutica pré-operatória com o intuito de promover 
o ‘downstaging’ tumoral e dessa forma facilitar a ressecção cirúrgica com intenção curativa, bem 
como diminuir a taxa de recidiva local. Consequentemente, o papel do radiologista consiste em 
classificar as lesões nestes grupos, de forma que o tratamento possa ser ajustado e 
individualizado para cada paciente no sentido de reduzir a probabilidade de surgir uma recidiva 
local. 
Recentemente temos vindo a testemunhar uma alteração no paradigma terapêutico desta 
patologia, com o aparecimento de tratamentos minimamente invasivos, incluindo a excisão local 
transanal ou mesmo um adiamento da cirurgia com vigilância regular e periódica naqueles 
doentes em que se consegue obter uma resposta tumoral completa após terapêutica 
neoadjuvante com radio- e quimioterapia combinadas (embora tal abordagem seja ainda objecto 
de considerável controvérsia).  
Contudo, no presente momento as técnicas de imagem não permitem seleccionar com acuidade 
suficiente quais os tumores que irão responder de forma satisfatória a este tipo de tratamento 
nem quais os casos que atingirão uma eventual resposta completa. Estas afirmações são 
particularmente verdadeiras se considerarmos os métodos de imagem puramente morfológicos, 
pelo que se tem verificado um interesse crescente por técnicas de imagem mais ‘funcionais’, 
como sejam a difusão por Ressonância Magnética e a perfusão por Tomografia Computorizada.  
 
A Ressonância Magnética é amplamente utilizada no diagnóstico e estadiamento de tumores, 
fornecendo essencialmente informação morfológica macroscópica acerca dos tecidos. Para 
avaliação da agressividade e viabilidade do tumor ou da sua resposta à terapêutica, tornar-se-á 
necessário recorrer a métodos que forneçam informação sobre as características do tumor a 
nível celular. A intensidade de sinal das estruturas nas imagens de Ressonância Magnética 
ponderadas em difusão dependem da amplitude do movimento aleatório das moléculas de água, 
cuja mobilidade em cada voxel é determinada pela estrutura celular microscópica, isto é, pela 
presença de barreiras que restringem o movimento, como membranas celulares e 
macromoléculas. Assim sendo, a difusão por Ressonância Magnética pode tornar-se uma 
ferramenta útil na distinção de diferentes compartimentos teciduais baseando-se na sua distinta 
estrutura celular, teoricamente oferecendo a possibilidade de avaliar a viabilidade de um tumor e 
também o seu grau de resposta à terapêutica.  
 
A perfusão por Tomografia Computorizada é uma tecnologia que permite a avaliação da 
fisiologia vascular do tumor e a obtenção de mapas paramétricos de côr do fluxo sanguíneo, 
volume sanguíneo, tempo de trânsito médio e produto permeabilidade-superfície vascular. Este 
estudo pode facilmente ser repetido em diferentes tempos para avaliar a resposta do tumor e as 
alterações da sua angiogénese.  
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A nossa contribuição pessoal centrou-se principalmente em estudos referentes às técnicas de 
imagem ‘funcionais’ acima mencionadas. Ao fazê-lo, procurámos reforçar o seu papel no estudo 
do cancro do recto e também, de uma forma despretensiosa, oferecer o nosso próprio 
contributo para a consolidação do seu uso rotineiro na prática clínica diária no futuro. 
 
Foi-nos possível demonstrar que ambas as técnicas supra citadas, apesar de, em nosso entender, 
ainda incapazes de cumprir tal desiderato, podem desempenhar um relevante papel na 
caracterização dos tumores rectais e fornecer informação adicional acerca do grau de resposta 
tumoral e do prognóstico dos doentes.  
A difusão por Ressonância Magnética tem potencial para se tornar um biomarcador imagiológico 
destes tumores, pois ADCs mais baixos encontram-se associados a tumores mais agressivos. A 
volumetria tumoral efectuada com base nas imagens ponderadas em difusão pode auxiliar a 
prever a resposta tumoral à terapêutica neoadjuvante e a presença de uma resposta tumoral 
completa. 
A perfusão por Tomografia Computorizada pode de idêntica forma auxiliar na previsão da 
resposta, decorrendo do facto de tumores com menor fluxo sanguíneo responderem mais 
favoravelmente à terapêutica neoajduvante combinada com radio- e quimioterapia. 
 
CONCLUSÕES 
 
Demonstrámos correlações estatisticamente significativas entre os valores de ADC e o estado 
da fáscia mesorrectal e o estadiamento ganglionar na RM e o grau de diferenciação tumoral na 
histologia. Houve uma tendência no sentido de encontrar valores de ADC mais baixos em 
tumores com invasão da fáscia mesorrectal, na doença metastática ganglionar, em lesões 
histologicamente pouco diferenciadas, em neoplasias com crescimento extra-parietal, em casos 
de doseamentos de CEA iguais ou superiores a 5 ng/mL, e em tumores com invasão 
linfangiovascular, aspectos estes associados a lesões com um prognóstico mais sombrio. O nosso 
estudo sugere que o ADC revela potencial para se tornar um biomarcador imagiológico do 
perfil biológico dos cancros do recto. 
 
Provámos que a volumetria tumoral efectuada com base nas imagens ponderadas em difusão 
após o tratamento combinado com radio- e quimioterapia possui uma elevada acuidade na 
avaliação da resposta tumoral completa e significativamente superior à da volumetria baseada nas 
imagens pós-terapêutica ponderadas em T2. A mensuração da redução do volume tumoral 
efectuada nas imagens ponderadas em T2 ou nas imagens ponderadas em difusão revela idêntica 
acuidade à da volumetria baseada nas imagens pós- terapêutica ponderadas em difusão na 
avaliação da resposta tumoral completa. A volumetria tumoral efectuada com base nas imagens 
pré-terapêutica ponderadas em T2 ou em difusão revelou uma baixa acuidade na determinação 
de uma resposta tumoral completa. Desta forma, a volumetria tumoral baseada nas imagens pós-
terapêutica ponderadas em difusão pode ser aplicável na selecção clínica de pacientes com 
cancro do recto com uma resposta tumoral completa após tratamento combinado de radio- e 
quimioterapia, que podem dessa forma ser sujeitos a uma abordagem mais conservadora, não 
cirúrgica, através uma regular vigilância clínica, endoscópica e imagiológica.  
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Concluímos que na mensuração dos valores de ADC em pacientes com cancros do recto 
localmente avançados, esses mesmos valores e a variabilidade são altamente dependentes dos 
métodos de análise das regiões de interesse. Especificamente, o tamanho da região de interesse 
e o seu posicionamento sobre o tumor influenciam os valores de ADC tumoral e a variabilidade 
interobservador. Os resultados com maior reprodutibilidade derivam das mensurações 
efectuadas para todo o volume tumoral. A determinação dos valores de ADC é também mais 
reprodutível antes do que depois do tratamento pré-cirúrgico com uma combinação de radio- e 
quimioterapia. Como tal, as variações causadas pelas dimensões e posicionamento das regiões de 
interesse devem ser consideradas aquando da determinação dos valores de ADC. 
 
Encontrámos uma diferença significativa nos valores dos parâmetros de perfusão nos cancros do 
recto que mostraram boa resposta à radioquimioterapia relativamente àqueles que responderam 
de forma pouco satisfatória. Concretamente, o fluxo sanguíneo foi significativamente menor e o 
tempo de trânsito médio foi significativamente mais elevado nos tumores com uma boa resposta, 
e estes parâmetros provaram possuir elevada acuidade na determinação de uma resposta 
favorável à radioquimioterapia neoadjuvante. Comparando os dados basais com os obtidos após 
conclusão da radioquimioterapia, houve uma alteração significativa em todos os parâmetros de 
perfusão: o fluxo sanguíneo, o volume sanguíneo e o produto permeabilidade-superfície vascular 
decresceram, enquanto que o tempo de trânsito médio aumentou. No entanto, estas diferenças 
não foram estatisticamente significativas entre neoplasias com um distinto grau de resposta. 
Desta forma, a perfusão por Tomografia Computorizada pode auxiliar a selecção de doentes 
com elevado risco de recidiva, possuidores de tumores radio- e/ou quimiorresistentes e que 
podem beneficiar de uma abordagem terapêutica pré-cirúrgica mais agressiva. 
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